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ABSTRACT 
 
 The goal of this work is to demonstrate the utility of using systematically 
formatted mixture based libraries as part of the drug discovery processes.  While there 
are a number of different valid approaches for identifying hit and tool compounds, 
systematically formatted mixture based libraries, such as those described in this study, 
offer the ability to develop a significant amount of structure activity relationship data 
from the testing of very few samples.  In support of this claim a review of recent 
developments in the area of systematically formatted mixture based libraries as well as 
three case studies are presented.  The three case studies provide the detailed approach 
and results obtained from using systematically formatted mixture based libraries in 
programs focused on identifying broad spectrum antibiotics, therapeutics to treat 
leishmaniasis, and inhibitors of palmitoylation.  In each of these three cases 
approximately 200 samples were utilized to survey millions of compounds in order to 
develop a series of hit and tool compounds as well as significant structure-activity 
relationship (SAR) data around the compounds identified.  This information will be 
utilized in future studies to potentially uncover novel mechanisms of action for treating 
infections and diseases as well as developing therapeutics to treat the patients affect by 
them.  So while systematically formatted mixture based libraries are not the only option 
for identifying hit or tool compounds they do provide a very efficient method that can be 
! ix 
adapted to a variety of assay formats and therefor should be considered when 
conducting a screening campaign. 
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CHAPTER ONE: 
SYSTEMATICALLY FORMATTED MIXTURE BASED LIBRARIES 
 
Introduction 
The path to finding small molecule therapeutics to treat and cure diseases and 
infections is a challenging endeavor that utilizes expertise from different scientific 
disciplines.  Though new therapeutics can be discovered in a multitude of ways, at the 
heart of the process is identifying molecule(s) that interact with biological target(s) in a 
manner that is beneficial to the patient.  In order to accomplish this goal one of the first 
steps often necessitates identifying compounds that have some specific effect in a given 
assay system.  These assays range the gamut from relatively simple target based 
binding assays all the way to complex whole animal behavioral models.  While each 
assay system has its own strengths and weaknesses it is likely that the best approach 
to discovering novel therapeutics relies on the effective integration of multiple assays.  
In a similar manner there are a multitude of different approaches for sourcing 
compounds to test in the different assay systems, each with their own inherent 
strengths and weaknesses.  The goal of utilizing a given compound collection is to 
identify compounds that can be used to either study a given biological process (typically 
referred to as a tool or probe compound) or as starting points for further optimization 
through medicinal chemistry (typically referred to as a hit).  In the following sections a 
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brief overview of few different types of compound collections will be discussed followed 
by a more extensive overview of systematically arranged mixture-based libraries, 
specifically positional scanning libraries.  The subsequent chapters will detail the use of 
these systematically arranged mixture based libraries in three different assay systems 
targeting broad-spectrum antibiotics, anti-leishmaniasis, and inhibition of auto-
palmitoylation. 
 
Compound Libraries 
The origin of drug discovery traces its historical roots back to sourcing 
compounds directly from nature, with the reported use of opium as an anesthetic dating 
back to the Neolithic Age.  While modern drug discovery still utilizes compounds 
sourced directly from nature, a number of advances in synthetic chemistry over the past 
centuries and especially the past few decades have provided a range of compound 
collections.  One way to subdivide the different collections is by grouping them as 
mixtures or singletons and that is the approach that is taken below.  No matter how one 
distinguishes the different collections they each provide distinct advantages as well as 
challenges.  Below follows a brief overview, including advantages and challenges, for 
some of the more common compound collections utilized in the early stages of modern 
day drug discovery (Table 1.1). 
 
Large Individual Compound Libraries   
While original high throughput screening (HTS) programs utilized natural product 
extracts and dyes, the emergence of large individual compound collections began in 
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earnest in the late 1980s and 1990s ushered in by advances in combinatorial 
chemistry.1,2   The majority of these collections are built out of sourcing compounds 
from combinatorial projects, internal development campaigns, as well as left over 
starting materials and intermediates gathered from a diverse set of research 
laboratories.  The modern day collections utilized by pharmaceutical companies often 
run into the millions of compounds.  The combinatorial nature of these collections allows 
for the generation of a substantial amount of structure activity relationship (SAR) data 
during the initial screening.3 Some of the limitations associated with utilizing these 
collections include the need to miniaturize screening assays, necessity for robotics, 
significant population of “flat”4 and pan-assay interference compounds (PAINs) 
compounds.5 The need to use miniaturized assay volumes restricts the variety of assay 
types available6 while the necessity for robotics often limits the availability of screening 
to those research groups that can afford to build and maintain screening centers.  In 
recent years advancements in HTS technologies such as integration of high content 
screening and use of in vivo models such as zebrafish have allowed for an increased 
breadth in assay types available for use with these large compound collections.7 
Reduction in costs to robotics equipment coupled with pooling of resources through 
dedicated academic screening centers has provided opportunities to more groups.  
Additionally, applying cheminformatics and analyzing previous screening data enables 
the identification and elimination of PAINs compounds and sets of criteria such as 
Lipinski’s rules in order to produce hits that are more amenable for optimization.  
Regardless of the advances made in the compound collections and implementation of 
the collections it is always important to note that even at 1,000,000 compounds this is 
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only a tiny fraction of the >1060 potential molecules containing up to 30 C, N, O, and S 
atoms.8  
 
Fragment-Based Libraries   
Fragment-based libraries are collections of individual compounds with molecular 
weights generally between 100-250 Da.  Typically the compounds in these libraries 
obey the Rule of Three: molecular weight < 300, hydrogen bond donors ≤ 3, hydrogen 
bond acceptors ≤ 3, ClogP ≤ 3, and number of rotatable bonds ≤ 3.9,10 These libraries 
generally contain on the order of ~1,000 members.11 The key advantages of these 
libraries is derived from the relatively small number of compounds needed to screen 
(~1,000 compared to >1 million with large compound collections) as well as the fact that 
the hits are considered more amenable for optimizing orally bioavailable 
therapeutics.11,12 Generally, the hits obtained from screening fragment-based libraries 
have significantly weaker potencies than those obtained through other library 
collections.  However due to the relatively small number of heavy atoms in hits obtained 
from fragment-based libraries the ligand-target based interaction are often of high 
quality.10,12,13 The quality is generally quantified by calculating a compound’s ligand 
efficiency, the pIC50/N where N is the number of heavy atoms in the ligand.14 Ideally the 
3-D binding interactions of the target with the active fragments are determined through 
the use of X-ray crystallography or NMR.  Using this information, the fragments are 
optimized into leads through several methods generally centered around either linking 
together multiple fragments or growing a single fragment.11-13,15 The main drawbacks to 
fragment based libraries revolve around the necessary use of specific assays and 
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equipment that can accurately identify ligands with relatively poor potency (see Chen H, 
et al13 for a recent review of various methods and their associated pros and cons).  
Additionally, if accurate 3-D ligand-target binding information is not available for the hit 
fragments then optimizing the compounds will be extremely challenging.  
 
Focused Libraries   
As biological screening data accumulates for compounds screened in discovery 
programs individual compounds can be annotated and sorted based on biological 
activity profiles.  This information can be utilized to create “target focused libraries” 
based on desired biological activity such as when targeting g-protein-coupled receptors 
(GPCRs) or kinases.  Conversely the information can be utilized to create “biologically 
diverse focused libraries;” this is accomplished by selecting compounds that maximize 
the different biological activity patterns.16 These libraries can contain anywhere from 
one thousand compounds up to hundreds of thousands of compounds.  They have the 
advantage that significant biological data is known about any of the hits identified in the 
new screens.  Depending on the size of the libraries, a range of assay formats from 
moderate to high throughput can be accommodated.  The libraries can be utilized to 
classify biological targets or identify potential targets within a given phenotypic 
screen.17,18  A potential disadvantage to these types of libraries is that the chemical 
space is limited to only previously screened compounds.  Additionally if the library size 
is too numerous this may limit the types of assays that could be utilized. 
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Drug Repurposing or Repositioning   
The use of approved drugs and clinical candidates as a screening collection has 
several key advantages.  Most significantly the compounds in the collection have 
extensive biological data associated with them including safety and pharmacokinetic 
profiles, thus potentially reducing the substantial development cost associated with drug 
development.19,20 Additionally the number of compounds, typically less than 1,000, in 
these collections is often small enough to make screening them against virtually any 
assay format a viable option.  In fact the compounds included in the collection can be 
restricted to include only compounds previously reported to possess activities that are 
desired for the new therapeutic indication.   However there are some drawbacks to 
utilizing collections of these types and they mostly center around a true return on 
investment.  While the development cost associated with utilizing a repurposing strategy 
can be significantly less the patentability of the compounds is often challenging if not 
impossible thus reducing the potential return on investment to the point of 
unprofitable.19,20 Even though the compounds in the collection may not be viable as 
clinical candidates themselves they can be a valuable source for tool compounds in 
order to validate a target or increase understanding of mechanisms of human 
diseases.21   
 
Natural Product Extracts   
Natural products or more specifically the secondary metabolites produced by 
plants, microorganisms, or marine invertebrates were the original sources for drug 
discovery and are still utilized as compound collections today.  Reports of utilizing 
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natural products for therapeutic benefits date back to 2400 B.C.6 The isolation of 
morphine from opium poppy and later discovery of penicillin are the classic cases that 
set the stage for modern drug discovery efforts centered on natural products.  Natural 
product libraries are generally pools of secondary metabolites that have been 
fractionated though some single compound collections are commercially available (such 
as the greater than 25,000 member library available through!AnalytiCon Discovery, 
www.ac-discovery.com) The metabolites are typically more structurally complex and 
diverse than compounds found in traditional large compound collections.  While these 
properties can take them outside the rule of 5 criteria they often retain a high degree of 
bioactivity and are able to cross cell membranes, likely due to the fact they were 
produced by the bio-organism in order to serve a function.6,22 For these reasons they 
have been an extremely valuable source for the development of therapeutic agents with 
studies indicating that 34% of the small molecules approved by the FDA from 1981-
2010 can trace their origins to natural products.23 However, there are several often cited 
limitations to the use of natural product libraries including: challenges in isolating and 
characterizing the active component, difficult to synthetically scale up, source or 
harvest, non-specific toxicity, and ecological/legal constrains.24-25 
  
One-Bead-One-Compound (OBOC) and DNA-Encoded Libraries (DECLs)  
These collections are mixtures of compounds where each compound in the 
mixture is tethered to a specific resin bead (OBOC) or DNA fragment (DECLs).  The 
original OBOC and DEC libraries were peptide libraries but recent libraries have 
branched out into small molecules.26-27 The libraries can contain millions of structural 
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analogs as they are built in a combinatorial fashion.  This enables the cost efficient 
screening of large numbers of structural analogs around a given scaffold template.  The 
OBOC hits are typically identified by employing a tag based assay system that singles 
out molecules that bind to the target; the beads are then removed and the molecules 
released from the beads and analytically identified.26,28 The DEC libraries utilize DNA 
amplification technologies to identify the molecules that bind to the target.29 Since these 
libraries utilize compounds tethered to a resin bead or DNA fragment they are limited to 
use in affinity assays.  Additionally the resin or DNA may artificially restrict binding by 
masking the active site of a given molecule.  In the case of the DECLs the DNA 
fragment may artificially increase binding by increasing the overall solubility of the 
molecule relative to the free molecule.29 The use of OBOCs and DECLs is also limited 
to the chemical space that is synthetically viable with the combinatorial approaches 
employed. 
 
Mass Encoded Libraries   
Mass encoded libraries are pools of compounds where each compound in the 
mixture can be uniquely identified by its mass spectral fragment pattern.30-31 They are 
synthesized in a combinatorial fashion and therefore can provide extensive SAR around 
a given scaffold template.  The compounds are screened in solution and are not 
tethered to a support like OBOC libraries.  However their use is restricted to affinity-
based assays where compounds in a given mixture are separated based on their ability 
to bind to a given target.   
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While not meant to be an exhaustive review the previous sections provide a 
general overview of different types of compound collections utilized in the early stages 
of drug discovery and basic research (Table 1.1).  There are a number of additional 
compound library strategies that were not discussed above including mixture based 
methods such as orthogonal pooling32-33 and phage display libraries (limited to peptides 
and antibodies)34-35 as well as individual compound collections that are assembled 
based on virtual screening results.  As mentioned previously the use of each of the 
different compound collections comes with its own set of strengths and limitations.  In 
the following section a more detailed account will be provided for a specific type of 
mixture based library, namely positional scanning libraries. 
  
Development of Positional Scanning Libraries 
In 1963 Bruce Merrifield described the first use of a technique termed solid phase 
peptide synthesis (SPPS).36 The technique significantly simplified the synthesis of 
peptides and eventually paved the way for his Nobel Prize work involving the synthesis 
of hormones and enzymes.  The use of SPPS has had a far-reaching impact on the 
scientific community and is central to the work presented in this dissertation.  
While the early uses of SPPS allowed researchers the ability to synthesize 
peptides in quantities unprecedented before, the synthesis of >100 individual peptides 
at a time was still too costly for practical consideration.    However in the 1980s with 
inventions such as the Geysen pin,37 SPOT,38 and tea bag method39 which 
compartmentalized the solid support in polypropylene mesh containers (“tea bags”), the 
practical parallel synthesis of peptides became a reality.  These techniques allowed for 
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the synthesis of >100 individual peptides each with >10 residues and each at 10-20mg 
quantities in a matter of weeks rather than months.   While these techniques increased 
the number of peptides that could be practically synthesized, the number was still only a 
tiny fraction of peptides that were theoretically possible.  
In the early 1990s Houghten and colleagues developed methods that allowed 
researchers to synthesize and efficiently screen millions of peptides40,41 in what are 
termed synthetic peptide combinatorial libraries. The 1992 work by Pinilla et al.41 was 
the first to describe the generation and use of a positional scanning peptide library.  This 
N-Acetylated, C-Amide 6-mer peptide library was synthesized using chemical mixtures 
of protected amino acids.42 The use of these reaction mixtures allows one to 
systematically define any of the diversity positions, amino acids in the case of peptides.  
This is a critical feature that enabled expanding the practical use of the libraries.  These 
new positional scanning libraries provided researchers the ability to generate screening 
data on literally millions of peptides using only ~100 samples (Table 1.2). 
In the mid 1990s due to the success of peptide positional scanning libraries a 
push was made to extend the synthesis of positional scanning libraries to scaffolds 
other than peptides.  Initially utilizing the concept of libraries from libraries a 
hexapeptide positional scanning library was permethylated in order to produce the 
permethylated hexapeptide positional scanning library43 (Figure 1.1).  By the early 
2000s the technique of libraries from libraries was expanded to produce small molecule 
heterocyclic positional scanning libraries from peptide-like scaffolds.44,45 Figure 1.2 
depicts several of these small molecule heterocyclic libraries with the core peptide 
backbones indicated in red.  
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In order to provide more detail regarding the use of libraries from libraries the 
synthetic schemes of a group of heterocyclic libraries generated from a single common 
scaffold is shown (Figures 1.3 and 1.4).44,46-47  It should also be noted that these 
particular scaffolds are central to the work discussed in the subsequent chapters.  
Figure 1.3 shows the synthetic scheme that utilizes only simple amide coupling 
reactions in order to introduce three different diversity positions onto a branched 
peptide-like scaffold.  The synthesis employs the use of mBHA resin contained in tea 
bags (1.1, Figure 1.3).  After neutralizing the mBHA resin with 5%DIEA/DCM, 
orthogonally protected Boc-Lys(Fmoc)-OH is coupled using standard coupling 
conditions (6 fold excess amino acid, DIC, and HOBt in 0.1M DMF for 1 hour) (1.2, 
Figure 1.3).  The Fmoc group is selectively removed through the use of piperazine (20% 
piperazine in DMF, 2 x 10 minutes).  Following 3 washes with DMF in order to remove 
excess piperazine, the R1 functionality is incorporated through the use of a carboxylic 
acid, DIC, and HOBt (10 fold excess, 0.1M DMF, 2 hours) (1.3, Figure 1.3).  The Boc 
group is then removed with 55%TFA/DCM (30 min).  Following neutralization with 
5%DIEA/DCM an activated (DIC and HOBt) Boc-protected amino acid is coupled to the 
available free amine (1.4, Figure 1.3).  After the coupling is complete the subsequent 
Boc group is again removed with TFA and the R3 functionality is incorporated utilizing 
the same conditions as those described for R1 (1.5, Figure 1.3).  In this manner only 
amino acids and carboxylic acids are utilized in conjunction with well-established amide 
forming reactions to provide the core scaffold 1.5.  This is a key feature because it 
means that only the reaction ratios for these simple amide forming reactions need to be 
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considered in order to generate a diverse set of heterocyclic positional scanning 
libraries (Figure 1.4).   
Starting from 1.5 a multitude of different scaffolds can be generated such as the 
six different scaffolds (1.6, 1.9-1.14) shown in Figure 1.4.  The amide containing 
scaffold 1.6 can be obtained by removing the compound from the solid support with the 
use of HF and anisole (0 oC, 1.5 hr).  The amides on 1.5 can be reduced through the 
use of Borane-THF (40 fold excess over each amide, 1.0 M, 65 oC, 96 hr), followed by 
piperazine (65 oC, 24 hr), and finally washes with MeOH (1.7).48-49 The branched 
polyamine 1.7 can be removed from the solid support (HF, 0 oC, 1.5 hr) to afford the 
free polyamine 1.10.  Alternatively the branched bis-diketopiperazine scaffold, 1.8, can 
be obtained through the use of oxalyldiimidazole (5 fold excess in 0.1M DMF 24 hr).  
This scaffold can either be removed directly from the solid support (HF, 0 oC, 1.5 hr) to 
afford 1.9 or it can undergo the borane reduction described above and then removed 
from the solid support (HF, 0 oC, 7 hr) to afford the bis-piperazine 1.14.  In a similar 
manner the bis-cyclicguanidine (1.11), bis-cyclicurea (1.12), and bis-cyclicthiourea 
(1.13) can be obtained by treating the polyamine (1.7) with cyanogen bromide (5 fold 
excess 0.1 M DCM), carbonyldiimidazole (5 fold excess 0.1 M DCM), or 
thiocarbonyldiimidazole (5 fold excess 0.1M DCM) respectively followed by HF cleavage 
(0 oC, 1.5 hr). 
 
Synthesis of a Positional Scanning Library 
By way of example utilizing 42 different commercially available carboxylic acids 
for R1 and R3 and 26 different amino acids for R2 a positional scanning library of core 
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peptide like scaffold 1.5 (Figure 1.3) can be made.  This positional scanning library will 
have a total of 45,864 (42 x 26 x 42 = 45,864) individual compounds systematically 
formatted into 110 samples (42 + 26 + 42 = 110).  Starting with 110 separately labeled 
tea bags, each filled with 100mg of mBHA resin (ideally around ~1.0meq loading), the 
bags are all added to one reaction vessel and taken through the steps to afford the resin 
bound orthogonally protected L-Lysine (1.2, Figure 1.3).   
R1 coupling.  After Fmoc deprotection the 110 bags are sorted into different 
reagent vessels.  Bags 1 to 42 are each placed into separate vessels (Table 1.3), bag 1 
goes in the vessel with pre-activated (DIC/HOBt 0.1M DMF) 1-phenyl-1-
cyclopropanecarboxylic acid, bag 2 in the vessel with 2-phenylbutyric acid, etc.  In this 
manner after the coupling is complete bags 1 to 42 each contain a unique R1 
functionality.  Conversely bags 43 to 110 are all added to the same reaction vessel.  
This vessel contains a mixture of the 42 carboxylic acids, signified by an X on Table 1.3.  
The concentration of each carboxylic acid is varied so that an approximately equal 
molar amount of each carboxylic acid reacts with the available free amine.  (The exact 
ratio of each carboxylic acid is proprietary to TPIMS but a detailed method on how ratios 
can be calculated and validated is found in the publication by Giulianotti et al.50).  In this 
way each of the 68 bags, 43-110, have an approximately equal molar amount of 42 
different carboxylic acids coupled to the resin bound acylated lysine (1.3, Figure 1.3).   
R2 coupling.  After the R1 coupling reaction is complete all 110 bags are again 
combined into a single reaction vessel and the Boc protecting group is removed and the 
free amine is neutralized with DIEA.  The bags are once again sorted.  This time bags 
43 to 68 are placed into separate reaction vessels each containing preactivated Boc 
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protected amino acids (Table 1.4).  After the reaction is complete bags 43 to 68 will 
each have a unique single functionality at R2.  However since during the R1 coupling all 
26 of these bags (bags 43 to 68 Table 1.3) were included in the mixture coupling these 
26 bags each now contain 42 compounds of type 1.4 (Figure 1.3).  By way of example 
bag 43 contains an equal molar mixture of the 42 compounds produced by utilizing Boc-
L-Ala at R2 and all 42 different carboxylic acids at R1.  Bag 44 contains an equal molar 
mixture of the 42 compounds produced by utilizing Boc-L-Phe at R2 and all 42 different 
carboxylic acids at R1.  Bags 1-42 and 69-110 are all placed in a reaction vessel that 
contains a mixture of the 26 amino acids.  The concentration of each amino acid is 
varied so that an approximately equal molar amount of each amino acid reacts with the 
available free amine.  After the reaction is complete bags 1-42 contains a unique 
mixture of 26 compounds of type 1.4 (Figure 1.3) while bags 69-110 will each contain 
an equal molar mixture of the same 1,092 compounds of type 1.4.  By way of example 
bag 20 will contain the 26 compounds produced by utilizing butyric acid at R1 (Table 
1.3) and all 26 different amino acids at R2 (Table 1.4). However since bags 69 to 110 
have all been in the R1 and R2 mixture coupling reaction vessels (Tables 1.3 and 1.4 
respectively) they each now contain an equal molar concentration of the 1,092 
compounds produced from using all 42 carboxylic acids in R1 and 26 amino acids in R2. 
R3 Coupling.  After the R2 coupling reaction is complete all 110 bags are again 
combined into a single reaction vessel and the Boc protecting group is removed and the 
free amine is neutralized with DIEA.  The bags are once again sorted.  Bags 69 to 110 
are each placed into separate vessels (Table 1.5); bag 69 goes in the vessel with pre-
activated 1-phenyl-1-cyclopropanecarboxylic acid, bag 70 goes in the 2-phenylbutyric 
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acid vessel, etc.  In this manner after the coupling is complete bags 69 to 110 each 
contain a unique R3 functionality; these bags now each contain a unique mixture of 
1,092 compounds of type 1.5 (Figure 1.3).  By way of example bag 76 contains the 
1,092 compounds produced from using p-tolylacetic acid for the R3 coupling (Table 1.5), 
all 26 amino acids for R2 (Table 1.4) and all 42 carboxylic acids for R1 (Table 1.3).  
Conversely bags 1 to 68 are all added to a common reaction vessel.  This vessel 
contains a mixture of the 42 carboxylic acids (Table 1.5).  The concentration of each 
carboxylic acid is varied so that an approximately equal molar amount of each 
carboxylic acid reacts with the available free amine. After this mixture coupling is 
completed bags 1 to 42 each contain a unique set of 1,092 compounds (1.5, Figure 1.3) 
produced by utilizing a specific R1 reagent (Table 1.3) in combination with all 26 R2 and 
42 R3 reagents (Tables 1.4 and 1.5 respectively); bags 43-68 each contain a unique set 
of 1,764 compounds (1.5, Figure 1.3) produced by utilizing a specific R2 (Table 1.4) 
reagent in combination with all 42 R1 and 42 R3 reagents (Tables 1.3 and 1.5 
respectively).   
The final product of this procedure is the production of 110 separate equal molar 
mixtures. Bags 1-42 have a unique defined functionality at the R1 position, bags 43-68 
at the R2 position, and 69-110 at the R3 position.  It is important to note that if an equal 
molar amount of material is removed from each of bags 1 to 42 and combined the result 
would be an equal molar mixture of all 45,864 individual compounds possible from 
utilizing the 42 R1, 26 R2, and 42 R3 reagents.  The same would be true if an equal 
molar amount of material was taken from bags 43 to 68 and combined or from bags 69 
to 110 and combined.  In other words the same 45,864 individual compounds have 
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been systematically synthesized into three sets of mixtures defined by the given R 
groups. 
The 110 mixtures can now undergo any of the chemical transformations 
illustrated in Figure 1.4.  In this way a series of different non-peptide heterocyclic 
positional scanning libraries can be synthesized by taking advantage of the same 
common amide forming mixture reactions. 
 
Scaffold Ranking Library 
Over the past two decades a number of different positional scanning libraries 
comprised of peptides, peptidomimetics, and small molecules have been synthesized.  
In fact the number of libraries has increased to the point where screening all libraries 
would require the testing of over 10,000 samples.  While screening all the positional 
scanning libraries in a given assay system will provide extensive SAR data it may not be 
practical for a number of low throughput assay systems.51 In order to help prioritize the 
screening of positional scanning libraries the scaffold ranking library was developed.  
Using the same synthetic strategies outlined above a single sample containing all 
45,864 compounds for a given scaffold can be generated either synthetically or by 
mixing together aliquots of the library.   The synthetic version is obtained using an extra 
tea bag (or multiple bags depending on how much material is desired) during the 
synthesis of the library.  The tea bag goes in each of the reagent mixture solutions and 
has no defined positions; it therefore contains all 45,864 compounds.  Alternatively an 
aliquot from each of the 110 final product samples can be combined to generate a 
sample that contains all 45,864 compounds (note: this could also be accomplished by 
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just taking the 42 R1 samples, 26 R2 samples, or 42 R3 samples but it is better practice 
to utilize all R positions).52 In this way a single sample for each of the available 
positional scanning libraries can be generated.  Depending on the throughput of the 
assay the use of the scaffold ranking samples as the first screening collection allows a 
researcher the opportunity to survey a series of different scaffolds in order to identify 
positional scanning libraries that provide likely opportunities for finding hit individual 
compounds (Figure 1.5).  The use of scaffold ranking samples in order to prioritize the 
screening of positional scanning libraries was first verified as a viable approach through 
the use of a µ-opioid radioreceptor binding assay, and it was then subsequently applied 
to an in vivo screening assay for psychiatric indications.52    
 
How Scaffold Ranking and Positional Scanning Libraries Work 
The successful uses of positional scanning libraries have been reported in 
numerous publications (See section below Uses of Positional Scanning Libraries for a 
summary) and have led to at least one current FDA Phase III clinical candidate 
(currently in development by Cara Therapeutics).53 Additionally mathematical models 
developed and validated against historical screening data demonstrate how 
systematically formatted mixtures of close structural analogs can be used to predict 
active individual compounds51,54 Figure 1.6 provides a simplified overview of the 
process for identifying active individual compounds from scaffold ranking and positional 
scanning libraries.  Figure 1.6 Panel A shows the screening results from assaying two 
different scaffold ranking samples.  In this case both scaffold ranking samples contain 
27 compounds generated from utilizing three different functionalities at each diversity 
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position.  Since the triangle scaffold ranking sample contains compounds (in this 
simplified case a single compound, the black triangle) that are more active than the 
circle scaffold the triangle positional scanning library would be prioritized for screening 
over the circle positional scanning library.  At the positional scanning level (Figure 1.6 
Panel B) the 27 triangle compounds are systematically formatted three different ways: 
the first three samples contain the 27 compounds formatted by what is fixed at Position 
1, the second three samples by Position 2, and the last three samples by Position 3.  
The screening data (Figure 1.6 Panel B) shows that the red mixture is the most active of 
the three Position 1 samples, blue for Position 2, and yellow for Position 3.  The reason 
these samples are the most active is because in this simplified model the active triangle 
is only found in the red mixture Position 1 sample, the blue Position 2 sample, and the 
yellow Position 3 sample.  Based on the screening data from the positional scanning 
library the triangle containing a red circle at Position 1, a blue circle at Position 2, and a 
yellow circle at Position 3 would be selected for synthesis and in fact this is the most 
active compound. While this is a simplified example the same concepts hold for the 
more complex mixture-based libraries; the systematic formatting of the mixture samples 
leads to the identification of the individual compounds most likely responsible for the 
activity being measured. 
 
Advantages, Limitations, and Potential Concerns 
Advantages.  The main advantages to using scaffold ranking and positional 
scanning libraries derive from the ability to efficiently screen large numbers of very close 
structural analogs.  The method used to format the libraries allows for the systematic 
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assessment of thousands to millions of analogs through the testing of exponentially 
fewer samples.  This is advantageous when assessing whether a given scaffold is a 
good starting point; rather than testing only one hundred or fewer individual analogs for 
a given scaffold, thousands to millions of analogs can be assessed using fewer than 
one hundred assay pools. This significantly reduces the chance of discarding a 
potentially viable scaffold due to lack of representative analogs. Additionally the 
reduction in sample numbers allows for the use of a wider range of screening platforms 
including assays with very low through-put.  This allows for the utilization of assays that 
have extremely beneficial implications but are too cost or time prohibitive for other 
compound collections (Table 1.1).  In fact by starting with the scaffold ranking library an 
initial assessment of millions of structural analogs covering a wide range of scaffold 
types can be made by screening 80 or fewer samples. 
Limitations.  The synthesis of positional scanning libraries is limited by the 
ability to effectively synthesize near equal molar mixtures of analogs.  This means that 
only reactions in which chemical reaction ratios can be generated are amenable; this 
also means the reactions are limited to solid phase chemistry as to date it is the only 
effective method for controlling the equal molar synthesis of mixtures of compounds. 
Additionally all R group functionalities have to be amenable to any chemistry 
transformations that take place after they are included.  However even with these 
limitations the technology is amenable to the synthesis of peptides, cyclic peptides, 
peptoids, and many heterocyclic small molecules.   
Potential Concerns.  The main concerns associated with the use of these 
mixture-based libraries are similar concerns expressed when using other mixture-based 
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libraries such as natural products.  These concerns center on whether or not it is 
possible to find a single active compound diluted in a large mixture of inactive 
compounds as well as if a mixture contains agonists and antagonists or synergistic 
compounds.  Synthetic mixture-based libraries such as positional scanning libraries are 
collections of very close structural analogs and since compounds that are close 
structural analogs have an increased chance of having similar activities it is unlikely that 
only a single compound in a given mixture of more than hundreds to thousands of 
compounds will be active.   The mathematical limits associated with utilizing mixtures of 
compounds have been previously reported.51,54 While it is true that structurally similar 
compounds can be agonists and antagonists or behave in synergistic ways the use of 
positional scanning libraries enables the identification of these effects as well as 
potential solutions.  For example, since a given positional scanning library is actually the 
same collection of compounds formatted multiple ways (three different sets when there 
are 3 R groups, 4 different sets when 4 R groups, etc.) the distribution of activity across 
all the different formats should be even.  In other words the harmonic mean of the 
activity of the samples where R1 is defined should be approximately the same as the 
harmonic mean of the samples where any of the other R groups are defined.54 If this is 
not the case it either indicates a problem with the screening or an indication of some 
sort of agonist/antagonist or synergistic effect.  If it is not a screening problem then an 
iterative approach to deconvoluting the library40 can be applied to separate out 
agonist/antagonist and/or synergist compounds. 
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Reported Uses of Positional Scanning Libraries 
Since the inception of positional scanning libraries there have been numerous 
published reports on their successful use in a range of assays.  In 199955, 200356, and 
again in 200852 summaries of published results were reported.  Since 2008 positional 
scanning libraries have continued to be utilized in a variety of assays by a significant 
number of research groups as evidenced by the greater than 100 publications that have 
appeared in the past 7 years (Table 1.6). A large number of the publications over this 
recent period have reported the use of positional scanning libraries in substrate 
specificity studies.   These substrate studies, which include the use of fluorescently 
labeled libraries,57-58 capitalize on the fact that literally trillions of peptides can be 
assessed through the use of just a couple hundred systematically arranged mixtures.  In 
addition to the numerous binding assay formats reported in Table 1.6, in 2013 Pinilla et 
al.59 compared and contrasted results obtained from utilizing different compound 
collections including positional scanning libraries for the identification of formyl peptide 
receptor ligands. Small molecule and peptide positional scanning libraries have also 
been utilized in a number of functional assays such as for activators of methionine 
sulfoxide reductase A and B,60 inducers of oncogenic domains,61 and melanocortin 
agonists.62 The positional scanning libraries have found utility in phenotypic screening 
assay formats such as those designed to find novel antibacterial,63,47 antimalarial,64 and 
antinociceptive compounds.65-66 Recently the use of the scaffold ranking method as a 
first step in the screening process has been utilized in a number of published reports 
(Table 1.6, “scaffold” under the first column).  Following in this recent development of 
utilizing a scaffold ranking library as a first step in the screening process, the remaining 
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three chapters in this dissertation describe in detail its use in three different screening 
campaigns.  These chapters summarize the results from using scaffold ranking and 
positional scanning libraries to develop hit compound series for antibacterial, anti-
leishmaniasis, and auto-palmitoylation programs.   
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Tables 
 
Table 1.1. Different Compound Collections. 
 
 Total # of Compounds 
Total # of 
Samples 
Total # of 
Scaffolds SAR 
Assay 
Amenability 
Large 
Individual  +++ +++ +++ ++ + 
Fragment 
Based ++ ++ ++ + ++ 
Focused 
Libraries ++ ++ ++ + +++ 
Drug 
Repurposing + + ++ + +++ 
Natural 
Product ++ ++ ++ + ++ 
OBOC 
DECLs +++ + + +++ + 
Mass 
Encoded ++ + ++ ++ + 
Positional 
Scanning +++ + + +++ +++ 
 
The different compound collections discussed each utilize specific approaches that effect factors such as 
the total # of compounds, samples and scaffolds tested as well as the amount of SAR generated and 
assay amenability.  The table above indicates + for a relatively low amount, ++ for a moderate amount, 
and +++ for a relatively high amount.  By example Large Individual Compound Collections have a relatively 
high total # of compounds, samples to test, and scaffolds versus the other collections but have relatively 
low assay amenability as compared to Drug Repurposing Libraries.   
 
Table 1.2. Total Number of Peptides. 
 
Peptide 
Library Length 
Total # of 
Peptides 
Total # of 
Samples 
Dipeptide  400 40 
Tripeptide 8,000 60 
Tetrapeptide 160,000 80 
Pentapeptide 3,200,000 100 
Hexapeptide 6.4x107 120 
Heptapeptide 1.28x109 140 
Octapeptide 2.56x1010 160 
Nonapeptide 5.12x1011 180 
Decapeptide 1.02x1013 200 
 
Utilizing only the 20 natural amino acids the number of total peptides increases exponentially as the 
length of the peptide increases. However the total number of samples needed to test by positional 
scanning increases additively.   
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Table 1.3. R1 Position Carboxylic Acid Coupling 
 
R1 Position 
Bag # Carboxylic Acid 
1   1-Phenyl-1-cyclopropanecarboxylic acid 
2   2-Phenylbutyric acid 
3   3-Phenylbutyric acid 
4  m-Tolylacetic acid 
5   3-Fluorophenylacetic acid 
6   3-Bromophenylacetic acid 
7   (α-α-α-Trifluoro-m-tolyl) acetic acid 
8  p-Tolylacetic acid 
9   4-Fluorophenylacetic acid 
10   3-Methoxyphenylacetic acid 
11   4-Bromophenylacetic acid 
12   4-Methoxyphenylacetic acid 
13   4-Ethoxyphenylacetic acid 
14   4-Isobutyl-α-methylphenylacetic acid 
15   3,4-Dichlorophenylacetic acid 
16   3,5-Bis(trifluoromethyl)-phenylacetic acid 
17   3-(3,4-Dimethoxyphenyl)-propionic acid 
18  Phenylacetic acid 
19   3,4,5-Trimethoxybenzoic acid 
20  Butyric acid 
21  Heptanoic acid 
22  Isobutyric acid 
23  2-Methylbutyric acid 
24  Isovaleric acid 
25   3-Methylvaleric acid 
26   4-Methylvaleric acid 
27 p-Toluic acid 
28 Cyclopentanecarboxylic acid 
29 Cyclohexanecarboxylic acid 
30 Cyclohexylacetic acid 
31 Cyclohexanebutyric acid 
32 Cycloheptanecarboxylic acid 
33 2-Methylcyclopropanecarboxylic acid 
34 Cyclobutanecarboxylic acid 
35 3-Cyclopentylpropionic acid 
36 Cyclohexanepropionic acid 
37 4-Methyl-1-cyclohexanecarboxylic acid 
38 4-tert-Butyl-cyclohexanecarboxylic acid 
39  4-Biphenylacetic acid 
40 1-Adamantanecarboxylic acid 
41 1-Adamantaneacetic acid 
42 2-Norbornaneacetic acid 
43-110 X 
 
X signifies an equal molar mixture of all 42 different carboxylic acids. 
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Table 1.4. R2 Position Amino Acid Coupling 
 
R2 Position 
Bag # Amino Acid 
1-42 X 
43  Boc-L-Ala 
44  Boc-L-Phe 
45  Boc-Gly 
46  Boc-L-Ile 
47  Boc-L-Leu 
48  Boc-L-Ser(Bzl) 
49  Boc-L-Thr(Bzl) 
50  Boc-L-Val 
51  Boc-L-Tyr(BrZ) 
52  Boc-D-Ala 
53  Boc-D-Phe 
54  Boc-D-Ile 
55  Boc-D-Leu 
56  Boc-D-Ser(Bzl) 
57  Boc-D-Thr(Bzl) 
58  Boc-D-Val 
59  Boc-D-Tyr(BrZ) 
60  Boc-L-Phenylglycine 
61  Boc-L-Norvaline 
62  Boc-D-Norvaline 
63  Boc-L-Norleucine 
64  Boc-D-Norleucine 
65  Boc-L-Naphthylalanine 
66  Boc-D-Naphthylalanine 
67  Boc-L-Cyclohexylalanine 
68 Boc-D-Cyclohexylalanine 
69-110 X 
 
X signifies an equal molar mixture of all 26 different amino acids. 
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Table 1.5. R3 Position Carboxylic Acid Coupling 
 
R3 Position 
Bag # Carboxylic Acid 
1-68 X 
69   1-Phenyl-1-cyclopropanecarboxylic acid 
70   2-Phenylbutyric acid 
71   3-Phenylbutyric acid 
72  m-Tolylacetic acid 
73   3-Fluorophenylacetic acid 
74   3-Bromophenylacetic acid 
75   (α-α-α-Trifluoro-m-tolyl) acetic acid 
76  p-Tolylacetic acid 
77   4-Fluorophenylacetic acid 
78   3-Methoxyphenylacetic acid 
79   4-Bromophenylacetic acid 
80   4-Methoxyphenylacetic acid 
81   4-Ethoxyphenylacetic acid 
82   4-Isobutyl-α-methylphenylacetic acid 
83   3,4-Dichlorophenylacetic acid 
84   3,5-Bis(Trifluoromethyl)-phenylacetic acid 
85   3-(3,4-Dimethoxyphenyl)-propionic acid 
86  Phenylacetic acid 
87   3,4,5-Trimethoxybenzoic acid 
88  Butyric acid 
89  Heptanoic acid 
90  Isobutyric acid 
91  2-Methylbutyric acid 
92  Isovaleric acid 
93   3-Methylvaleric acid 
94   4-Methylvaleric acid 
95  p-Toluic acid 
96  Cyclopentanecarboxylic acid 
97  Cyclohexanecarboxylic acid 
98  Cyclohexylacetic acid 
99  Cyclohexanebutyric acid 
100  Cycloheptanecarboxylic acid 
101  2-Methylcyclopropanecarboxylic acid 
102  Cyclobutanecarboxylic acid 
103  3-Cyclopentylpropionic acid 
104  Cyclohexanepropionic acid 
105  4-Methyl-1-cyclohexanecarboxylic acid 
106  4-tert-Butyl-cyclohexanecarboxylic acid 
107   4-Biphenylacetic acid 
108  1-Adamantanecarboxylic acid 
109  1-Adamantaneacetic acid 
110  2-Norbornaneacetic cid 
 
X signifies an equal molar mixture of all 42 different carboxylic acids. 
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Table 1.6. Publications Utilizing Positional Scanning Libraries Since 2008a 
 
Started 
Screeningb  
Scaffold 
Typec 
Assay Objectived Contact 
Affiliatione 
scaffold small 
molecule 
Antinociception65 TPIMS 
scaffold small 
molecule 
Inhibitors of Human As(III) S-
Adenosylmethionine Methyltransferase67  
FIU 
scaffold cyclic 
peptide 
Antibacterial Activity63 TPIMS 
scaffold cyclic 
peptide 
Activators of Methionine Sulfoxide 
Reductases A and B60 
FAU 
positional peptoid Inducers of Apoptosis that Target 
Karyopherins and Tubulin68 
Max-Planck 
positional peptide Peptide Binding Motif for the Common 
Equine Leukocyte Antigen69 
LIAI 
positional peptoid Substrate Specificity (Oryza sativa) 
Phytaspase70,57 
WUT 
positional peptide Biochemical Characterization of FIKK871 UT 
scaffold small 
molecule 
Broad Spectrum Antimicrobials47 USF 
positional peptide Brain-derived Neurotrophic Factor 
Modulators72,73 
SU 
positional peptide α1-Antitrypsin (AT) Deficiency74 NCCU 
positional peptide Melanocortin Agonists62 UMN 
positional peptide Define Caspase Substrate Specificity75 WUT 
positional peptide Peptide-binding Specificities of HLA-C76 UC 
positional peptide Binding Specificities of Bovine Leucocyte 
Class I Molecules77 
UC 
positional cyclic 
peptide 
Nicotinic Acetylcholine Receptor (nAChR) 
Selective Compounds78 
TPIMS 
positional peptide Human Nonreceptor Tyrosine Kinase 
Specificity79 
YU 
scaffold small 
molecule 
Activity Modulators for GTPases80 UNM 
scaffold small 
molecule 
Melanoma M14 Cell Line Viability81 TPIMS 
positional small 
molecule 
Formyl Peptide Receptor Ligands51,59,82  TPIMS and 
UNM 
positional peptide Dissecting the Active Site of the 
Collagenolytic Cathepsin L3 Protease83 
UDELAR 
positional peptide Cross-reactivity Footprints of HIV-1-
specific CD8+ T Cells84  
KU 
scaffold small 
molecule 
Nicotinic Acetylcholine Receptor (nAChR) 
Selective Compounds85 
TPIMS 
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Table 1.6 (cont). Publications Utilizing Positional Scanning Libraries Since 2008a 
 
Started 
Screeningb  
Scaffold 
Typec 
Assay Objectived Contact 
Affiliatione 
positional cyclic 
peptide 
Nicotinic Acetylcholine Receptor (nAChR) 
Potency and Selectivity86 
UU 
positional cyclic 
peptide 
Antinociception87 TPIMS 
positional peptide Preference for a Priming Phosphorylated 
Tyrosine88 
Harvard 
positional peptide Substrate Specificity of MarP89 UCSF 
positional peptide TCR/peptide-MHCI Engagement90 CUSM 
scaffold peptide Inhibitors of Protein-Protein Interactions 
(NMR)91 
SBMRI 
positional peptide Quantitative Measurement of the Capacity 
of Peptide Ligands to Bind Class I and 
Class II MHC molecules92 
LIAI 
positional peptide Peptide-binding Specificity of Swine 
Leukocyte Antigen93 
USDA 
positional peptide Beryllium-dependent Peptides94 UCO 
positional small 
molecule 
Antimalarial Activity64 TPIMS 
positional peptide Angiotensin I-converting Enzyme N-domain 
Selectivity95 
UFSP 
scaffold small 
molecule 
Inhibition of A Disintegrin And 
Metalloprotease proteases96 
TPIMS 
positional peptide Agonists for FPR1 and FPR297 SU 
positional peptide Substrate specificity of Staphylococcus 
aureus Cysteine Proteases--Staphopains 
A, B and C98 
JU 
positional peptide Proprotein Convertases (PCs) specific 
inhibitors99 
 
US 
positional peptide Identify Peptides Recognized by MAbs and 
T Cells100 
TPIMS 
scaffold small 
molecule 
Inhibit Functional Excisive Recombination 
Pathway101 
SDSU 
positional peptide Substrate-specificity Requirements of 
PCTAIRE-1 Kinase102 
UD 
positional peptide Identifying Independent Substrates for 
IKKα and IKKβ103 
CWRUSM 
positional peptide Assess the Potential Contribution of DR2a 
to Disease Etiology104 
UBC 
positional peptide Identification of Immunoprevalent 
Antigens105 
TPIMS 
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Table 1.6 (cont). Publications Utilizing Positional Scanning Libraries Since 2008a 
 
Started 
Screeningb  
Scaffold 
Typec 
Assay Objectived Contact 
Affiliatione 
positional peptide Mucosa-associated Lymphoid Tissue 
Lymphoma Translocation Protein 1 
Specificity106 
SBMRI 
positional cyclic 
peptide 
Mu Opioid Binding107 TPIMS 
scaffold small 
molecule 
Activation of PML Oncogenic Domains61 SBMRI 
positional peptide Inhibitors of Proprotein Convertases108 UMB 
positional peptide Peptide-binding Motifs for the Porcine 
Major Histocompatibility Complex109 
UC 
positional peptide Characterization of a Small Ubiquitin-
Related Modifier (SUMO) Deconjugating 
Protease110 
SUSM 
positional peptide Biochemical Characterization of 
Plasmodium Falciparum Dipeptidyl 
Aminopeptidase 1111 
VPISU 
positional small 
molecule 
Inhibitors of Prohormone Convertase 2 
112 
UMB 
positional peptide Characterize Peptide Binding of MHC 
Class I Allele Mamu-*07 During 
SIVmac239 Infection113 
UW 
positional peptide Suppress CUG-induced Lethality in 
Drosophila114 
UV 
positional peptide Cytotoxic Lymphocyte Protease GrM 
(Granzyme M) Cleavage115 
UMCU 
positional peptide Context-Dependent Mitotic Signaling116 MIT 
positional peptide Determining Substrate Specificity of C-
Terminal Src Kinase-homologous 
Kinase117 
UM-A 
positional peptide Reporter Peptide Substrates for MS-based 
Protease Profiling118 
UHM 
positional peptide Characterized the Primary Sequence Motif 
Specificity of mTOR119 
MIT 
positional peptide Antagonists of Protein Enriched in 
Diabetes ⁄ Phosphoprotein Enriched in 
Astrocytes15120 
UNINA 
positional peptide High Affinity Binding to HLA-DQ2.5121 OUHR 
positional peptide Characterize the Chinese Rhesus 
Macaques’ MHC122 
LIAI 
positional peptide Activate YAe62 CD8+ T Cells from MHCII– 
Mice123 
NJH 
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Table 1.6 (cont). Publications Utilizing Positional Scanning Libraries Since 2008a 
 
Started 
Screeningb  
Scaffold 
Typec 
Assay Objectived Contact 
Affiliatione 
positional peptide Assessment of the Preferences for the 
Amino Acid Residues Flanking Archaeal N-
linked Glycosylation Sites124 
KU 
positional peptoid High-Throughput Profiling of Cellular 
Events125 
NUS 
positional peptide Identification of Immunoprevalent 
Antigens126 
TPIMS 
scaffold small 
molecule 
Antinociception66 TPIMS 
positional peptide Characterize the Chinese Rhesus 
Macaques’ MHC127 
CSUSM 
positional peptide T Cell Cross-Reactivity128 CSUSM 
scaffold small 
molecule 
Inhibitors of Lambda Site-specific 
Recombination and Bind Holliday 
Junction101 
SDSU 
positional peptide Determine Preferred Tetrapeptide 
Sequence Recognized by Autophagin-
1/Atg4B129 
SBMRI 
positional peptide Binding Predictions for HLA DR, DP and 
DQ molecules130 
LIAI 
positional peptide Probing Substrate Specificity of 
Proteases131 
SBMRI 
positional peptide Specificity and Activity of the Wildtype 
Caspase-10132 
SBMRI 
positional peptide Protein Kinase Specificity133 YU and 
SUSM 
positional peptide Protein Kinase Specificity134 UG 
positional peptide Protein Kinase Specificity135 YU 
positional peptide Agonists of the Glucagon-Like Peptide-1 
Receptor136 
BMRSD 
positional peptide Design High Affinity Binders to Human 
Leukocyte Antigen (HLA)-DQ2137 
OUHR 
positional peptide Identify Consensus Sequences for Type-II 
Transmembrane Serine Proteases138 
UEA 
positional peptide Proliferative Response of TCC MN27139 NIH 
positional peptoid Inhibitors of Trypsin140 IQAC 
positional peptide Cleavage Preference for Caspase-3141 KRIBB 
positional peptide Substrate Specificity of Dipeptidyl 
Carboxypeptidase from Escherichia coli142 
UFSP 
positional peptide Substrate Specificity for SmCL3, a 
Gastrodermal Cysteine Protease143 
UCSF 
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Table 1.6 (cont). Publications Utilizing Positional Scanning Libraries Since 2008a 
 
Started 
Screeningb  
Scaffold 
Typec 
Assay Objectived Contact 
Affiliatione 
positional peptide Determine the Optimal Phosphorylation 
Motif for IKKepsilon144 
HMS 
positional small 
molecule 
Affinity for Mu- and Kappa-opioid 
Receptors145 
TPIMS 
positional peptide Ligands for the Cancer-specific Receptor 
Mutation EFGRvIII146 
UC 
positional peptide Determining the Preferred Substrate 
Cleavage Sequence of Proteases147 
UCSF 
positional peptide Inhibit the Growth of a Variety of Bacteria 
and Unicellular Fungi148 
AU 
positional peptide Substrate Specificities of the V266E Mutant 
of Caspase-3149 
NCSU 
positional small 
molecule 
Melanin-concentrating Hormone Ligands112 UCI 
 
positional peptide Agonists of Murine Endothelial Cells (MS-1 
cells)150 
SI 
positional peptide Substrate Specificity151 UCSF 
positional peptide C-terminal Recognition Region of Ubiquitin 
by DUBs58 
SBIMR 
positional peptide Integrin alpha5beta1 Antagonists152 HU 
positional peptide Substrate Specificity Profile of T. foetus 
CP8153 
SUNY 
positional small 
molecule 
Affinity for Kappa-opioid Receptor154 TPIMS 
positional peptide MHC Class I-Restricted Antigens Relevant 
to Autoimmune Diabetes155 
AECM 
positional peptide Binding Specificity of Class I MHC 
Molecules156 
LIAI 
positional peptide Define Sequence Preference for 
Drosophila Nedd2-like Caspase 
(DRONC)157 
SBMRI 
positional peptide Substrate Specificity of the Integral 
Membrane Protease Plasminogen 
Activator158 
UTMB 
 
a. Only publications dated after the last positional scanning library summary are 
reported.  The last positional scanning library summary was in 2008 Houghten et al. 
b. Started Screening indicates whether the reported results were obtained by starting 
directly with a specific positional scanning library, “positional,” or if a scaffold ranking 
library, “scaffold,” was utilized as first step prior to selecting a specific positional 
scanning library. 
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c. The general chemical nature of the library is reported as, peptide, peptoid, cyclic 
peptide, or small molecule. 
d. A general description of the primary assay objective for the positional scanning library 
is given for each published report. 
e. The affiliation of the corresponding author(s) is provided utilizing the following 
acronyms and abbreviations, TPIMS: Torrey Pines Institute for Molecular Studies; FIU: 
Florida International University; Max-Planck: Max-Planck-Institut für Molekulare 
Physiologie; LIAI: La Jolla Institute for Allergy and Immunology; WUT: Wroclaw 
University of Technology; UT: University of Toronto; USF: University of South Florida; 
SU: Sungkyunkwan University; NCCU: National Chung Cheng University; UMN: 
University of Minnesota; UNM: University of New Mexico; UC: University of 
Copenhagen; YU: Yale University; UDELAR: Universidad de la República; KU: 
Kumamoto University; UU: University of Utah; UCSF: University of California, San 
Francisco; CUSM: Cardiff University School of Medicine; SBMRI: Sanford-Burnham 
Medical Research Institute; USDA: United States Department of Agriculture; UCO: 
University of Colorado; UFSP: Universidade Federal de São Paulo; JU: Jagiellonian 
University; US: Universitéde Sherbrooke; SDSU: San Diego State University; UD: 
University of Dundee; CWRUSM: Case Western Reserve University School of 
Medicine; UBC: University of British Columbia; UMB: University of Maryland-Baltimore; 
SUSM: Stanford University School of Medicine; VPISU: Virginia Polytechnic Institute 
and State University; UW: University of Wisconsin; UV: University of Valencia; UMCU: 
University Medical Center Utrecht; MIT: Massachusetts Institute of Technology; UM-A: 
University of Melbourne, Australia; UHM: University Hospital Mannheim; UNINA: 
University of Naples Federico II; OUHR: Oslo University Hospital-Rikshospitalet; NJH: 
National Jewish Health; KU: Kyushu University; NUS: National University of Singapore; 
CSUSM: California State University, San Marcos; UG: University of Gothenburg; 
BMSRD: Bristol-Myers Squibb Research & Development; UEA: University of East 
Anglia; NIH: National Institutes of Health; IQAC: Instituto de Química Avançada de 
Catalunya; KRIBB: Korea Research Institute of Bioscience and Biotechnology; HMS: 
Harvard Medical School; AU: Ajou University; NCSU: North Carolina State University; 
UCI: University of California, Irvine; SI: SIGMOL Inc.; HU: Hoseo University; SUNY: 
SUNY Upstate Medical University; AECM: Albert Einstein College of Medicine; UTMB: 
The University of Texas Medical Branch 
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Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1. Initial Libraries From Libraries. 
 
Utilizing the concept of libraries from libraries a hexapeptide positional scanning library 
was permethylated in order to produce the permethylated hexapeptide positional 
scanning library.56   
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Figure 1.2. Small Molecule Heterocyclic Libraries From Libraries. 
 
Utilizing the concept of libraries from libraries small molecule heterocyclic libraries can 
be generated from peptides.  The original core peptide backbones are indicated in red.   
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Figure 1.3. Synthesis of Peptide Like Scaffold Utilizing Only Amide Coupling Reactions. 
 
a) 5%DIEA/DCM b) Fmoc-Lys(Boc), DIC, HOBt, DMF c) 20%Piperidine/DMF d) R1-
COOH, DIC, HOBt, DMF e) 55% TFA/DCM; 5% DIEA/DCM f) Boc-AA(R2)-OH, DIC, 
HOBt, DMF g) R3-COOH, DIC, HOBt, DMF.   
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Figure 1.4. Libraries From Libraries – Synthesis of Multiple Heterocyclic Scaffolds From 
a Common Peptide Like Scaffold. 
 
a) HF 0oC 1.5hr b) Borane-THF 65 oC 96 hr; Piperazine 65 oC, 24 hr c) HF 0 oC 7hr d) 
Oxalyldiimidazole, DMF e) Cyanogen bromide, DCM f) Carbonyldiimidazole, DMF g) 
Thiocarbonyldiimidazole, DCM.   
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Figure 1.5. Individual Compounds, Positional Scanning Libraries, and Scaffold Ranking 
Library. 
 
Utilizing the synthetic scheme described in Figure 1.3 and 1.4 and the reagents listed in 
Tables 1.3, 1.4, and 1.5 45,864 different individual compounds can be made for each of 
the 6 scaffolds 1.9-1.14.  In order to test all these compounds as singletons 275,184 
individual samples would need to be screened.  The same set of compounds can be 
systematically formatted into positional scanning libraries. Each scaffold is screened by 
testing 110 samples, a significant reduction in samples from singleton screening.  In 
order to further reduce the number of samples needed to test one can start by 
screening the scaffold ranking samples.  Each of these 6 samples contains all 45,864 
compounds of a given scaffold type.  The information from the scaffold ranking screen 
can be used to prioritize the screening of the positional scanning libraries. 
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110 x 6  = 660  
1 x 6  = 6 
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Figure 1.6.  A Simplified Example. 
 
Figure originally found in Santos, et al.66 
 
 
 
 
Position 1 Position 2 Position 3 
A) Scaffold Ranking  
B) Positional Scanning Library  
C) Active Individual Compound  
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CHAPTER TWO: 
SYSTEMATICALLY FORMATTED MIXTURE BASED LIBRARIES – ESKAPE 
PATHOGENS 
 
Introduction 
Currently in United States health care settings there are more than 2 million 
infections a year caused by bacterial pathogens resulting in approximately 100,000 
deaths.1 These infections are typically caused by extreme drug resistant/pan-drug 
resistant pathogens.2 However the last couple of decades have seen a reduction in the 
number of new therapeutics approved to combat these pathogens.   As a result of 
declining new antibacterial approvals and rising antibiotic resistance, society clearly 
needs new treatments for bacterial infections.2  
The six bacterial species Enterococcus faecium, Staphylococcus aureus, 
Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and 
Enterobacter cloace collectively termed the ESKAPE pathogens account for 
approximately two-thirds of all US nosocomial infections.3 In conjunction with Dr. 
Lindsey Shaw’s group systematically arranged mixture based libraries were utilized for 
the identification of a novel set of broad spectrum antibacterial compounds.  The 
following chapter details the process and results of this study. 
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  Starting from a scaffold ranking library a bis-cyclic guanidine scaffold was 
identified as a scaffold likely to provide individual compounds with potency against both 
Gram-negative and positive organisms.  After screening a positional scanning library a 
SAR profile was developed around the bis-cyclic guanidine scaffold.  This data led to 
the synthesis of 27 individual compounds predicted to possess potent activity against 
the ESKAPE pathogens.  In addition to the 27 predicted potent compounds a control set 
of analog bis-cyclic guanidine predicted to be less potent were also screened.   After 
confirming the predicted activities a sub-set of the 27 potent antibacterial compounds 
were selected for further testing in the lab of Dr. Lindsey Shaw. 
 
Scaffold Ranking 
In order to prioritize the screening of the 37 different small molecule positional 
scanning libraries, a scaffold ranking library was assembled (Table 2.1).  The 37 
different positional scanning libraries contain over 5 million individual compounds 
formatted into 5,336 systematically arranged mixtures.  However, utilizing a scaffold 
ranking approach, the 37 different positional scanning libraries can undergo a 
preliminary assessment for broad-spectrum antibacterial activity by screening just 37 
mixture samples.  Each of the 37 mixture samples contains an equal molar mixture of 
every compound available for a given scaffold.  For example, the scaffold ranking 
sample for positional scanning library Lib1 contains an equal molar mixture of 45,864 
individual bis-cyclic guanidine analogs (Table 2.1).  As described in Chapter 1 and 
elsewhere4,5 these scaffold ranking samples can be prepared as synthetic mixtures or 
by pooling together aliquots of each sample in a given positional scanning library. 
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The 37 scaffold ranking samples were screened for broad-spectrum antimicrobial 
activity against the six ESKAPE pathogens using a microbroth dilution assay (Table 
2.1).  Of the 37 scaffold ranking samples tested, 26 of the samples inhibited at least one 
pathogen at a concentration of 100 µg/mL or less.  The Lib1 scaffold ranking sample 
produced the most potent broad-spectrum antimicrobial activity inhibiting Gram-positive 
E. faecium and S. aureus as well as Gram-negative A. baumannii and E. cloacae down 
to 5 µg/mL. 
The Lib1 positional scanning library is part of a group of positional scanning 
libraries that were synthesized from the same starting peptide-like library (Figure 2.1).  
This libraries from libraries approach6 enables the evaluation of different core scaffolds 
generated from the same reagents in the R1, R2, and R3 position (See Chapter 1 for 
more detail on “libraries from libraries”).  The five different scaffold ranking samples 
Lib1, Lib3, Lib7, Lib12, and Lib23 each contain a unique equal molar mixture of 
45,864 compounds based on the core scaffold (Table 2.2).  In this manner a preliminary 
structure activity relationship (SAR) analysis can be conducted.  The data shows that 
the dicationic bis-cyclic guanidine scaffold ranking sample Lib1 has more potent broad 
spectrum activity than the less basic bis-piperazine scaffold sample Lib3.  Following a 
similar trend, the neutral bis-diketopiperazine scaffold Lib23 has no Gram-negative 
activity (up to 100 µg/mL) and very limited Gram-positive activity   The flexible 
polyamine scaffold sample Lib7 is very effective against Gram-positive and Gram-
negative pathogens at the higher doses but rapidly loses activity against all the Gram-
negative pathogens as the dosage decreases.   A similar SAR trend was observed for a 
slightly different set of scaffold ranking samples (Figure 2.2 and Table 2.3).  The bis-
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guanidine (Lib2), bis-piperazine (Lib6) and polyamine (Lib10) scaffold ranking samples 
all had broad-spectrum antimicrobial activity at the highest dose of 100 µg/mL, with the 
polyamine scaffold ranking sample inhibiting all six ESKAPE pathogens.  The bis-
guanidine Lib2 and bis-piperazine Lib6 scaffold ranking samples maintained potency 
against Gram-positive S. aureus and Gram-negative A. baumannii pathogens down to 
10 µg/mL.  Again the scaffold ranking sample containing the diketopiperazines had the 
least inhibitory activity of the set. 
While the Lib1 bis-cyclic guanidine scaffold ranking sample showed the most 
promise for identifying broad spectrum antimicrobial compounds, it was important to 
determine if the activity was being driven by specific compounds in the mixture or if it 
was due to the bis-cyclic guanidine scaffold motif in general.  In order to determine this, 
a positional scanning library of bis-cyclic guanidines was assembled and tested for 
broad-spectrum antimicrobial activity against the six ESKAPE pathogens using a 
microbroth dilution assay. 
 
Positional Scanning 
Positional scanning library Lib1 was synthesized using the synthesis scheme 
shown in Figure 2.1 as well as Chapter 1 (Figures 1.3 and 1.4) and elsewhere.5,7  As 
described in Chapter 1, 110 different mixture samples were synthesized using the 
reagents listed in Table 1.3, 1.4, and 1.5.  After the synthesis was completed, 110 
different mixture samples of bis-cyclic guanidine analogs are obtained (Table 2.4, 2.5, 
and 2.5).   
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The first 42 samples, Table 2.4, were systematically formatted by R1 functionality.  
For example sample Lib1.020 contains the 1,092 bis-cyclic guanidines that have a butyl 
in the R1 position.  The 1,092 compounds come from the combination of 26 different R2 
functionalities and 42 different R3 functionalities (26 x 42 = 1,092).  Similarly sample 
Lib1.021 contained the 1,092 bis-cyclic guanidines that have a heptyl in the R1 position.  
In total each of the first 42 samples (Lib1.001 to Lib1.042) contained a unique set of 
1,092 analogs organized by their R1 functionality.  In this way the 45,864 bis-cyclic 
guanidine analogs contained in the Lib1 scaffold ranking sample were systematically 
arranged into 42 samples by R1 functionality (42 x 1,092 = 45,864). 
The next set of 26 samples, Table 2.5, were systematically formatted by R2 
functionality.  For example sample Lib1.043 contained all 1,764 (42 R1 x 42 R3 = 1,764) 
bis-cyclic guanidines that have S-methyl in the R2 position and sample Lib1.044 
contained all 1,764 analogs that have S-benzyl fixed in the R2 position.  In this way the 
entire set of 45,864 bis-cyclic guanidines were formatted by R2 functionality into 26 
mixtures each containing 1,764 compounds. 
Finally the last set of 42 samples, Table 2.6, were formatted by R3 functionality.  
Each sample contains 1,092 analogs uniquely fixed with a given R3 functionality.  In 
total the 110 samples (Tables 2.4, 2.5, 2.6) contained all 45,864 bis-cyclic guanidines 
formatted three separate ways. 
The 110 bis-cyclic guanidine positional scanning library samples were screened 
for broad-spectrum antimicrobial activity against the six ESKAPE pathogens using a 
microbroth dilution assay (Tables 2.4, 2.5, 2.6).  The samples show significant 
differences in the ability to inhibit the growth of the different pathogens.  For example, 
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while sample Lib1.020 demonstrated only a modest inhibitory effect (10-25 µg/mL) 
against only one pathogen (E. faecium) sample Lib1.041 demonstrated potent broad-
spectrum antimicrobial activity.  These differences in activity indicate that the different R 
group functionalities are critical to the activity of individual bis-cyclic guanidine 
compounds.  If the core scaffold were solely responsible for the activity then every 
sample in the positional scanning library would produce very similar potency against 
each of the pathogens.   
Examining the positional scanning library data leads to the identification of some 
SAR trends.  The 26 R2 mixtures (Lib1.043 to Lib1.068) reveal that there is no clear 
preference for absolute configuration of the diastereomers (Table 2.5 and Figure 2.3).  
For example the diastereomeric pair Lib1.043 and Lib1.052 produced similar minimal 
potency against the pathogens.  Likewise the diastereomeric pair Lib1.047 and 
Lib1.055 also produced similar activity to each other, although exhibiting strong broad-
spectrum activity.  The same trend is seen for a number of the R2 diastereomeric pairs 
such as Lib1.063 and Lib1.064 as well as Lib1.065 and Lib1.066 (Table 2.5).  
The length of the carbon chain for a given R group functionality appears to play a 
role in the potency of the sample.  This SAR is most clearly seen in the R2 position 
(Table 2.5 and Figure 2.4) where increasing the length of the functionality from a methyl 
to a propyl and then to a butyl corresponds with an increase in the potency and number 
of pathogens inhibited.  While not as clear, a similar trend can be seen for the R1 and R3 
samples.  Figure 2.5 shows the R1 cyclohexyl groups with various carbon length 
attachments.  Broad-spectrum potency necessitates having at least an ethyl linker 
(Lib1.030) and moving to a propyl linker increases further both potency and broad-
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spectrum effects.  This same SAR trend is seen in the equivalent R3 samples: Lib1.097, 
Lib1.098, Lib1.104, and Lib1.099 (Table 2.6).  The increase in broad-spectrum activity 
that corresponds with an increase in carbon length is likely due to an overall increase in 
lipophilicity of the compounds.  The increased lipophilicity likely aids in the compounds’ 
abilities to penetrate the pathogens’ cell walls thus increasing its potency. 
The substitution pattern of a given phenyl functionality also appears to be a 
critical factor in broad-spectrum potency.  For example, the broad-spectrum potency of 
the unsubstituted sample Lib1.044 is further increased when a naphthyl group 
(Lib1.065) is utilized (Figure 2.6).  However, the broad-spectrum potency is decreased 
when a phenol (Lib1.051) is utilized.  This same trend was seen in the R1 and R3 
positions where different phenyl substitutions played a role in activity.  In general the 
samples with methoxy or ethoxy phenyl substitutions had potencies restricted to the first 
three pathogens (Tables 2.4 and 2.6).  There was also a trend that the R1 and R3 
samples with halogenated phenyl groups possessed broad-spectrum antimicrobial 
activity.  As noted previously the samples fixed with a given functionality in R1 (Table 
2.4) tended to show a similar activity profile when that functionality was fixed in the R3 
position (Table 2.5), this is likely due to the somewhat symmetric geometry of the 
scaffold. 
 
Individual Compounds 
Based on the data from the positional scanning library, 27 individual compounds 
were selected for synthesis (Table 2.7 Set A and 2.8).  These 27 compounds were 
synthesized by making all 27 combinations generated from fixing 3 functionalities at 
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each of the 3 different R groups (Table 2.7 Set A and 2.8).  Each of the functionalities 
chosen came from a positional scanning library sample that possessed broad-spectrum 
antimicrobial activity.  Additionally at least one aliphatic and one aromatic functionality 
were selected for each of the three positions.  At the time of the synthesis a second set 
of 27 compounds (Table 2.9) was made for a malaria program with Dr. Dennis Kyle’s 
group (malaria data not shown).  These 27 compounds were also bis-cyclic guanidines 
but the functionalities used for this second set of 27 compounds were derived from 
mixtures that did not possess the same level of broad-spectrum antimicrobial activity as 
the first set of 27 compounds (Table 2.8).  It was therefore predicted that the second set 
of 27 compounds (Set B) should have less broad-spectrum antimicrobial activity than 
the first set.   
As a check both sets of compounds were screened for broad-spectrum 
antimicrobial activity against the six ESKAPE pathogens using a microbroth dilution 
assay (Tables 2.8 and 2.9).  Initially the compounds were all screened as crude 
material, meaning they did not undergo any column purification after the synthesis was 
complete (all compounds were analyzed by LCMS and all 54 compounds had purities 
>80% measured by UV 214nM.  Details are presented in the Experimental Section).  
The compounds were screened as crude material in order to simulate the synthesis and 
screening conditions of the mixture samples.  Any side product that was generated 
during the synthesis of the library should also be present in these 54 samples.   
A total of 25 of the 27 compounds synthesized based on combinations of active 
functionalities defined in the positional scanning library samples produced potent broad-
spectrum antimicrobial activity (Table 2.8).  Also, 21 of the 27 compounds demonstrated 
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inhibition of at least 5 different pathogens at a dose of 5 µM (Table 2.8).  Conversely, 
only 3 of the 27 compounds from Set B produced any inhibition against the pathogens 
at 10 µM (Table 2.9).  The only compound from Set B that had activity below 10 µM was 
compound 32 which combines the most potent broad-spectrum functionalities from this 
set of 27 (Table 2.7: R1 heptyl, R2 S-2-butyl, R3 m-tolylethyl).   
The screening data from these 54 compounds confirms the SAR profile 
generated from screening the positional scanning library Lib1 is useful for identifying 
potent broad-spectrum antimicrobial compounds.  The data also demonstrates that 
predictions can be made about inactive compounds as shown with the screening of Set 
B, compounds 28 to 54.  The 54 compounds also verify that the broad-spectrum activity 
is derived from the combination of R group functionalities and the core scaffold rather 
than just the core scaffold itself decorated with any R group functionalities. 
 When looking at the data from compounds 1 to 27, some SAR trends are 
apparent.  In general the analogs with S-butyl fixed in the R2 position possess the most 
potent broad-spectrum antimicrobial activity while the compounds fixed with R-2-
naphthylmethyl at the R2 position generally provided the least potent analogs (i.e. Table 
2.8; 1 to 3 vs. 4 to 6).  For each grouping using either heptyl or cyclohexylbutyl in the R3 
position provided more potent analogs than using 2-biphenyl-4-yl-ethyl (i.e. Table 2.8; 1 
and 2 vs. 3, 4 and 5 vs. 6, etc.).  Finally there appears to be a slight preference for 
utilizing 2-(3-trifluoromethyl-phenyl)-ethyl over adamantan-1-yl-ethyl in the R1 position; 
however, both of these functionalities appear to be favored over cyclohexylbutyl. 
From the set of individual compounds, 5 compounds (1, 2, 7, 16 and 19) were 
selected for purification and further characterization.  After purification, the five 
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compounds were rescreened for broad-spectrum antimicrobial activity against the six 
ESKAPE pathogens using a microbroth dilution assay.  All 5 compounds produced 
inhibition of all 6 ESKAPE pathogens at concentrations lower than 2 µM thus confirming 
their broad-spectrum activity.7 
 
Further Characterization 
The 5 compounds, 1, 2, 7, 16 and 19 were further characterized by Dr. Lindsay 
Shaw’s group and the results have been published in Fleeman et al.7 The published 
work will be briefly summarized.   
Antibacterial Activity.  The 5 compounds were tested for antibacterial potency 
against a panel of additional clinically relevant ESKAPE pathogens.  Except for some 
variations that are most likely attributed to efflux detoxification of some isolates, the 5 
compounds produced potent antibacterial activity against the broad spectrum of 
pathogens tested.  
Bactericidal Characterization.  The 5 compounds were screened using a 
minimal bactericidal concentration (MBC) assay.  The compounds were found to be 
bactericidal at concentrations close to their MICs.  In order to rule out the activity was 
not because of cell lysis, a time kill assay was performed.  The 5 compounds behaved 
similar to a known non-lysating compound, doxycycline, and significantly different from 
a known lysating agent, lysostaphin.  Therefore it was concluded that the while the 5 
compounds demonstrate potent bactericidal activity the activity is likely not being driven 
by cell lysing. 
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Antibiofilm Activity.  The 5 compounds were assessed for antibiofilm activity 
using a minimum biofilm eradication assays (MBEC), as described previously.8 
Although the 5 compounds possessed less MBEC potency as compared to MIC or MBC 
activity they did demonstrate significant antibiofilm effects.  All 5 compounds provided 
MBEC values below 20 µM against 4 pathogens, S. aureus, K. pneumonia, A. 
baumannii, and P. aeruginosa. 
Toxicity Toward Human Cells.  The 5 compounds were assessed for 
cytotoxicity against human A549 adenocarcinomic alveolar basal cells. The compounds 
showed preferential toxicity against the pathogens as compared to the human cell line.  
4 of the 5 compounds allowed for >60% recovery of the A549 cells at concentrations 
greater than 100 µM with all 5 compounds displaying selectivity indexes of >40 (the 
selectivity index was calculated by taking the IC50 against the A549 cells divided by the 
MIC). 
  In Vivo Efficacy.  The 5 compounds were also tested for in vivo efficacy in 
mice.  The compounds were administered to mice that had been infected with MRSA.  
All 5 compounds improved the survival rate of the mice over that of the positive control, 
vancomycin, and negative control, vehicle only.  100% of the mice survived past 5 days 
after receiving compound 1, 80% survived past 5 days after receiving compounds 2, 16, 
or 19, and 60% survived after being administered compound 7.  This compares to 50% 
for vancomycin and 0% for the vehicle control group.   
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Conclusion and Future Studies 
 In the above reported study only 201 samples were screened in total: 37 scaffold 
ranking, 110 positional scanning, and 54 individual compounds.  From the 37 scaffold 
ranking library samples, several million compounds grouped by scaffold type were 
initially surveyed in order to identify a scaffold mixture sample that likely contained 
broad-spectrum antimicrobial agents.  The 110 positional scanning library samples were 
utilized to confirm that the broad-spectrum activity was due to specific R group 
functionalities.  Utilizing the 110 positional scanning library samples a preliminary SAR 
profile was built around the bis-cyclic guanidine scaffold.   The initial SAR profile was 
confirmed after the testing of 54 individual structural analogs.  From this set 5 
compounds were advanced to undergo further chemical and biological characterization 
studies.7 
 The 5 lead compounds as well as a few additional analogs (not reported here) 
are currently being utilized by Dr. Shaw’s group to determine the mechanism of action 
driving the broad-spectrum antibacterial activity.  While these specific compounds likely 
will not become therapeutics themselves, at least not without additional medicinal 
chemistry optimization, they are serving as valuable tool compounds that will hopefully 
reveal a novel mechanism of action to target in the treatment of pathogen infections.  
 
Experimental 
 The following information regarding the microbroth dilution assay as well as the 
synthesis, purification, and characterization of individual compounds 1, 2, 7, 16 and 19 
was previously reported in detail in Freeman et al.7 and is provided here as well with 
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little modification from what appears in the published manuscript.  Some additional 
information not reported in Freeman et al. is provided on the synthesis and 
characterization of the 54 individual compounds. 
 
Synthesis and Characterization of Bis-cyclic Guanidines 
 The individual compounds (1−54) were synthesized following the same synthetic 
scheme (Figure 2.8).9,10 Utilizing the “tea-bag” methodology,11 100 mg of p-
methylbenzhydrylamine (MBHA) resin (1.1 mmol/g, 100−200 mesh) was sealed in a 
mesh “tea-bag,” neutralized with 5% diisopropylethylamine (DIEA) in dichloromethane 
(DCM), and subsequently swelled with additional DCM washes (2.1, Figure 2.8). Fmoc-
L- Lys(Boc)-OH was coupled in dimethylformamide (0.1 M DMF) for 120 min in the 
presence of diisopropylcarbodiimide (DIC, 6 equiv) and 1-hydroxybenzotriazole hydrate 
(HOBt, 6 equiv) (2.2, Figure 2.8).  The coupling solution was removed and the tea-bag 
was washed with three rounds of DMF (1 min each wash). The Fmoc protecting group 
was removed with 20% piperidine in DMF for 20 min, followed by two rounds of DMF 
washes (1 min each).  The R1 carboxylic acids were coupled (10 equiv) in the presence 
of DIC (10 equiv) and HOBt (10 equiv) in DMF (0.1 M) for 120 min (2.3, Figure 2.8). The 
coupling solution was removed and the tea-bag was washed with three rounds of DMF 
(1 min each wash). The Boc protecting group was then removed with trifluoroacetic acid 
(TFA) in DCM for 30 min and subsequently neutralized with 5% DIEA/DCM (3 times 2 
min).  After two DMF washes (1 min each) Boc-amino acids (R2) were coupled utilizing 
standard coupling procedures (6 equiv) with DIC (6 equiv) and HOBt (6 equiv) in DMF 
(0.1 M) for 120 min. The coupling solution was removed and the tea-bag was washed 
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with three rounds of DMF (1 min each wash).  The Boc group was removed with 55% 
TFA/DCM for 30 min and subsequently neutralized with 5% DIEA/DCM (3 times 2 min). 
After two DMF washes (1 min each) carboxylic acids (R3) were coupled (10 equiv) in the 
presence of DIC (10 equiv) and HOBt (10 equiv) in DMF (0.1M) for 120 min (2.5, Figure 
2.8). The coupling solution was removed and the tea-bag was washed with three rounds 
of DMF (1 min each wash), two rounds of DCM (1 min each), and then allowed to dry.  
All coupling reactions were monitored for completion by the ninhydrin test. Reductions 
were performed in a 4000 mL Wilmad LabGlass vessel under nitrogen. Tetrahydrofuran 
(THF, 1.0 M) borane complex solution was used in 40- fold excess for each amide 
bond. The vessel was heated to 65 °C and maintained at this temperature for 96 h. The 
solution was then removed and the bags washed with THF and methanol (MeOH). 
Once completely dry, bags were treated overnight with piperidine at 65 °C and washed 
several times with DMF, DCM, and methanol (2.6, Figure 2.8). As previously reported, 
the reduction of polyamides with borane is free of racemization.12-14 Before proceeding, 
the completion of reduction was monitored by LCMS analysis of a control compound 
that was cleaved from solid support (HF, anisole, 0 °C 7 h). Cyclization (2.7, Figure 2.8) 
was performed with a 5-fold excess (for each cyclization) of cyanogen bromide (CNBr) 
in a 0.1 M anhydrous DCM solution overnight. Following the cyclization, the bags were 
rinsed with DMF and DCM (3 times 1 min each). The resin was cleaved with HF in the 
presence of anisole in an ice bath at 0 °C for 90 min (2.8, Figure 2.8). After removal of 
the HF by gaseous N2, the products were then extracted from the vessels with 95% 
acetic acid in water, transferred to scintillation vials, frozen, and lyophilized. Compounds 
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were then reconstituted in 50% acetonitrile and water, frozen, and lyophilized three 
more times.  
LCMS Analysis of Crude Material. Purity and identity of initial crude 
compounds was verified using a Shimadzu 2010 LCMS system, consisting of an LC-
20AD binary solvent pumps, a DGU-20A degasser unit, a CTO-20A column oven, and a 
SIL-20A HT auto sampler. A Shimadzu SPD-M20A diode array detector was used for 
detections. A full spectra range of 190−600 nm was obtained during analysis. 
Chromatographic separations were obtained using a Phenomenex Luna C18 analytical 
column (5 µm, 50 mm × 4.6 mm i.d.). The column was protected by a Phenomenex C18 
column guard (5 µm, 4 × 3.0 mm i.d.). All equipment was controlled and integrated by 
Shimadzu LCMS solutions software version 3. Mobile phases for LCMS analysis were 
HPLC grade or LCMS grade obtained from Sigma-Aldrich and Fisher Scientific. The 
mobile phases consisted of a mixture of LCMS grade acetonitrile/water (both with 0.1% 
formic acid for a pH of 2.7). The initial setting for analysis was 5% acetonitrile (v/v), then 
linearly increased to 95% acetonitrile over 6 min. The gradient was then held at 95% 
acetonitrile for 2 min before being linearly decreased to 5% over 0.1 min and held until 
stop for an additional 1.9 min. The total run time was equal to 12 min, and the total flow 
rate was 0.5 mL/min. The column oven and flow cell temperature for the diode array 
detector was 30 °C. The auto sampler temperature was held at 15 °C, and 5 µL was 
injected for analysis. 
HPLC Purification (Compounds 1, 2, 7, 16, and 19). All purifications were 
performed on a Shimadzu Prominence preparative HPLC system, consisting of LC-8A 
binary solvent pumps, a SCL-10A system controller, a SIL-10AP auto sampler, and a 
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FRC-10A fraction collector. A Shimadzu SPD-20A UV detector was used for detection. 
The wavelength was set at 214 nm during analysis. Chromatographic separations were 
obtained using a Phenomenex Luna C18 preparative column (5 µm, 150 mm × 21.5 mm 
i.d.). The column was protected by a Phenomenex C18 column guard (5 µm, 15 mm × 
21.2 mm i.d.). Prominence prep software was used to set all detection and collection 
parameters. The mobile phases for HPLC purification were HPLC grade obtained from 
Sigma-Aldrich and Fisher Scientific. The mobile phase consisted of a mixture of 
acetonitrile/ water (both with 0.1% formic acid). The initial setting for separation was 2% 
acetonitrile, which was held for 2 min, then the gradient was linearly increased to 20% 
acetonitrile over 4 min. The gradient was then linearly increased to 55% acetonitrile 
over 36 min. The HPLC system was set to automatically flush and re-equilibrate the 
column after each run for a total of four column volumes. The total flow rate was set to 
12 mL/min, and the total injection volume was set to 3900 µL. The fraction collector was 
set to collect from 6 to 40 min. The corresponding fractions were then combined and 
lyophilized. 
LCMS Analysis of Purified Compounds. The purity and identity of purified 
compounds 1, 2, 7, 16, and 19 were carried out using a Shimadzu 2020 LCMS system, 
consisting of a LC-20AD binary solvent pumps, a DGU-20A degasser unit, a CTO-20A 
column oven, and a SIL-20A HT auto sampler. A Shimadzu SPD-M20A diode array 
detector was used for detections. A full spectra range of 190−460 nm was obtained 
during analysis. Chromatographic separations were obtained using a Phenomenex 
Gemini C18 analytical column (5 µm, 250 mm × 2 mm i.d.). The column was protected 
by a Phenomenex C18 column guard (5 µm, 4 mm × 2 mm i.d.). All equipment was 
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controlled and integrated by Shimadzu Lab Solutions software version 5.53 SP3. Three 
different sets of conditions were used for analysis. Condition 1 (acetonitrile/water pH 
2.7): The mobile phase consisted of a mixture of LCMS grade acetonitrile/water (both 
with 0.1% formic acid for a pH of 2.7) with initial settings for analysis of 5% organic 
mobile phase (v/v), which was linearly increased to 95% organic mobile phase over 38 
min. The gradient was then held at 95% organic mobile phase for 4 min, then linearly 
decreased to 5% over 2 min and held until stop for an additional 1 min. The total run 
time was equal to 46 min. Condition 2 (methanol/ water pH 7.4): The mobile phase 
consisted of LCMS grade methanol/ water containing 10 mM ammonium bicarbonate 
(adjusted to pH 7.4 with formic acid). The initial setting for analysis was 5% organic 
mobile phase (v/v), which was linearly increased to 95% organic mobile phase over 38 
min. The gradient was then held at 95% organic mobile phase for 4 min, then linearly 
decreased to 5% over 2 min and held until stop for an additional 1 min. The total run 
time was equal to 46 min. Condition 3 (methanol/water pH 5.14): The mobile phase 
consisted of LCMS grade methanol/water containing 50 mM ammonium formate 
(adjusted to pH 5.14 with formic acid). The initial setting for analysis was 60% methanol 
(v/v), which was linearly increased to 80% methanol over 10 min, before!the gradient 
was linearly increased to 83% methanol over 25 min. The gradient was again linearly 
increased to 95% methanol over 3 min and held at 95% for an additional 4 min. Then 
the gradient was linearly decreased to 60% methanol over 2 min and held until stop for 
a total run time of 46 min. 
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NMR Analysis of Purified Compounds. 1H NMR spectra were obtained utilizing 
the Bruker 400 Ascend (400 MHz). NMR chemical shifts were reported in δ (ppm) using 
the δ 7.26 signal of CDCl3 (1H NMR) as the internal standard. 
(S)-4-Butyl-3-hexyl-1-(4-((S)-2-imino-3-(3-(trifluoromethyl)- 
phenethyl)imidazolidin-4-yl)butyl)imidazolidin-2-imine (1). Using the synthetic approach 
described in Figure 2.8 compound 1 was synthesized using the following reagents: (α-α-
α- trifluoro-m-tolyl) acetic acid (R1), Boc-L-norleucine (R2), and heptanoic acid (R3). 
Final crude product was purified by HPLC as described above. 1H NMR (400 MHz, 
CDCl3): δ 8.67 (br s, 2 H) 7.53 − 7.58 (m, 2 H) 7.41 − 7.51 (m, 2 H) 4.00 − 4.11 (m, 1 H) 
3.76 − 3.85 (m, 1 H) 3.48 − 3.72 (m, 5 H) 3.31 − 3.47 (m, 2 H) 3.07 − 3.28 (m, 3 H) 2.89 
− 3.05 (m, 2 H) 1.65 − 1.86 (m, 1 H) 1.52 − 1.63 (m, 5 H) 1.46 − 1.52 (d, 2 H) 1.22 − 
1.43 (m, 14 H) 0.85 − 1.04 (m, 6 H). LCMS (ESI+) m/z calcd for C30H49F3N6 [M + H]+: 
551.40, found 551.35. LCMS retention time (214 nm): condition 1 (acetonitrile/water pH 
2.7), 17.168 min; condition 2 (methanol/water pH 7.4), 33.528 min; condition 3 
(methanol/water pH 5.14), 9.254 min. All three conditions showed the desired 
compound accounting for 100% peak area and peak height. 
(S)-4-Butyl-3-(4-cyclohexylbutyl)-1-(4-((S)-2-imino-3-(3- 
(trifluoromethyl)phenethyl)imidazolidin-4-yl)butyl)imidazolidin-2- imine (2). Using the 
synthetic approach described in Figure 2.8 compound 2 was synthesized using the 
following reagents: (α-α-α-trifluoro-m-tolyl) acetic acid (R1), Boc-L-norleucine (R2), 
cyclohexanebutyric acid (R3). Final crude product was purified by HPLC as described 
above. 1H NMR (400 MHz, CDCl3): δ 8.67 (br s, 2 H) 7.54 − 7.58 (m, 2 H) 7.41 − 7.51 
(m, 2 H) 4.02 − 4.12 (m, 1 H) 3.81 (d, 1 H) 3.54 − 3.27 (m, 3 H) 3.51 (br s, 1 H) 3.32 − 
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3.47 (m, 2 H) 3.08 − 3.30 (m, 3 H) 2.88 − 3.04 (m, 2 H) 2.22 (br s, 3 H) 1.60 − 1.85 (m, 
8 H) 1.53 − 1.60 (m, 3 H) 1.45 − 1.53 (m, 2 H) 1.15 − 1.43 (m, 14 H) 0.81 − 1.00 (m, 3 
H). LCMS (ESI+) m/z calcd for C33H53F3N6 [M + H]+: 591.43, found 591.45. LCMS 
retention time (214 nm): condition 1 (acetonitrile/water pH 2.7), 18.363 min; condition 2 
(methanol/water pH 7.4), 34.487 min; condition 3 (methanol/water pH 5.14), 12.048 min. 
All three conditions showed the desired compound accounting for 100% peak area and 
peak height. 
(S)-4-(Cyclohexylmethyl)-3-hexyl-1-(4-((S)-2-imino-3-(3- 
(trifluoromethyl)phenethyl)imidazolidin-4-yl)butyl)imidazolidin-2- imine (7). Using the 
synthetic approach described in Figure 2.8 compound 7 was synthesized using the 
following reagents: (α-α-α-trifluoro-m-tolyl) acetic acid (R1), Boc-L-cyclohexylalanine 
(R2), and heptanoic acid (R3). Final crude product was purified by HPLC as described 
above. 1H NMR (400 MHz, CDCl3): δ 8.67 (br s, 2 H) 7.54 − 7.59 (m, 2 H) 7.41 − 7.50 
(m, 2 H) 4.02 − 4.12 (m, 1 H) 3.79 − 3.90 (m, 1 H) 3.54 − 3.74 (m, 3 H) 3.32 − 3.53 (m, 
3 H) 3.08 − 3.28 (m, 3 H) 2.80 − 3.06 (m, 3 H) 1.58 − 1.82 (m, 8 H) 1.46 − 1.58 (m, 4 H) 
1.16 − 1.38 (m, 15 H) 0.86 −1.11 (m, 5 H). LCMS (ESI+) m/z calcd for C33H53F3N6 [M + 
H]+: 591.43, found 591.45. LCMS retention time (214 nm): condition 1 
(acetonitrile/water pH 2.7), 18.380 min; condition 2 (methanol/water pH 7.4), 35.664 
min; condition 3 (methanol/water pH 5.14), 12.373 min. All three conditions showed the 
desired compound accounting for 100% peak area and peak height. 
(S)-1-(4-((S)-3-(4-Cyclohexylbutyl)-2-iminoimidazolidin-4-yl)- butyl)-4-
(cyclohexylmethyl)-3-hexylimidazolidin-2-imine (16). Using the synthetic approach 
described Figure 2.8 compound 16 was synthesized using the following reagents: cyclo- 
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hexanebutyric acid (R1), Boc-L-cyclohexylalanine (R2), and heptanoic acid (R3). Final 
crude product was purified by HPLC as described above. 1H NMR (400 MHz, CDCl3): δ 
8.67 (br s, 2 H) 3.81 − 3.93 (m, 2 H) 3.57 − 3.75 (m, 5 H) 3.38 − 3.49 (m, 1 H) 3.29 − 
3.36 (m, 1 H) 3.09 − 3.20 (m, 3 H) 1.50 −1.78 (m, 18 H) 1.15 − 1.38 (m, 23 H) 1.03 − 
1.15 (m, 2 H) 0.82 − 1.00 (m, 6 H). LCMS (ESI+) m/z calcd for C34H64N6 [M + H]+: 
557.52, found 557.50. LCMS retention time (214 nm): condition 1 (acetonitrile/water pH 
2.7), 19.706 min; condition 2 (methanol/water pH 7.4), 37.568 min; condition 3 
(methanol/water pH 5.14), 14.248 min. All three conditions showed the desired 
compound accounting for 100% peak area and peak height. 
(S)-1-(4-((S)-3-(2-((3S,5S,7S)-Adamantan-1-yl)ethyl)-2-iminoimidazolidin-4-
yl)butyl)-4-butyl-3-hexylimidazolidin-2-imine (19). Using the synthetic approach 
described in Figure 2.8 compound 19 was synthesized using the following reagents: 1- 
adamantaneacetic acid (R1), Boc-L-norleucine (R2), and heptanoic acid (R3). Final crude 
product was purified by HPLC as described above. 1H NMR (400 MHz, CDCl3): δ 8.68 
(br s, 2 H) 3.87 − 4.13 (m, 1 H) 3.76 − 3.86 (m, 1 H) 3.58 − 3.76 (m, 5 H) 3.36 − 3.51 
(m, 1 H) 3.27 − 3.36 (m, 1 H) 3.02 − 3.25 (m, 3 H) 1.98 (br s, 4 H) 1.50 − 1.76 (m, 19 H) 
1.24 − 1.43 (m, 16 H) 0.87 − 1.0 (m, 6 H). LCMS (ESI+) m/z calcd for C33H60N6 [M + 
H]+: 541.49, found [M + H]+, 541.45. LCMS retention time (214 nm): condition 1 
(acetonitrile/water pH 2.7), 18.270 min; condition 2 (methanol/water pH 7.4), 36.038 
min; condition 3 (methanol/water pH 5.14), 12.692 min. All three conditions showed the 
desired compound accounting for 100% peak area and peak height. 
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LCMS Analysis of Crude Compounds.  The 54 crude individual samples were 
synthesized utilizing the general scheme provided in Figure 2.8 and LCSM data for 
crude material was obtained as described above. 
(S)-4-Butyl-3-hexyl-1-(4-((S)-2-imino-3-(3-(trifluoromethyl)- 
phenethyl)imidazolidin-4-yl)butyl)imidazolidin-2-imine (1). Using the synthetic approach 
described in Figure 2.8 compound 1 was synthesized using the following reagents: (α-α-
α-trifluoro-m-tolyl) acetic acid (R1), Boc-L-norleucine (R2), and heptanoic acid (R3). Final 
crude product was analyzed by LCMS as described above. LCMS (ESI+) m/z calcd for 
C30H49F3N6 [M + H]+: 551.40, found 551.35. LCMS retention time (214 nm) 4.458 min; 
purity 82.7%. 
(S)-4-Butyl-3-(4-cyclohexylbutyl)-1-(4-((S)-2-imino-3-(3- 
(trifluoromethyl)phenethyl)imidazolidin-4-yl)butyl)imidazolidin-2- imine (2). Using the 
synthetic approach described in Figure 2.8 compound 2 was synthesized using the 
following reagents: (α-α-α-trifluoro-m-tolyl) acetic acid (R1), Boc-L-norleucine (R2), 
cyclohexanebutyric acid (R3). Final crude product was analyzed by LCMS as described 
above LCMS (ESI+) m/z calcd for C33H53F3N6 [M + H]+: 591.43, found 591.45. LCMS 
retention time (214 nm) 4.582 min; purity 84.9%. 
(S)-3-(2-([1,1'-biphenyl]-4-yl)ethyl)-4-butyl-1-(4-((S)-2-imino-3-(3-
(trifluoromethyl)phenethyl)imidazolidin-4-yl)butyl)imidazolidin-2-imine (3). Using the 
synthetic approach described in Figure 2.8 compound 3 was synthesized using the 
following reagents: (α-α-α-trifluoro-m-tolyl) acetic acid (R1), Boc-L-norleucine (R2), 4-
biphenylacetic acid (R3). Final crude product was analyzed by LCMS as described 
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above LCMS (ESI+) m/z calcd for C33H53F3N6 [M + H]+: 591.43, found 591.45. LCMS 
retention time (214 nm) 4.582 min; purity 84.9%. 
(R)-3-heptyl-1-(4-((S)-2-imino-3-(3-(trifluoromethyl)phenethyl)imidazolidin-4-
yl)butyl)-4-(naphthalen-1-ylmethyl)imidazolidin-2-imine (4). Using the synthetic 
approach described in Figure 2.8 compound 4 was synthesized using the following 
reagents: (α-α-α-trifluoro-m-tolyl) acetic acid (R1), Boc-D-naphthylalanine (R2), 
heptanoic acid (R3). Final crude product was analyzed by LCMS as described above 
LCMS (ESI+) m/z calcd for C37H47F3N6 [M + H]+: 633.38, found 633.30. LCMS retention 
time (214 nm) 4.512 min; purity 84.6%. 
(R)-3-(4-cyclohexylbutyl)-1-(4-((S)-2-imino-3-(3-
(trifluoromethyl)phenethyl)imidazolidin-4-yl)butyl)-4-(naphthalen-1-ylmethyl)imidazolidin-
2-imine (5). Using the synthetic approach described in Figure 2.8 compound 5 was 
synthesized using the following reagents: (α-α-α-trifluoro-m-tolyl) acetic acid (R1), Boc-
D-naphthylalanine (R2), cyclohexanebutyric acid (R3). Final crude product was analyzed 
by LCMS as described above LCMS (ESI+) m/z calcd for C37H49F3N6 [M + H]+: 675.43, 
found 675.30. LCMS retention time (214 nm) 4.57 min; purity 84.6%. 
(R)-3-(2-([1,1'-biphenyl]-4-yl)ethyl)-1-(4-((S)-2-imino-3-(3-
(trifluoromethyl)phenethyl)imidazolidin-4-yl)butyl)-4-(naphthalen-1-ylmethyl)imidazolidin-
2-imine (6). Using the synthetic approach described in Figure 2.8 compound 6 was 
synthesized using the following reagents: (α-α-α-trifluoro-m-tolyl) acetic acid (R1), Boc-
D-naphthylalanine (R2), 4-biphenylacetic acid (R3). Final crude product was analyzed by 
LCMS as described above LCMS (ESI+) m/z calcd for C44H47F3N6 [M + H]+: 717.38, 
found 717.30. LCMS retention time (214 nm) 4.597 min; purity 87.4%. 
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(S)-4-(Cyclohexylmethyl)-3-hexyl-1-(4-((S)-2-imino-3-(3- 
(trifluoromethyl)phenethyl)imidazolidin-4-yl)butyl)imidazolidin-2- imine (7). Using the 
synthetic approach described in Figure 2.8 compound 7 was synthesized using the 
following reagents: (α-α-α-trifluoro-m-tolyl) acetic acid (R1), Boc-L-cyclohexylalanine 
(R2), and heptanoic acid (R3). Final crude product was analyzed by LCMS as described 
above.  LCMS (ESI+) m/z calcd for C33H53F3N6 [M + H]+: 591.43, found 591.45. LCMS 
retention time (214 nm) 4.632 min; purity 83.8%. 
(S)-3-(4-cyclohexylbutyl)-4-(cyclohexylmethyl)-1-(4-((S)-2-imino-3-(3-
(trifluoromethyl)phenethyl)imidazolidin-4-yl)butyl)imidazolidin-2-imine (8). Using the 
synthetic approach described in Figure 2.8 compound 8 was synthesized using the 
following reagents: (α-α-α-trifluoro-m-tolyl) acetic acid (R1), Boc-L-cyclohexylalanine 
(R2), cyclohexanebutyric acid (R3). Final crude product was analyzed by LCMS as 
described above LCMS (ESI+) m/z calcd for C36H57F3N6 [M + H]+: 631.46, found 
631.40. LCMS retention time (214 nm) 4.813 min; purity 89.5%. 
(S)-3-(2-([1,1'-biphenyl]-4-yl)ethyl)-4-(cyclohexylmethyl)-1-(4-((S)-2-imino-3-(3-
(trifluoromethyl)phenethyl)imidazolidin-4-yl)butyl)imidazolidin-2-imine (9). Using the 
synthetic approach described in Figure 2.8 compound 9 was synthesized using the 
following reagents: (α-α-α-trifluoro-m-tolyl) acetic acid (R1), Boc-L-cyclohexylalanine 
(R2), 4-biphenylacetic acid (R3). Final crude product was analyzed by LCMS as 
described above LCMS (ESI+) m/z calcd for C40H51F3N6 [M + H]+: 673.41, found 
673.25. LCMS retention time (214 nm) 4.651 min; purity 92.6%. 
(S)-4-butyl-1-(4-((S)-3-(4-cyclohexylbutyl)-2-iminoimidazolidin-4-yl)butyl)-3-
heptylimidazolidin-2-imine (10). Using the synthetic approach described in Figure 2.8 
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compound 10 was synthesized using the following reagents: cyclohexanebutyric Acid 
(R1), Boc-L-norleucine (R2), heptanoic acid (R3). Final crude product was analyzed by 
LCMS as described above LCMS (ESI+) m/z calcd for C31H60N6 [M + H]+: 517.49, found 
517.35. LCMS retention time (214 nm) 4.647 min; purity 80.9%. 
(S)-4-butyl-3-(4-cyclohexylbutyl)-1-(4-((S)-3-(4-cyclohexylbutyl)-2-
iminoimidazolidin-4-yl)butyl)imidazolidin-2-imine (11). Using the synthetic approach 
described in Figure 2.8 compound 11 was synthesized using the following reagents: 
cyclohexanebutyric Acid (R1), Boc-L-norleucine (R2), cyclohexanebutyric acid (R3). Final 
crude product was analyzed by LCMS as described above LCMS (ESI+) m/z calcd for 
C34H64N6 [M + H]+: 557.52, found 557.35. LCMS retention time (214 nm) 4.832 min; 
purity 80.3%. 
(S)-3-(2-([1,1'-biphenyl]-4-yl)ethyl)-4-butyl-1-(4-((S)-3-(4-cyclohexylbutyl)-2-
iminoimidazolidin-4-yl)butyl)imidazolidin-2-imine (12). Using the synthetic approach 
described in Figure 2.8 compound 12 was synthesized using the following reagents: 
cyclohexanebutyric Acid (R1), Boc-L-norleucine (R2), 4-biphenylacetic acid (R3). Final 
crude product was analyzed by LCMS as described above LCMS (ESI+) m/z calcd for 
C38H58N6 [M + H]+: 599.47, found 599.40. LCMS retention time (214 nm) 4.629 min; 
purity 88.4%. 
(R)-1-(4-((S)-3-(4-cyclohexylbutyl)-2-iminoimidazolidin-4-yl)butyl)-3-heptyl-4-
(naphthalen-1-ylmethyl)imidazolidin-2-imine (13). Using the synthetic approach 
described in Figure 2.8 compound 13 was synthesized using the following reagents: 
cyclohexanebutyric Acid (R1), Boc-D-naphthylalanine (R2), heptanoic acid (R3). Final 
crude product was analyzed by LCMS as described above LCMS (ESI+) m/z calcd for 
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C38H60N6 [M + H]+: 601.49, found 601.40. LCMS retention time (214 nm) 4.759 min; 
purity 85.0% 
(R)-3-(4-cyclohexylbutyl)-1-(4-((S)-3-(4-cyclohexylbutyl)-2-iminoimidazolidin-4-
yl)butyl)-4-(naphthalen-1-ylmethyl)imidazolidin-2-imine (14). Using the synthetic 
approach described in Figure 2.8 compound 14 was synthesized using the following 
reagents: cyclohexanebutyric Acid (R1), Boc-D-naphthylalanine (R2), cyclohexanebutyric 
acid (R3). Final crude product was analyzed by LCMS as described above LCMS (ESI+) 
m/z calcd for C41H64N6 [M + H]+: 641.52, found 641.45. LCMS retention time (214 nm) 
4.898 min; purity 84.2%. 
(R)-3-(2-([1,1'-biphenyl]-4-yl)ethyl)-1-(4-((S)-3-(4-cyclohexylbutyl)-2-
iminoimidazolidin-4-yl)butyl)-4-(naphthalen-1-ylmethyl)imidazolidin-2-imine (15). Using 
the synthetic approach described in Figure 2.8 compound 15 was synthesized using the 
following reagents: cyclohexanebutyric Acid (R1), Boc-D-naphthylalanine (R2), 4-
biphenylacetic acid (R3). Final crude product was analyzed by LCMS as described 
above LCMS (ESI+) m/z calcd for C45H58N6 [M + H]+: 683.47, found 683.40. LCMS 
retention time (214 nm) 4.747 min; purity 84.4%. 
(S)-1-(4-((S)-3-(4-Cyclohexylbutyl)-2-iminoimidazolidin-4-yl)- butyl)-4-
(cyclohexylmethyl)-3-hexylimidazolidin-2-imine (16). Using the synthetic approach 
described Figure 2.8 compound 16 was synthesized using the following reagents: 
cyclohexanebutyric Acid (R1), Boc-L-cyclohexylalanine (R2), and heptanoic acid (R3). 
Final crude product was analyzed by LCMS as described above. LCMS (ESI+) m/z 
calcd for C34H64N6 [M + H]+: 557.52, found 557.50. LCMS retention time (214 nm) 4.841 
min; purity 86.9%. 
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(S)-3-(4-cyclohexylbutyl)-1-(4-((S)-3-(4-cyclohexylbutyl)-2-iminoimidazolidin-4-
yl)butyl)-4-(cyclohexylmethyl)imidazolidin-2-imine (17). Using the synthetic approach 
described in Figure 2.8 compound 17 was synthesized using the following reagents: 
cyclohexanebutyric Acid (R1), Boc-L-cyclohexylalanine (R2), cyclohexanebutyric acid 
(R3). Final crude product was analyzed by LCMS as described above LCMS (ESI+) m/z 
calcd for C37H68N6 [M + H]+: 597.55, found 597.40. LCMS retention time (214 nm) 5.028 
min; purity 84.6%. 
(S)-3-(2-([1,1'-biphenyl]-4-yl)ethyl)-1-(4-((S)-3-(4-cyclohexylbutyl)-2-
iminoimidazolidin-4-yl)butyl)-4-(cyclohexylmethyl)imidazolidin-2-imine (18). Using the 
synthetic approach described in Figure 2.8 compound 18 was synthesized using the 
following reagents: cyclohexanebutyric acid (R1), Boc-L-cyclohexylalanine (R2), 4-
biphenylacetic acid (R3). Final crude product was analyzed by LCMS as described 
above LCMS (ESI+) m/z calcd for C41H62N6 [M + H]+; 639.50, found 639.40. LCMS 
retention time (214 nm) 4.832min; purity 89.5%. 
(S)-1-(4-((S)-3-(2-((3S,5S,7S)-Adamantan-1-yl)ethyl)-2-iminoimi- dazolidin-4-
yl)butyl)-4-butyl-3-hexylimidazolidin-2-imine (19). Using the synthetic approach 
described in Figure 2.8 compound 19 was synthesized using the following reagents: 1-
adamantaneacetic acid (R1), Boc-L-norleucine (R2), and heptanoic acid (R3). Final crude 
product was analyzed by LCMS as described above. LCMS (ESI+) m/z calcd for 
C33H60N6 [M + H]+: 541.49, found 541.45. LCMS retention time (214 nm) 4.644 min; 
purity 84.4%. 
(4S)-1-(4-((4S)-3-(2-((1S,3R)-adamantan-1-yl)ethyl)-2-iminoimidazolidin-4-
yl)butyl)-4-butyl-3-(4-cyclohexylbutyl)imidazolidin-2-imine (20). Using the synthetic 
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approach described in Figure 2.8 compound 20 was synthesized using the following 
reagents: 1-adamantaneacetic acid (R1), Boc-L-norleucine (R2), cyclohexanebutyric acid 
(R3). Final crude product was analyzed by LCMS as described above LCMS (ESI+) m/z 
calcd for C36H64N6 [M + H]+: 581.52, found 581.45. LCMS retention time (214 nm) 4.797 
min; purity 84.4%. 
(4S)-3-(2-([1,1'-biphenyl]-4-yl)ethyl)-1-(4-((4S)-3-(2-((1S,3R)-adamantan-1-
yl)ethyl)-2-iminoimidazolidin-4-yl)butyl)-4-butylimidazolidin-2-imine (21). Using the 
synthetic approach described in Figure 2.8 compound 21 was synthesized using the 
following reagents: 1-adamantaneacetic acid (R1), Boc-L-norleucine (R2), 4-
biphenylacetic acid (R3). Final crude product was analyzed by LCMS as described 
above LCMS (ESI+) m/z calcd for C40H58N6 [M + H]+: 623.47, found 623.40. LCMS 
retention time (214 nm) 4.649 min; purity 87.4%. 
(4R)-1-(4-((4S)-3-(2-((1S,3R)-adamantan-1-yl)ethyl)-2-iminoimidazolidin-4-
yl)butyl)-3-heptyl-4-(naphthalen-1-ylmethyl)imidazolidin-2-imine (22). Using the 
synthetic approach described in Figure 2.8 compound 22 was synthesized using the 
following reagents: 1-adamantaneacetic acid (R1), Boc-D-naphthylalanine (R2), 
heptanoic acid (R3). Final crude product was analyzed by LCMS as described above 
LCMS (ESI+) m/z calcd for C40H60N6 [M + H]+: 625.49, found 625.40. LCMS retention 
time (214 nm) 4.717 min; purity 82.7%. 
(4R)-1-(4-((4S)-3-(2-((1S,3R)-adamantan-1-yl)ethyl)-2-iminoimidazolidin-4-
yl)butyl)-3-(4-cyclohexylbutyl)-4-(naphthalen-1-ylmethyl)imidazolidin-2-imine (23). Using 
the synthetic approach described in Figure 2.8 compound 23 was synthesized using the 
following reagents: 1-adamantaneacetic acid (R1), Boc-D-naphthylalanine (R2), 
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cyclohexanebutyric acid (R3). Final crude product was analyzed by LCMS as described 
above LCMS (ESI+) m/z calcd for C43H64N6 [M + H]+: 665.52, found 665.45. LCMS 
retention time (214 nm) 4.898 min; purity 83.5%. 
(4R)-3-(2-([1,1'-biphenyl]-4-yl)ethyl)-1-(4-((4S)-3-(2-((1S,3R)-adamantan-1-
yl)ethyl)-2-iminoimidazolidin-4-yl)butyl)-4-(naphthalen-1-ylmethyl)imidazolidin-2-imine 
(24). Using the synthetic approach described in Figure 2.8 compound 24 was 
synthesized using the following reagents: 1-adamantaneacetic acid (R1), Boc-D-
naphthylalanine (R2), 4-biphenylacetic acid (R3). Final crude product was analyzed by 
LCMS as described above LCMS (ESI+) m/z calcd for C47H58N6 [M + H]+: 707.47, found 
707.40. LCMS retention time (214 nm) 4.747 min; purity 84.4%. 
(4S)-1-(4-((4S)-3-(2-((1S,3R)-adamantan-1-yl)ethyl)-2-iminoimidazolidin-4-
yl)butyl)-4-(cyclohexylmethyl)-3-heptylimidazolidin-2-imine (25). Using the synthetic 
approach described in Figure 2.8 compound 25 was synthesized using the following 
reagents: 1-adamantaneacetic acid (R1), Boc-L-cyclohexylalanine (R2), heptanoic acid 
(R3). Final crude product was analyzed by LCMS as described above LCMS (ESI+) m/z 
calcd for C36H64N6 [M + H]+: 581.52, found 581.40. LCMS retention time (214 nm) 4.810 
min; purity 84.7%. 
(4S)-1-(4-((4S)-3-(2-((1S,3R)-adamantan-1-yl)ethyl)-2-iminoimidazolidin-4-
yl)butyl)-3-(4-cyclohexylbutyl)-4-(cyclohexylmethyl)imidazolidin-2-imine (26). Using the 
synthetic approach described in Figure 2.8 compound 26 was synthesized using the 
following reagents: 1-adamantaneacetic acid (R1), Boc-L-cyclohexylalanine (R2), 
cyclohexanebutyric acid (R3). Final crude product was analyzed by LCMS as described 
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above LCMS (ESI+) m/z calcd for C39H68N6 [M + H]+: 621.55, found 621.45. LCMS 
retention time (214 nm) 5.002 min; purity 87.6%. 
(4S)-3-(2-([1,1'-biphenyl]-4-yl)ethyl)-1-(4-((4S)-3-(2-((1S,3R)-adamantan-1-
yl)ethyl)-2-iminoimidazolidin-4-yl)butyl)-4-(cyclohexylmethyl)imidazolidin-2-imine (27). 
Using the synthetic approach described in Figure 2.8 compound 27 was synthesized 
using the following reagents: 1-adamantaneacetic acid (R1), Boc-L-cyclohexylalanine 
(R2), 4-biphenylacetic acid (R3). Final crude product was analyzed by LCMS as 
described above LCMS (ESI+) m/z calcd for C43H62N6 [M + H]+: 663.50, found 663.40. 
LCMS retention time (214 nm) 4.791 min; purity 92.6%. 
(S)-1-heptyl-5-(4-(2-iminoimidazolidin-1-yl)butyl)imidazolidin-2-imine (28). Using 
the synthetic approach described in Figure 2.8 compound 28 was synthesized using the 
following reagents: heptanoic acid (R1), Boc-Gly (R2), 1-phenyl-1-
cyclopropanecarboxylic acid (R3). Final crude product was analyzed by LCMS as 
described above LCMS (ESI+) m/z calcd for C17H34N6 [M + H]+: 323.28, found 323.05. 
LCMS retention time (214 nm) 3.450 min; purity 86.1%. 
(S)-1-(4-(3-heptyl-2-iminoimidazolidin-4-yl)butyl)-3-(3-
methylphenethyl)imidazolidin-2-imine (29). Using the synthetic approach described in 
Figure 2.8 compound 29 was synthesized using the following reagents: heptanoic acid 
(R1), Boc-Gly (R2), m-tolylacetic acid (R3). Final crude product was analyzed by LCMS 
as described above LCMS (ESI+) m/z calcd for C26H44N6 [M + H]+: 441.36; found 
441.15. LCMS retention time (214 nm) 4.008 min; purity 86.0%. 
1-(4-((S)-3-heptyl-2-iminoimidazolidin-4-yl)butyl)-3-(2-methylbutyl)imidazolidin-2-
imine (30). Using the synthetic approach described in Figure 2.8 compound 30 was 
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synthesized using the following reagents: heptanoic acid (R1), Boc-Gly (R2), 2-
methylbutyric acid (R3). Final crude product was analyzed by LCMS as described above 
LCMS (ESI+) m/z calcd for C22H44N6 [M + H]+: 393.36, found 393.10. LCMS retention 
time (214 nm) 3.956 min; purity 80.5%. 
(S)-4-((S)-sec-butyl)-1-(4-((S)-3-heptyl-2-iminoimidazolidin-4-
yl)butyl)imidazolidin-2-imine (31). Using the synthetic approach described in Figure 2.8 
compound 31 was synthesized using the following reagents: heptanoic acid (R1), Boc-L-
Ile (R2), 1-phenyl-1-cyclopropanecarboxylic acid (R3). Final crude product was analyzed 
by LCMS as described above LCMS (ESI+) m/z calcd for C21H42N6 [M + H]+: 379.35, 
found 379.10. LCMS retention time (214 nm) 3.884 min; purity 87.7%. 
(S)-4-((S)-sec-butyl)-1-(4-((S)-3-heptyl-2-iminoimidazolidin-4-yl)butyl)-3-(3-
methylphenethyl)imidazolidin-2-imine (32). Using the synthetic approach described in 
Figure 2.8 compound 32 was synthesized using the following reagents: heptanoic acid 
(R1), Boc-L-Ile (R2), m-tolylacetic acid (R3). Final crude product was analyzed by LCMS 
as described above LCMS (ESI+) m/z calcd for C30H52N6 [M + H]+: 497.43, found 
497.20. LCMS retention time (214 nm) 4.299 min; purity 82.8%. 
(4S)-4-((S)-sec-butyl)-1-(4-((S)-3-heptyl-2-iminoimidazolidin-4-yl)butyl)-3-(2-
methylbutyl)imidazolidin-2-imine (33). Using the synthetic approach described in Figure 
2.8 compound 33 was synthesized using the following reagents: heptanoic acid (R1), 
Boc-L-Ile (R2), 2-methylbutyric acid (R3). Final crude product was analyzed by LCMS as 
described above LCMS (ESI+) m/z calcd for C26H52N6 [M + H]+: 449.43, found 449.25. 
LCMS retention time (214 nm) 4.211 min; purity 81.2%. 
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(R)-1-(4-((S)-3-heptyl-2-iminoimidazolidin-4-yl)butyl)-4-propylimidazolidin-2-imine 
(34). Using the synthetic approach described in Figure 2.8 compound 34 was 
synthesized using the following reagents: heptanoic acid (R1), Boc-D-norvaline (R2), 1-
phenyl-1-cyclopropanecarboxylic acid (R3). Final crude product was analyzed by LCMS 
as described above LCMS (ESI+) m/z calcd for C20H40N6 [M + H]+: 365.33, found 
365.10. LCMS retention time (214 nm) 3.801 min; purity 85.9%. 
(R)-1-(4-((S)-3-heptyl-2-iminoimidazolidin-4-yl)butyl)-3-(3-methylphenethyl)-4-
propylimidazolidin-2-imine (35). Using the synthetic approach described in Figure 2.8 
compound 35 was synthesized using the following reagents: heptanoic acid (R1), Boc-
D-norvaline (R2), m-tolylacetic acid (R3). Final crude product was analyzed by LCMS as 
described above LCMS (ESI+) m/z calcd for C29H50N6 [M + H]+: 483.41, found 483.20. 
LCMS retention time (214 nm) 4.256 min; purity 80.5%. 
(4R)-1-(4-((S)-3-heptyl-2-iminoimidazolidin-4-yl)butyl)-3-(2-methylbutyl)-4-
propylimidazolidin-2-imine (36). Using the synthetic approach described in Figure 2.8 
compound 36 was synthesized using the following reagents: heptanoic acid (R1), Boc-
D-norvaline (R2), 2-methylbutyric acid (R3). Final crude product was analyzed by LCMS 
as described above LCMS (ESI+) m/z calcd for C25H50N6 [M + H]+: 435.41, found 
435.20. LCMS retention time (214 nm) 4.158 min; purity 84.6%. 
(S)-1-(cyclohexylmethyl)-5-(4-(2-iminoimidazolidin-1-yl)butyl)imidazolidin-2-imine 
(37). Using the synthetic approach described in Figure 2.8 compound 37 was 
synthesized using the following reagents: cyclohexanecarboxylic acid (R1), Boc-Gly 
(R2), 1-phenyl-1-cyclopropanecarboxylic acid (R3). Final crude product was analyzed by 
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LCMS as described above LCMS (ESI+) m/z calcd for C17H32N6 [M + H]+: 321.27, found 
321.05. LCMS retention time (214 nm) 3.195 min; purity 87.8%. 
(S)-1-(4-(3-(cyclohexylmethyl)-2-iminoimidazolidin-4-yl)butyl)-3-(3-
methylphenethyl)imidazolidin-2-imine (38). Using the synthetic approach described in 
Figure 2.8 compound 38 was synthesized using the following reagents: 
cyclohexanecarboxylic acid (R1), Boc-Gly (R2), m-tolylacetic acid (R3). Final crude 
product was analyzed by LCMS as described above LCMS (ESI+) m/z calcd for 
C26H42N6 [M + H]+: 439.35, found 439.15. LCMS retention time (214 nm) 3.848 min; 
purity 87.0%. 
1-(4-((S)-3-(cyclohexylmethyl)-2-iminoimidazolidin-4-yl)butyl)-3-(2-
methylbutyl)imidazolidin-2-imine (39). Using the synthetic approach described in Figure 
2.8 compound 39 was synthesized using the following reagents cyclohexanecarboxylic 
acid (R1), Boc-Gly (R2), 2-methylbutyric acid (R3). Final crude product was analyzed by 
LCMS as described above LCMS (ESI+) m/z calcd for C22H42N6 [M + H]+: 391.35, found 
391.10. LCMS retention time (214 nm) 3.688 min; purity 93.9%. 
(S)-4-((S)-sec-butyl)-1-(4-((S)-3-(cyclohexylmethyl)-2-iminoimidazolidin-4-
yl)butyl)imidazolidin-2-imine (40). Using the synthetic approach described in Figure 2.8 
compound 40 was synthesized using the following reagents: cyclohexanecarboxylic 
acid (R1), Boc-L-Ile (R2), 1-phenyl-1-cyclopropanecarboxylic acid (R3). Final crude 
product was analyzed by LCMS as described above LCMS (ESI+) m/z calcd for 
C21H40N6 [M + H]+: 377.33, found 377.10. LCMS retention time (214 nm) 3.687 min; 
purity 87.1%. 
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(S)-4-((S)-sec-butyl)-1-(4-((S)-3-(cyclohexylmethyl)-2-iminoimidazolidin-4-
yl)butyl)-3-(3-methylphenethyl)imidazolidin-2-imine (41). Using the synthetic approach 
described in Figure 2.8 compound 41 was synthesized using the following reagents: 
cyclohexanecarboxylic acid (R1), Boc-L-Ile (R2), m-tolylacetic acid (R3). Final crude 
product was analyzed by LCMS as described above LCMS (ESI+) m/z calcd for 
C30H50N6 [M + H]+: 495.41; found 495.20. LCMS retention time (214 nm) 4.182 min; 
purity 84.0%. 
(4S)-4-((S)-sec-butyl)-1-(4-((S)-3-(cyclohexylmethyl)-2-iminoimidazolidin-4-
yl)butyl)-3-(2-methylbutyl)imidazolidin-2-imine (42). Using the synthetic approach 
described in Figure 2.8 compound 42 was synthesized using the following reagents: 
cyclohexanecarboxylic acid (R1), Boc-L-Ile (R2), 2-methylbutyric acid (R3). Final crude 
product was analyzed by LCMS as described above LCMS (ESI+) m/z calcd for 
C26H50N6 [M + H]+: 447.41, found 447.25. LCMS retention time (214 nm) 4.080 min; 
purity 84.6%. 
(R)-1-(4-((S)-3-(cyclohexylmethyl)-2-iminoimidazolidin-4-yl)butyl)-4-
propylimidazolidin-2-imine (43). Using the synthetic approach described in Figure 2.8 
compound 43 was synthesized using the following reagents: cyclohexanecarboxylic 
acid (R1), Boc-D-norvaline (R2), 1-phenyl-1-cyclopropanecarboxylic acid (R3). Final 
crude product was analyzed by LCMS as described above LCMS (ESI+) m/z calcd for 
C20H38N6 [M + H]+: 363.32, found 363.05. LCMS retention time (214 nm) 3.584 min; 
purity 90.3%. 
(R)-1-(4-((S)-3-(cyclohexylmethyl)-2-iminoimidazolidin-4-yl)butyl)-3-(3-
methylphenethyl)-4-propylimidazolidin-2-imine (44). Using the synthetic approach 
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described in Figure 2.8 compound 44 was synthesized using the following reagents: 
cyclohexanecarboxylic acid (R1), Boc-D-norvaline (R2), m-tolylacetic acid (R3). Final 
crude product was analyzed by LCMS as described above LCMS (ESI+) m/z calcd for 
C29H48N6 [M + H]+: 481.39, found 481.25. LCMS retention time (214 nm) 4.125 min; 
purity 89.5%. 
(4R)-1-(4-((S)-3-(cyclohexylmethyl)-2-iminoimidazolidin-4-yl)butyl)-3-(2-
methylbutyl)-4-propylimidazolidin-2-imine (45). Using the synthetic approach described 
in Figure 2.8 compound 45 was synthesized using the following reagents: 
cyclohexanecarboxylic acid (R1), Boc-D-norvaline (R2), 2-methylbutyric acid (R3). Final 
crude product was analyzed by LCMS as described above LCMS (ESI+) m/z calcd for 
C25H48N6 [M + H]+: 433.39, found 433.20. LCMS retention time (214 nm) 4.006 min; 
purity 80.7%. 
(S)-5-(4-(2-iminoimidazolidin-1-yl)butyl)-1-((4-
methylcyclohexyl)methyl)imidazolidin-2-imine (46). Using the synthetic approach 
described in Figure 2.8 compound 46 was synthesized using the following reagents: 4-
methyl-1-cyclohexanecarboxylic acid (R1), Boc-Gly (R2), 1-phenyl-1-
cyclopropanecarboxylic acid (R3). Final crude product was analyzed by LCMS as 
described above LCMS (ESI+) m/z calcd for C18H34N6 [M + H]+: 335.28, found 335.10. 
LCMS retention time (214 nm) 3.379 min; purity 87.8%. 
(S)-1-(4-(2-imino-3-((4-methylcyclohexyl)methyl)imidazolidin-4-yl)butyl)-3-(3-
methylphenethyl)imidazolidin-2-imine (47). Using the synthetic approach described in 
Figure 2.8 compound 47 was synthesized using the following reagents: 4-methyl-1-
cyclohexanecarboxylic acid (R1), Boc-Gly (R2), m-tolylacetic acid (R3). Final crude 
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product was analyzed by LCMS as described above LCMS (ESI+) m/z calcd for 
C27H44N6 [M + H]+ 453.36; found 453.15. LCMS retention time (214 nm) 3.969 min; 
purity 89.4%. 
1-(4-((S)-2-imino-3-((4-methylcyclohexyl)methyl)imidazolidin-4-yl)butyl)-3-(2-
methylbutyl)imidazolidin-2-imine (48). Using the synthetic approach described in Figure 
2.8 compound 48 was synthesized using the following reagents: 4-methyl-1-
cyclohexanecarboxylic acid (R1), Boc-Gly (R2), 2-methylbutyric acid (R3). Final crude 
product was analyzed by LCMS as described above LCMS (ESI+) m/z calcd for 
C23H44N6 [M + H]+: 404.36; found 404.15. LCMS retention time (214 nm) 3.820 min; 
purity 98.5%. 
(S)-4-((S)-sec-butyl)-1-(4-((S)-2-imino-3-((4-
methylcyclohexyl)methyl)imidazolidin-4-yl)butyl)imidazolidin-2-imine (49). Using the 
synthetic approach described in Figure 2.8 compound 49 was synthesized using the 
following reagents: 4-methyl-1-cyclohexanecarboxylic acid (R1), Boc-L-Ile (R2), 1-
phenyl-1-cyclopropanecarboxylic acid (R3). Final crude product was analyzed by LCMS 
as described above LCMS (ESI+) m/z calcd for C22H42N6 [M + H]+: 391.35, found 
391.10. LCMS retention time (214 nm) 3.812 min; purity 81.4%. 
(S)-4-((S)-sec-butyl)-1-(4-((S)-2-imino-3-((4-
methylcyclohexyl)methyl)imidazolidin-4-yl)butyl)-3-(3-methylphenethyl)imidazolidin-2-
imine (50). Using the synthetic approach described in Figure 2.8 compound 50 was 
synthesized using the following reagents: 4-methyl-1-cyclohexanecarboxylic acid (R1), 
Boc-L-Ile (R2), m-tolylacetic acid (R3). Final crude product was analyzed by LCMS as 
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described above LCMS (ESI+) m/z calcd for C31H52N6 [M + H]+: 509.43, found 509.25. 
LCMS retention time (214 nm) 4.261 min; purity 84.6%. 
(4S)-4-((S)-sec-butyl)-1-(4-((S)-2-imino-3-((4-
methylcyclohexyl)methyl)imidazolidin-4-yl)butyl)-3-(2-methylbutyl)imidazolidin-2-imine 
(51). Using the synthetic approach described in Figure 2.8 compound 51 was 
synthesized using the following reagents: 4-methyl-1-cyclohexanecarboxylic acid (R1), 
Boc-L-Ile (R2), 2-methylbutyric acid (R3). Final crude product was analyzed by LCMS as 
described above LCMS (ESI+) m/z calcd for C27H52N6 [M + H]+: 461.43, found 461.25. 
LCMS retention time (214 nm) 4.163 min; purity 89.5%. 
(R)-1-(4-((S)-2-imino-3-((4-methylcyclohexyl)methyl)imidazolidin-4-yl)butyl)-4-
propylimidazolidin-2-imine (52). Using the synthetic approach described in Figure 2.8 
compound 52 was synthesized using the following reagents: 4-methyl-1-
cyclohexanecarboxylic acid (R1), Boc-D-norvaline (R2), 1-phenyl-1-
cyclopropanecarboxylic acid (R3). Final crude product was analyzed by LCMS as 
described above LCMS (ESI+) m/z calcd for C21H40N6 [M + H]+: 377.33, found 377.10. 
LCMS retention time (214 nm) 3.730 min; purity 86.1%. 
(R)-1-(4-((S)-2-imino-3-((4-methylcyclohexyl)methyl)imidazolidin-4-yl)butyl)-3-(3-
methylphenethyl)-4-propylimidazolidin-2-imine (53). Using the synthetic approach 
described in Figure 2.8 compound 53 was synthesized using the following reagents: 4-
methyl-1-cyclohexanecarboxylic acid (R1), Boc-D-norvaline (R2), m-tolylacetic acid (R3). 
Final crude product was analyzed by LCMS as described above LCMS (ESI+) m/z calcd 
for C30H50N6 [M + H]+: 495.41, found 495.25. LCMS retention time (214 nm) 4.214 min; 
purity 88.2%. 
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(4R)-1-(4-((S)-2-imino-3-((4-methylcyclohexyl)methyl)imidazolidin-4-yl)butyl)-3-
(2-methylbutyl)-4-propylimidazolidin-2-imine (54). Using the synthetic approach 
described in Figure 2.8 compound 54 was synthesized using the following reagents: 4-
methyl-1-cyclohexanecarboxylic acid (R1), Boc-D-norvaline (R2), 2-methylbutyric acid 
(R3). Final crude product was analyzed by LCMS as described above LCMS (ESI+) m/z 
calcd for C26H50N6 [M + H]+: 447.41, found 447.20. LCMS retention time (214 nm) 4.112 
min; purity 91.0%. 
 
MIC Determination Assays 
The minimum inhibitory concentration (MIC) for the combinatorial libraries, 
deconvolved Lib1 library, and individual compounds were determined as follows. Broth 
cultures of ESKAPE strains were grown overnight before being diluted 1 in 1000 in fresh 
media. Sterile 96-well plates were loaded with culture, and compounds (in DMF) were 
added at decreasing concentrations to equal a total volume of 200 µL per well. Care 
was taken to not add more than 2.0% DMF to any well. Plates were then incubated at 
37 °C, and MICs determined after 24 h by visual inspection for a lack of turbidity in 
wells. All assays were performed in triplicate with identical results obtained. 
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Tables 
Table 2.1. Scaffold Ranking ESKAPE 
ID # of samp Total # Core Scaffold 
100 
µg/mL 
50 
µg/mL 
25 
µg/mL 
10 
µg/mL 
5 
µg/mL 
Lib1 110 45,864 
 
ESAPE ESAPE ESAPE ESAPE ESAE 
Lib2 120 738,192 
 
ESAE SA SA SA S 
Lib3 110 45,864 
 
ESAE SA SA SA S 
Lib4 116 56,610 
 
ESA ESA ESA S S 
Lib5 116 56,610 
 
ESA ESA ES S S 
Lib6 120 738,192 
 
ESAE ESA ESA SA - 
Lib7 110 45,864 
 
ESKAP
E SKAE S S - 
Lib8 116 56,610 
 
ESA ESA SA S - 
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Table 2.1 (continued). Scaffold Ranking ESKAPE 
ID # of samp Total # Core Scaffold 
100 
µg/mL 
50 
µg/mL 
25 
µg/mL 
10 
µg/mL 
5 
µg/mL 
Lib9 96 31,320 
 
ESA SA SA S - 
Lib10 120 738,192 
 
ESKAPE SA S S - 
Lib11 125 72,283 
 
S S S S - 
Lib12 110 45,864 
 
ESA ESA SA - - 
Lib13 116 56,610 
 
ESA S S - - 
Lib14 83 17,340 
 
ESA S S - - 
Lib15 174 195,112 
 
SA S S - - 
Lib16 142 102,459 
 
SA S S - - 
Lib17 319 13,398 
 
S S S - - 
Lib18 83 17,340 
 
S S S - - 
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Table 2.1 (continued). Scaffold Ranking ESKAPE 
ID # of samp Total # Core Scaffold 
100 
µg/mL 
50 
µg/mL 
25 
µg/mL 
10 
µg/mL 
5 
µg/mL 
Lib19 96 31,320 
 
ESA S - - - 
Lib20 96 31,320 
 
ES S - - - 
Lib21 120 738,192 
 
SA S - - - 
Lib22 96 31,320 
 
S S - - - 
Lib23 110 45,864 
 
S S - - - 
Lib24 94 3,249 
 
ES - - - - 
Lib25 107 45,288 
 
S - - - - 
Lib26 150 125,000 
 
A - - - - 
Lib27 120 738,192 
 
- - - - - 
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Table 2.1 (continued). Scaffold Ranking ESKAPE 
ID # of samp Total # Core Scaffold 
100 
µg/mL 
50 
µg/mL 
25 
µg/mL 
10 
µg/mL 
5 
µg/mL 
Lib28 96 31,320 
 
- - - - - 
Lib29 135 85,248 
 
- - - - - 
Lib30 400 16,400 
 
- - - - - 
Lib31 400 16,000 
 
- - - - - 
Lib32 400 10,800 
 
- - - - - 
Lib33 128 38,250 
 
- - - - - 
Lib34 156 134,560 
 
- - - - - 
Lib35 127 3,990 
 
- - - - - 
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Table 2.1 (continued). Scaffold Ranking ESKAPE 
ID # of samp Total # Core Scaffold 
100 
µg/mL 
50 
µg/mL 
25 
µg/mL 
10 
µg/mL 
5 
µg/mL 
Lib36 125 3,876 
 
- - - - - 
Lib37 94 3,249 
 
- - - - - 
 
“ID” corresponds to the numbers used throughout the chapter.  “# of sample” is the 
number of samples in the corresponding positional scanning library for a given scaffold. 
“Total #” is the total number of compounds in a given scaffold ranking sample.  
“ESKAPE” for each of the given doses tested a letter corresponding with one of the 6 
pathogens is provided if the sample inhibited the growth of that pathogen. 
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Table 2.2. Scaffold Ranking ESKAPE – Libraries From Libraries Set 1. 
ID # of  Total # Core Scaffold 100 µg/mL 
50 
µg/mL 
25 
µg/mL 
10 
µg/mL 
5 
µg/mL 
Lib1 110 45,864 
 
ESAPE ESAPE ESAPE ESAPE ESAE 
Lib3 110 45,864 
 
ESAE SA SA SA S 
Lib7 110 45,864 
 
ESKAPE SKAE S S - 
Lib12 110 45,864 
 
ESA ESA SA - - 
Lib23 110 45,864 
 
S S - - - 
 
“ID” corresponds to the numbers used throughout the chapter.  “# of” is the number of 
samples in the corresponding positional scanning library for a given scaffold. “Total #” is 
the total number of compounds in a given scaffold ranking sample.  “ESKAPE” for each 
of the given doses tested a letter corresponding with one of the 6 pathogens is provided 
if the sample inhibited the growth of that pathogen. 
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Table 2.3. Scaffold Ranking ESKAPE – Libraries From Libraries Set 2. 
ID # of  Total # Core Scaffold 100 µg/mL 
50 
µg/mL 
25 
µg/mL 
10 
µg/mL 
5 
µg/mL 
Lib2 120 738,192 
 
ESAE SA SA SA S 
Lib6 120 738,192 
 
ESAE ESA ESA SA - 
Lib10 120 738,192 
 
ESKAPE SA S S - 
Lib21 120 738,192 
 
SA S - - - 
Lib27 120 738,192 
 
- - - - - 
 
“ID” corresponds to the numbers used throughout the chapter.  “# of” is the number of 
samples in the corresponding positional scanning library for a given scaffold. “Total #” is 
the total number of compounds in a given scaffold ranking sample.  “ESKAPE” for each 
of the given doses tested a letter corresponding with one of the 6 pathogens is provided 
if the sample inhibited the growth of that pathogen. 
 
 
 
 
 
!96 
Table 2.4. Positional Scanning Data R1 ESKAPE. 
 
ID # R1 E S K A P E 
Lib1.001 hydrogen       
Lib1.002 2-phenylbutyl       
Lib1.003 3-phenylbutyl       
Lib1.004 m-tolylethyl       
Lib1.005 2-(3-fluoro-phenyl)-ethyl       
Lib1.006 2-(3-bromo-phenyl)-ethyl       
Lib1.007 2-(3-trifluoromethyl-phenyl)-ethyl       
Lib1.008 p-tolylethyl       
Lib1.009 2-(4-fluoro-phenyl)-ethyl       
Lib1.010 2-(3-methoxy-phenyl)-ethyl       
Lib1.011 2-(4-bromo-phenyl)-ethyl       
Lib1.012 2-(4-methoxy-phenyl)-ethyl       
Lib1.013 2-(4-ethoxy-phenyl)-ethyl       
Lib1.014 2-(4-Isobutyl-phenyl)-propyl       
Lib1.015 3,4-dichlorophenethyl       
Lib1.016 2-(3,5-bis-trifluoromethyl-phenyl)-ethyl       
Lib1.017 3-(3,4-dimethoxy-phenyl)-propyl       
Lib1.018 phenethyl       
Lib1.019 3,4,5-trimethoxy-benzyl       
Lib1.020 butyl       
Lib1.021 heptyl       
Lib1.022 isobutyl       
Lib1.023 2-methylbutyl       
Lib1.024 3-methylbutyl       
Lib1.025 3-methylpentyl       
Lib1.026 4-methylpentyl       
Lib1.027 4-methyl-benzyl       
Lib1.028 cyclopently-methyl       
Lib1.029 cyclohexyl-methyl       
Lib1.030 cyclohexyl-ethyl       
Lib1.031 cyclohexyl-butyl       
Lib1.032 cycloheptyl-methyl       
Lib1.033 2-methylcyclopropyl-methyl       
Lib1.034 cyclobutyl-methyl       
Lib1.035 3-cyclopentyl-propyl       
Lib1.036 cyclohexyl-propyl       
Lib1.037 4-methyl-1-cyclohexyl-methyl       
Lib1.038 4-tert-butyl-cyclohexyl-methyl       
Lib1.039 2-biphenyl-4-yl-ethyl       
Lib1.040 adamantan-1-yl-methyl       
Lib1.041 adamantan-1-yl-ethyl       
Lib1.042 2-bicyclo[2.2.1]hept-2-yl-ethyl       
 
MIC data obtained from the screening of the 42 R1 samples from positional scanning library 
Lib1.  Column R1 indicates the functionality defined in the R1 position of the core scaffold 
depicted above the table.  indicates a MIC ≤5 µg/mL,  a MIC 5-10 µg/mL,  a MIC 10-25 
µg/mL, and  > 25 µg/mL. 
!
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Table 2.5. Positional Scanning Data R2 ESKAPE. 
!
ID # R2 E S K A P E 
Lib1.043 S-methyl       
Lib1.044 S-benzyl       
Lib1.045 hydrogen       
Lib1.046 S-2-butyl       
Lib1.047 S-isobutyl       
Lib1.048 R-hydroxymethyl       
Lib1.049 (R,R)-1-hydroxyethyl       
Lib1.050 S-isopropyl       
Lib1.051 S-4-hydroxybenzyl       
Lib1.052 R-methyl       
Lib1.053 R-benzyl       
Lib1.054 R-2-butyl       
Lib1.055 R-isobutyl       
Lib1.056 S-hydroxymethyl       
Lib1.057 (S,S)-1-hydroxyethyl       
Lib1.058 R-isopropyl       
Lib1.059 R-4-hydroxybenzyl       
Lib1.060 S-phenyl       
Lib1.061 S-propyl       
Lib1.062 R-propyl       
Lib1.063 S-butyl       
Lib1.064 R-butyl       
Lib1.065 S-2-naphthylmethyl       
Lib1.066 R-2-naphthylmethyl       
Lib1.067 S-cyclohexylmethyl       
Lib1.068 R-cyclohexylmethyl       
!
MIC data obtained from the screening of the 42 R2 samples from positional scanning library 
Lib1.  Column R1 indicates the functionality defined in the R2 position of the core scaffold 
depicted above the table.  indicates a MIC ≤5 µg/mL,  a MIC 5-10 µg/mL,  a MIC 10-25 
µg/mL, and  > 25 µg/mL. 
!
!
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Table 2.6. Positional Scanning Data R3 ESKAPE. 
 
ID # R1 E S K A P E 
Lib1.069 hydrogen       
Lib1.070 2-phenylbutyl       
Lib1.071 3-phenylbutyl       
Lib1.072 m-tolylethyl       
Lib1.073 2-(3-fluoro-phenyl)-ethyl       
Lib1.074 2-(3-bromo-phenyl)-ethyl       
Lib1.075 2-(3-trifluoromethyl-phenyl)-ethyl       
Lib1.076 p-tolylethyl       
Lib1.077 2-(4-fluoro-phenyl)-ethyl       
Lib1.078 2-(3-methoxy-phenyl)-ethyl       
Lib1.079 2-(4-bromo-phenyl)-ethyl       
Lib1.080 2-(4-methoxy-phenyl)-ethyl       
Lib1.081 2-(4-ethoxy-phenyl)-ethyl       
Lib1.082 2-(4-Isobutyl-phenyl)-propyl       
Lib1.083 3,4-dichlorophenethyl       
Lib1.084 2-(3,5-bis-trifluoromethyl-phenyl)-ethyl       
Lib1.085 3-(3,4-dimethoxy-phenyl)-propyl       
Lib1.086 phenethyl       
Lib1.087 3,4,5-trimethoxy-benzyl       
Lib1.088 butyl       
Lib1.089 heptyl       
Lib1.090 isobutyl       
Lib1.091 2-methylbutyl       
Lib1.092 3-methylbutyl       
Lib1.093 3-methylpentyl       
Lib1.094 4-methylpentyl       
Lib1.095 4-methyl-benzyl       
Lib1.096 cyclopently-methyl       
Lib1.097 cyclohexyl-methyl       
Lib1.098 cyclohexyl-ethyl       
Lib1.099 cyclohexyl-butyl       
Lib1.100 cycloheptyl-methyl       
Lib1.101 2-methylcyclopropyl-methyl       
Lib1.102 cyclobutyl-methyl       
Lib1.103 3-cyclopentyl-propyl       
Lib1.104 cyclohexyl-propyl       
Lib1.105 4-methyl-1-cyclohexyl-methyl       
Lib1.106 4-tert-butyl-cyclohexyl-methyl       
Lib1.107 2-biphenyl-4-yl-ethyl       
Lib1.108 adamantan-1-yl-methyl       
Lib1.109 adamantan-1-yl-ethyl       
Lib1.110 2-bicyclo[2.2.1]hept-2-yl-ethyl       
!
MIC data obtained from the screening of the 42 R3 samples from positional scanning library 
Lib1.  Column R1 indicates the functionality defined in the R3 position of the core scaffold 
depicted above the table.  indicates a MIC ≤5 µg/mL,  a MIC 5-10 µg/mL,  a MIC 10-25 
µg/mL, and  > 25 µg/mL. 
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Table 2.7. Functionalities Used For The Synthesis of Individual Compounds. 
!
Set A: Predicted Broad-Spectrum Activity Set 
ID R1 E S K A P E 
Lib1.007 2-(3-trifluoromethyl-phenyl)-ethyl       
Lib1.031 cyclohexyl-butyl       
Lib1.041 adamantan-1-yl-ethyl       
ID R2 E S K A P E 
Lib1.063 S-butyl       
Lib1.066 R-2-naphthylmethyl       
Lib1.067 S-cyclohexylmethyl       
ID R3 E S K A P E 
Lib1.089 heptyl       
Lib1.099 cyclohexyl-butyl       
Lib1.107 2-Biphenyl-4-yl-ethyl       
 
Set B: Predicted To Have Less Broad-Spectrum Activity Than Set A 
ID R1 E S K A P E 
Lib1.021 heptyl       
Lib1.029 cyclohexyl-methyl       
Lib1.037 4-methyl-1-cyclohexyl-methyl       
ID R2 E S K A P E 
Lib1.045 hydrogen       
Lib1.046 S-2-butyl       
Lib1.062 R-propyl       
ID R3 E S K A P E 
Lib1.069 hydrogen       
Lib1.072 m-tolylethyl       
Lib1.091 2-methylbutyl       
!
Set A shows the 3 functionalities in each of the 3 R positions used for the synthesis of the 
individual compounds predicted to have broad spectrum antibacterial activity (1-27 Table 2.8).  
The 27 compounds in this set come from making every combination of the 3 functionalities in 
each of the three positions.  The second set of 27 compounds (28-54 Table 2.8) is made from 
the combination of the functionalities in Set B.  The table also indicates the ID numbers and 
ESKAPE activity values reported from Table 2.4 (R1), Table 2.5 (R2), and Table 2.6 (R3)  
indicates a MIC ≤5 µg/mL,  a MIC 5-10 µg/mL,  a MIC 10-25 µg/mL, and  > 25 µg/mL. 
!
!
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Table 2.8. 27 Individual Compounds Predicted to Have Broad-Spectrum Antimicrobial Activity!
ID R1 R2 R3 25 µM 10 µM 5 µM 4 µM 3 µM 2 µM 
1 2-(3-trifluoromethyl-phenyl)-ethyl S-butyl heptyl ESKAPE ESKAPE ESKAPE SK SK S 
2 2-(3-trifluoromethyl-phenyl)-ethyl S-butyl 
cyclohexyl-
butyl ESKAPE ESKAPE ESKAPE ESAP ES E 
3 2-(3-trifluoromethyl-phenyl)-ethyl S-butyl 
2-biphenyl-
4-yl-ethyl ESKAPE ESKAPE ESKAPE ESKA S - 
4 2-(3-trifluoromethyl-phenyl)-ethyl 
R-2-
naphthylmethyl heptyl ESKAPE ESKAE ESKAE ESA E - 
5 2-(3-trifluoromethyl-phenyl)-ethyl 
R-2-
naphthylmethyl 
cyclohexyl-
butyl ESKAPE ESKAE ESKAE K - - 
6 2-(3-trifluoromethyl-phenyl)-ethyl 
R-2-
naphthylmethyl 
2-biphenyl-
4-yl-ethyl ESKAPE ESKAE SKAE - - - 
7 2-(3-trifluoromethyl-phenyl)-ethyl 
S-
cyclohexylmethyl heptyl ESKAPE ESKAPE ESKAPE ESAP ES - 
8 2-(3-trifluoromethyl-phenyl)-ethyl 
S-
cyclohexylmethyl 
cyclohexyl-
butyl ESKAPE ESKAPE EKAPE P - - 
9 2-(3-trifluoromethyl-phenyl)-ethyl 
S-
cyclohexylmethyl 
2-biphenyl-
4-yl-ethyl ESKAPE ESKAPE ESKAPE EP - - 
10 cyclohexyl-butyl S-butyl heptyl ESKAPE ESKAPE ESKAPE ESAP - - 
11 cyclohexyl-butyl S-butyl cyclohexyl-butyl ESKAPE ESKAPE ESAPE EA E E 
12 cyclohexyl-butyl S-butyl 2-biphenyl-4-yl-ethyl ESKAPE ESKAPE ESKAE A - - 
13 cyclohexyl-butyl R-2-naphthylmethyl heptyl ESKAPE ESKAE ESKAE P - - 
14 cyclohexyl-butyl R-2-naphthylmethyl 
cyclohexyl-
butyl ESKAPE ESKAE SKAE - - - 
15 cyclohexyl-butyl R-2-naphthylmethyl 
2-biphenyl-
4-yl-ethyl ESKAPE ESKE SE - - - 
16 cyclohexyl-butyl S-cyclohexylmethyl heptyl ESKAPE ESKAPE ESKAPE EAP EA - 
17 cyclohexyl-butyl S-cyclohexylmethyl 
cyclohexyl-
butyl ESKAPE ESKAPE ESKAPE - - - 
18 cyclohexyl-butyl S-cyclohexylmethyl 
2-biphenyl-
4-yl-ethyl ESKAPE ESKAPE ESKAPE - - - 
19 adamantan-1-yl-ethyl S-butyl heptyl ESKAPE ESKAPE ESKAPE ESAP ES - 
20 adamantan-1-yl-ethyl S-butyl 
cyclohexyl-
butyl ESKAPE ESKAPE ESKAPE EAP E E 
21 adamantan-1-yl-ethyl S-butyl 
2-biphenyl-
4-yl-ethyl ESKAPE ESKAPE ESKAPE EA E - 
22 adamantan-1-yl-ethyl 
R-2-
naphthylmethyl heptyl ESKAPE ESKAE ESKAE EAP - - 
23 adamantan-1-yl-ethyl 
R-2-
naphthylmethyl 
cyclohexyl-
butyl ESE S S S - - 
24 adamantan-1-yl-ethyl 
R-2-
naphthylmethyl 
2-Biphenyl-
4-yl-ethyl ES S - - - - 
25 adamantan-1-yl-ethyl 
S-
cyclohexylmethyl heptyl ESKAPE ESKAPE ESKAPE EAP E E 
26 adamantan-1-yl-ethyl 
S-
cyclohexylmethyl 
cyclohexyl-
butyl ESKAPE ESKAPE ESKAPE - - - 
27 adamantan-1-yl-ethyl 
S-
cyclohexylmethyl 
2-biphenyl-
4-yl-ethyl ESKAPE ESKPE SKP - - - 
!
The R1, R2, and R3 functionalities for each compound are listed (the complete structures for 
each compound are shown in Figure 2.7).  “ESKAPE” for each of the given doses tested a letter 
corresponding with one of the 6 pathogens is provided if the sample inhibited the growth of that 
pathogen at that dose. 
!
!101 
Table 2.9. 27 Individual Compounds – Set B.!
ID R1 R2 R3 25 µM 10 µM 5 µM 4 µM 3 µM 2 µM 
28 heptyl hydrogen hydrogen - - - - - - 
29 heptyl hydrogen m-tolylethyl S - - - - - 
30 heptyl hydrogen 2-methylbutyl - - - - - - 
31 heptyl S-2-butyl hydrogen S - - - - - 
32 heptyl S-2-butyl m-tolylethyl ESAP ES S S S - 
33 heptyl S-2-butyl 2-methylbutyl S - - - - - 
34 heptyl R-propyl hydrogen S - - - - - 
35 heptyl R-propyl m-tolylethyl ESAP S - - - - 
36 heptyl R-propyl 2-methylbutyl S - - - - - 
37 cyclohexyl-methyl hydrogen hydrogen - - - - - - 
38 cyclohexyl-methyl hydrogen m-tolylethyl S - - - - - 
39 cyclohexyl-methyl hydrogen 2-methylbutyl - - - - - - 
40 cyclohexyl-methyl S-2-butyl hydrogen - - - - - - 
41 cyclohexyl-methyl S-2-butyl m-tolylethyl S - - - - - 
42 cyclohexyl-methyl S-2-butyl 2-methylbutyl S - - - - - 
43 cyclohexyl-methyl R-propyl hydrogen - - - - - - 
44 cyclohexyl-methyl R-propyl m-tolylethyl S - - - - - 
45 cyclohexyl-methyl R-propyl 2-methylbutyl S - - - - - 
46 4-methyl-1-cyclohexyl-methyl hydrogen hydrogen - - - - - - 
47 4-methyl-1-cyclohexyl-methyl hydrogen m-tolylethyl S - - - - - 
48 4-methyl-1-cyclohexyl-methyl hydrogen 2-methylbutyl - - - - - - 
49 4-methyl-1-cyclohexyl-methyl S-2-butyl hydrogen S - - - - - 
50 4-methyl-1-cyclohexyl-methyl S-2-butyl m-tolylethyl ESA ES - - - - 
51 4-methyl-1-cyclohexyl-methyl S-2-butyl 2-methylbutyl S - - - - - 
52 4-methyl-1-cyclohexyl-methyl R-propyl hydrogen S - - - - - 
53 4-methyl-1-cyclohexyl-methyl R-propyl m-tolylethyl S - - - - - 
54 4-methyl-1-cyclohexyl-methyl R-propyl 2-methylbutyl S - - - - - 
!
The R1, R2, and R3 functionalities for each compound are listed (the complete structures for 
each compound are shown in Figure 2.7).  “ESKAPE” for each of the given doses tested a letter 
corresponding with one of the 6 pathogens is provided if the sample inhibited the growth of that 
pathogen. 
 
 
 
 
 
 
 
!102 
Figures 
 
Figure 2.1. Libraries from Libraries ESKAPE Set 1 – Synthesis of Multiple Heterocyclic Scaffolds From a 
Common Peptide Like Scaffold. 
a) Borane-THF 65 oC 96 hr; Piperazine 65 oC, 24 hr b) HF 0 oC 7 hr c) Oxalyldiimidazole, DMF d) HF 0 oC 
1.5 hr e) Cyanogen bromide, DCM f) Thiocarbonyldiimidazole, DCM.   
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Figure 2.2. Libraries from Libraries ESKAPE Set 2 – Synthesis of Multiple Heterocyclic 
Scaffolds From a Common Peptide Like Scaffold. 
a) Borane-THF 65 oC 96 hr; Piperazine 65 oC, 24 hr b) HF 0 oC 7 hr c) Oxalyldiimidazole, DMF 
d) HF 0 oC 1.5 hr e) Cyanogen bromide, DCM f) Thiocarbonyldiimidazole, DCM.   
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ID # R2 E S K A P E 
Lib1.043 S-methyl       
Lib1.052 R-methyl       
Lib1.047 S-isobutyl       
Lib1.055 R-isobutyl       
 
Figure 2.3. SAR for Diastereomer Mixtures.   
  indicates a MIC ≤5 µg/mL,  a MIC 5-10 µg/mL,  a MIC 10-25 µg/mL, and  > 25 µg/mL. 
 
 
ID # R2 E S K A P E 
Lib1.043 S-methyl       
Lib1.061 S-propyl       
Lib1.063 S-butyl       
 
Figure 2.4. SAR Length of R2 Functionality.   
 indicates a MIC ≤5 µg/mL,  a MIC 5-10 µg/mL,  a MIC 10-25 µg/mL, and  > 25 µg/mL. 
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ID # R1 E S K A P E 
Lib1.029 cyclohexyl-methyl       
Lib1.030 cyclohexyl-ethyl       
Lib1.036 cyclohexyl-propyl       
Lib1.031 cyclohexyl-butyl       
 
Figure 2.5. SAR Length of R1 Functionality.   
 indicates a MIC ≤5 µg/mL,  a MIC 5-10 µg/mL,  a MIC 10-25 µg/mL, and  > 25 µg/mL. 
 
 
ID # R2 E S K A P E 
Lib1.044 S-benzyl       
Lib1.065 S-2-naphthylmethyl       
Lib1.051 S-4-hydroxybenzyl       
 
Figure 2.6. SAR Phenyl Substitutions.   
 indicates a MIC ≤5 µg/mL,  a MIC 5-10 µg/mL,  a MIC 10-25 µg/mL, and  > 25 µg/mL. 
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Figure 2.7. 54 Individual Compounds   
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Figure 2.7 (continued). 54 Individual Compounds  (Compounds 10 to 18) 
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Figure 2.7 (continued). 54 Individual Compounds  (Compounds 19 to 27) 
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Figure 2.7 (continued). 54 Individual Compounds  (Compounds 28 to 36) 
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Figure 2.7 (continued). 54 Individual Compounds  (Compounds 37 to 45) 
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Figure 2.7 (continued). 54 Individual Compounds  (Compounds 46 to 54) 
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Figure 2.8. Synthesis of Bis-cyclic Guanidines. 
a) 5%DIEA/DCM b) Fmoc-Lys(Boc), DIC, HOBt, DMF c) 20% Piperidine/DMF d) R1-COOH, 
DIC, HOBt, DMF e) 55% TFA/DCM; 5% DIEA/DCM f) Boc-AA(R2)-OH, DIC, HOBt, DMF g) R3-
COOH, DIC, HOBt, DMF h) Borane-THF 65 oC 96 hr; Piperazine 65 oC, 24 hr i) Cyanogen 
bromide, DCM j) HF 0 oC 1.5 hr. 
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CHAPTER THREE: 
SYSTEMATICALLY FORMATED MIXTURE BASED LIBRAIRES - 
LEISHMANIASIS 
 
Introduction  
Leishmaniasis is a disease caused by infection with Leishmania parasites, which 
are spread by the bite of phlebotomine sand flies.  The most severe form of the disease 
is visceral leishmaniasis caused by the protozoan parasites Leishmania donovani and 
Leishmania infantum.1,2  People suffering from visceral leishmaniasis experience 
cachexia, cytopenia, fever, hepatosplenomegaly and death if not treated.2 It is 
estimated that there are 200,000 to 400,000 new cases of visceral leishmaniasis each 
year and >20,000 deaths a year due to the disease.3 Current therapeutics for patients 
with visceral leishmaniasis include liposomal amphotericin B, paromomycin sodium 
stiboglucontate, miltefosine, and pentamidine.  All of these therapeutics lack in terms of 
ease-of-use, efficacy, cost, safety, or drug resistance.4 While much effort is underway 
on developing new therapeutics there is a pressing need to continue to identify novel 
compounds for the treatment of this disease. 
 In collaboration with Dr. Dennis Kyle’s group a mixture based scaffold ranking 
library was initially screened in a L. donovani axenic amastigote assay as well as a 
high-content imaging screen utilizing macrophages infected with L. donovani 
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amastigotes.  From this initial screen the bis-cyclic guanidine scaffold ranking sample, 
Lib1, demonstrated potency in both leishmaniasis assays with no sign of cytotoxicity in 
an uninfected macrophage counter screen.  The Lib1 positional scanning library was 
then screened in the axenic amastigote and infected macrophage assays in order to 
develop a SAR profile around the core bis-cyclic guanidine scaffold.  Additionally the 
Lib1 positional scanning data was compared to the ESKAPE pathogen screening data 
generated in Chapter 2.  From this analysis the 27 broad spectrum antimicrobial 
compounds identified in Chapter 2 (compounds 1 to 27) were selected as good 
candidate individual compounds for screening in the high-content L. donovani 
amastigote infected macrophage assay. 
 After the SAR trends were confirmed with the 27 individual compounds a series 
of analogs were synthesized and tested in the infected macrophage assay (Dr. Kyle’s 
group) and the ESKAPE pathogen assays (Dr. Shaw’s group) in order to identify hit 
compounds that were selective for L. donovani over the ESKAPE pathogens.  From this 
work several new L. donovani specific compounds possessing sub 1 µM IC50s in the 
infected macrophage assay were identified.  Among the hits is a monocyclic guanidine 
compound, 86.    
 
Scaffold Ranking 
In order to prioritize the screening of positional scanning libraries a scaffold 
ranking library was assembled (Table 3.1) in a similar manner to that as described in 
Chapter 2. Each of the 30 mixture samples shown in Table 3.1 contained an equal 
molar mixture of every compound available for a given scaffold.  For example, the 
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scaffold ranking sample Lib1 contained an equal molar mixture of 45,864 individual bis-
cyclic guanidine analogs (Table 3.1).  As described in Chapters 1 and 2 and 
elsewhere5,6, these scaffold ranking samples can be prepared as synthetic mixtures or 
by pooling together aliquots of each sample in a given positional scanning library.  For 
28 of the 30 scaffolds shown in Table 3.1, antibacterial data was obtained and reported 
in Chapter 2 (Table 2.1) 
Of the 30 scaffold ranking samples shown in Table 3.1, 28 were screened at 4 
doses (25, 12.5, 2.5, and 1.25 µg/ml) in an assay using axenic L. donovani amastigote 
strains, CR6 and CS1 as described in Wang et al.7 Only scaffold ranking sample Lib1 
showed substantial activity at any of the doses tested, producing >90% inhibition at the 
12.5 and 25 µg/ml doses.  No other sample produced >30% inhibition at any of the 
doses tested  (Table 3.1 shows the 12.5 µg/ml data).  Interestingly, while Lib1 was the 
scaffold ranking sample that produced the most potent broad spectrum antibacterial 
activity (Chapter 2), some of the other potent antibacterial scaffold ranking samples 
showed no potency in the amastigote assay, including the other bis-guanidine scaffold 
Lib2. Table 3.1 contains a column indicating the “Rank” of the given scaffold in terms of 
broad-spectrum antibacterial potency (data from Chapter 2).   
While the axenic amastigote assay allows for a quick assessment of a sample’s 
intrinsic antileishmanial activity, it does however have the major weakness in that the 
effect of the host mammalian cell cannot be taken into account.  In order to assess the 
antileishmanial efficacy of the scaffold ranking samples against intracellular parasites, a 
high content screening (HCS) assay with L. donovani infected J774 macrophages was 
utilized.  In addition, a counter screen assay utilizing non-infected J774 macrophages 
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was performed on the scaffold ranking samples to assess their potential toxicity to the 
host mammalian cell.  From these two assays a selectivity index was calculated by 
dividing the IC50 obtained from the non-infected macrophage by the IC50 from the 
infected macrophage assay.  The IC50 from the infected macrophage assay as well as 
the selectivity index are also reported in Table 3.1.  In addition to scaffold ranking 
sample Lib1, several other samples produced sub 1.0 µg/ml IC50 values with >50 fold 
selectivity (Table 3.1).  These additional scaffold ranking samples included two 
polyamine scaffolds (Lib20 and Lib38), a bis-piperazine (Lib3), a bis-cyclic thiourea 
(Lib21) and a scaffold with a hydroproline and piperazine group (Lib37).  Of note, there 
were other scaffolds with similar cores that were not as potent in the HCS assay, 
including the polyamine scaffolds (Lib7 and Lib10) and bis-cyclic thiourea scaffold 
(Lib12).  Due to its activity in both the amastigote and infected macrophage assays, as 
well as its lack of activity in the counterscreen assay, the scaffold ranking sample Lib1 
was prioritized for positional scanning library screening. 
 
Positional Scanning 
Positional scanning library Lib1 was synthesized using the synthesis scheme 
shown in Chapter 2 (Figure 2.1) as well as in Chapter 1 (Figures 1.3 and 1.4).6  As 
described in Chapter 1, 110 different mixture samples were synthesized using the 
reagents listed in Table 1.3, 1.4, and 1.5.  After the synthesis was completed, 110 
different mixture samples of bis-cyclic guanidine analogs were obtained (Table 3.2, 3.3, 
and 3.4).   
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The first 42 samples, Table 3.2, were systematically formatted by R1 functionality.  
For example, sample Lib1.020 contained the 1,092 bis-cyclic guanidines incorporating 
a butyl in the R1 position.  The 1,092 comes from the combination of 26 different R2 
functionalities and 42 different R3 functionalities (26 x 42 = 1,092).  Similarly, sample 
Lib1.021 contained the 1,092 bis-cyclic guanidines possessing a heptyl in the R1 
position.  In total, each of the first 42 samples (Lib1.001 to Lib1.042) contained a 
unique set of 1,092 analogs organized by their R1 functionality.  In this way, the 45,864 
bis-cyclic guanidine analogs contained in the Lib1 scaffold ranking sample were 
systematically arranged into 42 samples by R1 functionality (42 x 1,092 = 45,864). 
The next set of 26 samples, Table 3.3, were systematically formatted by R2 
functionality.  For example, sample Lib1.043 contained all 1,764 (42 R1 x 42 R3 = 
1,764) bis-cyclic guanidines that have S-methyl in the R2 position and sample Lib1.044 
contained all 1,764 analogs that have S-benzyl fixed in the R2 position.  In this way, the 
entire set of 45,864 bis-cyclic guanidines were formatted by R2 functionality into 26 
mixtures, each containing 1,764 compounds. 
Finally the last set of 42 samples, Table 3.4, were formatted by R3 functionality.  
Each sample contained 1,092 analogs uniquely fixed with a given R3 functionality.  In 
total, the 110 samples (Tables 3.2, 3.3, 3.4) contained all 45,864 bis-cyclic guanidines 
formatted three separate ways. 
Positional Scanning Library Lib1 was screened in the Leishmania donovani 
axenic amastigote assay at 20, 5, 2.5, 1.25, 0.625, and 0.5 µg/ml.   For the 20 and 5 
µg/ml doses >95% of the 110 samples tested produced a >95% response (data not 
shown), while for the 1.25, 0.625, and 0.5 µg/ml doses, >95% of the samples produced 
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a negligible response (data not shown).  However, at the 2.5 µg/ml dose, the full 
spectrum of % response was observed for the 110 samples.  Furthermore, the full 
spectrum of % responses were observed across each of the three diversity positions at 
2.5 µg/ml (Table 3.2, 3.3, and 3.4).  For these reasons, the data observed at the 2.5 
µg/ml dose is ideal for use in analyzing positional scanning data for the selection of 
potentially active compounds.8 This data allows the user the opportunity to rank order 
the relative likelihood that active individual compounds contain certain functionalities at 
a given position.  For example, based on the 2.5 µg/ml data, it is clear that the mixture 
defined with cyclohexyl-butyl at the R1 position (Table 3.2 sample Lib1.031), is more 
active (100%) than the one defined with isobutyl (-14%) at the same R1 position (Table 
3.2 sample Lib1.022).  This implies that it is more likely to find active individual 
compounds with cyclohexyl-butyl defined at R1 than with isobutyl at R1.  In general, 
larger aliphatic groups are favored over both smaller aliphatic and aromatic substitutions 
at each of the 3 diversity positions.  However, there are a few notable exceptions with 
the R1 position (Table 3.2) showing the most tolerance to aromatic groups such as 2-
biphenyl-4-yl-ethyl (Lib1.039), 3-phenylbutyl (Lib1.003), and even 2-(3-trifluoromethyl-
phenyl)-ethyl (Lib1.007).  Samples with defined functionalities containing hydroxy, 
methoxy, or ethoxy groups all produced limited activity at the 2.5µg/ml dose.   Finally, 
there appears to be little preference for stereochemecial specificity at the R2 position 
(Table 3.3) with each of the tested stereoisomers producing relatively similar activity at 
the 2.5 µg/ml dose (i.e. S-2-butyl 99.8% vs R-2-butyl 99.3% and R-hydroxylmethyl -
4.3% vs S-hydroxylmethyl -18.5%).   
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In addition to the axenic amastigotes data in Tables 3.2, 3.3, and 3.4 the IC50 
data from the HCS infected macrophage assay is also provided.  The infected 
macrophage data does not correlate perfectly with the axenic amastigote data, a result 
that is not uncommon as evidenced by the scaffold ranking data (Table 3.1).  While both 
assays measure the ability of a sample to inhibit the growth of the amastigotes at a 
given dose, the infected macrophage assay requires the samples to penetrate the 
macrophage first in order to get to the amastigote.  Regardless, a number of the 
samples that produced sub 1.0 µg/ml IC50 in the infected macrophage assay also 
produced >80% response at the 2.5µg/ml dose in the axenic amastigotes assay, 
demonstrating these samples’ ability to inhibit the growth of the amastigotes in both 
assay formats. 
Finally, since this positional scanning library was also screened against the 
ESKAPE pathogens (Chapter 2), the MIC data reported in Chapter 2 for each sample is 
also reported here in Tables 3.2, 3.3, and 3.4 for comparison.  A number of the 
functionalities, such as R1 cyclohexyl-butyl (Lib1.031) and 2-(3-trifluoromethyl-phenyl)-
ethyl (Lib1.007) that were selected for synthesis of individual compounds for the 
ESKAPE pathogens, also demonstrated potent activity in the leishmaniasis assays 
(Table 3.2).  For this reason, the 27 individual compounds previously made for the 
ESKAPE work (Chapter 2 Table 2.8) were also tested for anti-leishmaniasis activity 
(Table 3.5). 
 
 
 
! 120 
Individual Compounds 
Compounds were synthesized incorporating 3 different functionalities in each of 
the R1, R2 and R3 positions resulting in 27 structural analogs (Table 3.5). The 5 and 2.5 
µM axenic amastigote % inhibition, IC50 infected macrophage and cytotoxicity counter 
screen data, as well as the selectivity index data for the 27 compounds are shown in 
Table 3.5 (The corresponding ESKAPE MIC data was previously shown on Table 2.8).  
In general, when cyclohexyl-butyl is fixed in the R1 position (Compounds 10 to 18), the 
compounds show an increased % response in the axenic amastigote assay (6 out of 9 
>65% at 2.5 µM) relative to when adamantan-1-yl-ethyl (2 out of 9 >65% at 2.5 µM) or 
2-(3-trifluoromethyl-phenyl)-ethyl (0 out of 9 >65% at 2.5 µM) are fixed at the R1 
position.  These results are consistent with the data generated from the positional 
scanning library data (Table 3.2) where the mixtures defined with cyclohexyl-butyl and 
adamantan-1-yl-ethyl at the R1 position produced a more significant response in the 
axenic amastigote assay than the one with 2-(3-trifluoromethyl-phenyl)-ethyl.  Of the 9 
individual compounds with cyclohexyl-butyl defined at the R1 position, the 6 compounds 
that produced >65% response at the 2.5 µM dose all had S-cyclohexylmethyl or S-butyl 
rather than R-2-naphthylmethyl at the R2 position (Table 3.5).  Again, this is consistent 
with the positional scanning data where samples fixed with either S-cyclohexylmethyl or 
S-butyl at the R2 position produced stronger responses in the axenic amastigote assay 
than the sample with R-2-naphthylmethyl (Table 3.3).  Of these 6 individual compounds 
defined with cyclohexyl-butyl at the R1 position and either S-cyclohexylmethyl or S-butyl 
at the R2 position, there appears to be less of a preference for the R3 substitution (Table 
3.5; 10-12 or 16-18 respectively).   It is notable though that the infected macrophage 
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assay provided a range of activities for these 6 compounds.  Of particular note are the 
very similar structural analog pairs (10/11 and 16/17) that produced a significant 
reduction in activity in the infected macrophage model when the R3 heptyl group (10 
and 13) is replaced with the slightly larger aliphatic cyclohexyl-butyl group (11 and 17).  
In order to further explore the leishmaniasis and ESKAPE pathogen SAR around the set 
of compounds, several additional series of individual compounds were synthesized and 
tested.  Special emphasis was placed on reducing the molecular weight of the next 
generation of analogs. 
 
Analogs of 16 
Compound 16 provided robust activity in both the leishmaniasis assays as well 
as the ESKAPE pathogen assay.  A diastereomer and several deletion analogs were 
synthesized and assessed for activity in the leishmaniasis infected macrophage model 
and ESKAPE pathogen MIC assays (Table 3.6).  By altering the absolute 
stereochemistry of the carbon chain linking group (16 to 55), the antibacterial potency 
was maintained while the leishmaniasis activity was dramatically reduced, a trend that 
was also seen for some of the other diastereomer analogs studied (Tables 3.7 and 3.8).  
Elimination of the R3 functionality (56) provided a compound that was less effective 
against the gram-negative pathogens and slightly less effective than 16 in the infected 
macrophage assay.  Elimination of the R2 functionality (57) provided a compound with 
no measurable effect against any of the gram-negative pathogens.  Compound 57 was 
>4 fold less effective than 16 in the infected macrophage model and possessed very 
little selectivity for potency in the counter screen assay. Elimination of the R1 
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functionality (58) all but eliminated the compounds antibacterial activity at the doses 
tested, while the reduction in potency in the leishmaniasis assay was less dramatic.  
Finally, the double elimination (59 and 60) and triple elimination (61) analogs possessed 
no antibacterial activity (measured up to 25 µM) and significantly reduced 
antileishmanial potency.   
Overall, the results indicate that the aliphatic R group functionalities play a role in 
the potency of the compounds, potentially contributing to their ability to penetrate cell 
membranes.  Of note for the antibacterial work, the elimination of the R1 functionality 
had a greater effect than the R2 functionality; likewise, elimination of the R2 had a 
greater effect than elimination of R3.  Compound 58 is a potentially useful analog for 
future studies.  It possesses modest potency and robust selectivity in the leishmaniasis 
assay.  Additionally, the potency appears to be selective for leishmaniasis over the 
bacterial species, indicating a potential mechanism of action specific for leishmaniasis. 
 
Analogs of 21 
Compound 21 is an interesting compound in that it possessed strong activity in 
the infected macrophage model, but limited activity in the amastigote assay (Table 3.5).  
It was also very potent against the ESKAPE pathogens assays (Table 3.7).  Modifying 
the absolute stereochemistry (Table 3.7 21 to 62) had little effect on the antibacterial 
properties, but did substantially reduce the potency against leishmania; this is similar to 
the results observed for the diastereomer analogs (16 to 55 Table 3.6).  Independent 
removal of the R1, R2, or R3 functionalities (63, 64, and 65, respectively) eliminated the 
gram-negative activity of the compounds; however, compounds 64 and 65 retained 
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good antileishmanial potency with IC50 values at ~1 µM with good selectivity.  The 
compounds with two (66, 67, 68) and three (61) of the R group functionalities removed 
had no antibacterial effect against the 6 pathogens (tested up to 25µM) and very limited 
antileishmanial potency.  Interestingly an analog of compound 68, compound 69, 
demonstrated significant antileishmanial potency, good selectivity, and no antibacterial 
activity. 
 
Analogs 1, 2, and 3 
Compounds 1, 2, and 3 are an interesting set of analogs that only differ at the R3 
position.  They all possessed broad spectrum antibacterial activity at doses down to 5 
µM (Table 3.8); however, while they showed limited activity in the axenic amastigotes 
assay, two of them had significant activity in the infected macrophage model (Table 
2.8).  Similar to the previous analog studies from this Chapter, some deletion analogs of 
1, 2, and 3 maintained antileishmanial activity with reduced ESKAPE pathogen potency 
(Table 3.8).  Of significant interest is compound 72, which only maintained the R1 
functionality of the parent analogs, demonstrated sub 1 µM antileishmanial potency 
while losing all antibacterial potency (Table 3.8). 
 
Analogs of 72 
From the previous analog sets (Tables 3.6 to 3.8), all the compounds with 
hydrogen replacing the R2 and R3 functionalities had no activity in the ESKAPE assays; 
however, a few of them, including compound 72, maintained some potency in the 
infected macrophage model.  In order to explore the SAR around analogs with 
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hydrogens fixed in the R2 and R3 positions, some additional analogs of 72 were 
examined (Table 3.9).  Again, none of these compounds demonstrated any potency in 
the ESKAPE assays (tested up to 25 µM).  However, a few of the analogs possessed 
low µM potency in the infected macrophage assay, including 77, 79, 80, and 82. 
Compound 77 replaces the trifluoromethyl group of 72 with a methyl. The result is that 
the two compounds produce the same 0.9 µM potency in the infected macrophage 
assay, but, due to the lack of toxicity in the counter screen assay, compound 77 has a 
significantly better selectivity index (56 versus 9).  Moving the methyl group from the 3 
position (77) to either the 2 or 4 position (76 or 78 respectively) significantly reduces the 
antileishmania activity.  Completely removing the methyl group (79) has a less dramatic 
effect on the antileishmanial activity (1.2 µM potency in the infected macrophage assay) 
but it does bring back the increased cytotoxicity in the counter screen.  A series of 
methyl substituted cyclohexyl analogs were also prepared and tested (80 to 83).  The 
two cyclohexyl analogs connected to the scaffold by an ethyl group maintained fairly 
potent activity (80 and 81) while the two with the reduced linker length produced 
significantly less activity in the infected macrophage assay (82 and 83).  
 
Monocyclic Guanidine Analogs 
 In order to test the importance of having two cyclic guanidine moieties, a series 
of monocyclic guanidines were examined utilizing compound 21 as a starting point 
(Table 3.10).  Four different analogs (84-87) explored the “right side” of 21 and two (88, 
89) explored the “left side.”  While all the analogs had a reduction in antibacterial 
potency, interestingly two of the monocyclic analogs (84 and 88) produced antibacterial 
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activity against S. aureus at 5 µM and inhibited the growth of both gram-negative and 
positive bacteria at 25 µM.  While these two analogs (84 and 88) did maintain some 
antibacterial potency, they were not the most potent antileishmanial monocyclic 
analogs.  The most potent antileishmanial compounds in this series were 86 and 89, 
both possessing IC50 values of 0.6 µM in the infected macrophage assay.  While 
compound 89 possessed significant cytotoxicity, compound 86 had a good selectivity 
index, making it a promising starting point for future antileishmanial in vitro and in vivo 
studies as well as medicinal chemistry optimization.  
 
Conclusion and Future Studies 
After testing 30 different scaffold ranking samples, positional scanning library 
Lib1 was selected for screening (Table 3.1).  Comparing the antileishmanial screening 
data for the 110 positional scanning library samples to the antibacterial data obtained 
previous (Tables 3.2 to 3.4), it was determined that the 27 compounds previously made 
for the ESKAPE pathogen studies would be useful compounds to screen for 
antileishmanial activity (Table 3.5).  The results from screening the 27 individual 
compounds confirmed the antileishmanial SAR trends identified from the positional 
scanning library screening.   
In order to further explore the SAR trends driving antibacterial and 
antileishmanial activity for these guanidine compounds, several series of analogs were 
made and screened for antileishmanial activity, as well as broad-spectrum antibacterial 
activity (Tables 3.6 to 3.10). The broad-spectrum antibacterial activity clearly depended 
on the presence of lipophilic groups, with all of the R group deletion analogs providing 
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significantly less antibacterial potency than the given parent compounds.  However, the 
antileishmanial activity was more tolerant to such deletions.  Due to this difference the 
analogs tested provided several new hit compounds possessing only antileishmanial 
activity.  Of these new antileishmanial compounds, several demonstrated IC50s of sub 1 
uM and selectivity indexes >25 (64, 69, 77, 83, and 86).   All five of these hit compounds 
have significantly lower MWs then the original hits.  Among the five hits is the 
monocyclic guanidine compound 86.    
While this work demonstrated that hit compounds possessing antileishmanial 
activity could be rapidly identified from the use of mixture based libraries, more studies 
are needed before a compound based on this work will be ready for clinical use.  For 
example, it will be important to demonstrate that these hit compounds have significant 
efficacy and limited toxicity in a relevant in vivo model.  It will also be important to try 
and understand the mechanism of action that these compounds are working through.  
Due to their structural similarity to pentamidine it will be important to test whether or not 
the compounds work against pentamidine resistant strains.  On that note it is intriguing 
that compound 86 departs from the dicationic motif of pentamidine and the other hits 
from this study.  In addition to these mechanism of action studies, it is likely that a 
concerted medicinal chemistry campaign will be undertaken to continue to optimize the 
compounds pharmacokinetic and pharmacodynamic properties ideally for oral 
administration.  
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Experimental  
 Synthesis of Individual Compounds 55 to 89 
 Synthesis of Compounds 57, 64, and 71.  The synthesis of compounds 57, 64, 
and 71 was accomplished utilizing the same synthetic conditions described for 
compounds 1 to 54 in Chapter 2 and elsewhere.9  Starting with 100 mg of p-
methylbenzhydrylamine (MBHA) resin (1.1 mmol/g, 100−200 mesh) sealed in a mesh 
“tea-bag” (3.1, Figure 3.1) the bags are first neutralized with 5% diisopropylethylamine 
(DIEA) in dichloromethane (DCM).  After neutralization Fmoc-L-Lys(Boc)-OH (6 equiv), 
diisopropylcarbodiimide (DIC, 6 equiv) and 1-hydroxybenzotriazole hydrate (HOBt, 6 
equiv) all dissolved in dimethylformamide (0.1 M DMF) was added to the reaction vessel 
containing the neutralized tea bag and allowed to react for 120 (3.2, Figure 3.1).  The 
coupling solution was removed and the tea-bag was washed with three rounds of DMF 
(1 min each wash). The Fmoc group is removed with 20% piperidine in  DMF (20 
minutes), followed by two rounds of DMF washes (1 min each).    The R1 carboxylic acid 
group is coupled using a 10 fold excess of the carboxylic acid, DIC, and HOBT in 0.1M 
DMF (120 minutes) (3.3).  The coupling solution was removed and the tea-bag was 
washed with three rounds of DMF (1 min each wash). Following acylation the Boc group 
is removed using 55%TFA in DCM (30 minutes).  The free amine is then neutralized 
with 5% DIEA/DCM and the R2 amino acid is coupled using a 6 fold excess of the Boc 
protected acid, DIC, and HOBT in 0.1 M DMF (120 minutes) (3.4). The subsequent Boc 
group is removed with the same TFA conditions as before and the R3 carboxylic acid is 
coupled as descried for the R1 carboxylic acid coupling (3.5).  All coupling reactions 
were monitored for completion by the ninhydrin test.   The reduction was performed in 
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glass vessels under nitrogen using tetrahydrofuran (THF, 1.0 M) borane complex 
solution (40 fold excess over each amide, 65 °C, 96 h).   The solution was then 
removed and the bags washed with THF and methanol.  Once completely dry, the tea 
bags were treated overnight with piperidine at 65 °C and washed several times with 
DMF, DCM, and methanol (3.6, Figure 3.1). As previously reported, the reduction of 
polyamides with borane is free of racemization.10-12 Completion of the reduction was 
monitored by cleaving a control compound and analyzing the presence of desired 
products by LCMS.  After borane reduction the polyamine 3.6 was obtained and was 
converted into the bis-cyclic guanidine (3.7) through the use of excess cyanogen 
bromide (5 fold excess per desired cyclization) in a 0.1 M anhydrous DCM solution 
overnight. Following the cyclization, the bags were rinsed with DMF and DCM (3 times 1 
min each). The final compounds were then cleaved from the solid support with 
hydrogen fluoride (3.8).  After removal of the HF by gaseous N2, the compounds were 
then extracted from the vessels with 95% acetic acid in water, transferred to scintillation 
vials, frozen, and lyophilized. Compounds were reconstituted in 50% acetonitrile and 
water, frozen, and lyophilized three more times before being purified. 
 Synthesis of Compounds 55, 62, and 70.  The synthesis of compounds 55, 62, 
and 70 (Figure 3.2) was accomplished utilizing the same synthetic conditions described 
for compounds 57, 64, and 71 (Figure 3.1) except that Fmoc-D-lys-Boc is used instead 
of Fmoc-L-Lys-Boc (Figure 3.2).  
Synthesis of Compounds 56, 59, 63, 66, 72, 73, and 76 to 83. The synthesis of 
compounds 56, 59, 63, 66, 72, 73, and 76 to 83 (Figure 3.3) was accomplished utilizing 
a similar synthetic strategy described for compounds 57, 64, and 71 (Figure 3.1) except 
! 129 
that no R3 carboxylic acid coupling is performed (Figure 3.3).   Up to the peptide like 
compound 3.4 the synthetic strategies are the same.  After the R2 Boc protecting group 
is removed 3.16 the reduction, cyclization, and cleavage conditions are exactly the 
same as described above for compounds 57, 64, and 71.   
Synthesis of Compounds 58, 60, 65, 68, 69, and 74.  The synthesis of 
compounds 58, 60, 65, 68, 69, and 74 (Figure 3.4) was accomplished utilizing a similar 
synthetic strategy described for compounds 57, 64, and 71 (Figure 3.1).  This synthesis 
utilized all the same coupling, reduction, cyclization, and cleavage conditions as 
described for the other analogs however since an amino acid is coupled off the lysine 
side chain first a different orthogonally protected lysine reagent needed to be employed.  
Boc-Lys-Fmoc was used (Figure 3.4) instead of Fmoc-Lys-Boc.  Using Fmoc-Lys-Boc 
would have potentially lead to premature removal of the Fmoc group during the 5%DIEA 
neutralization step.   
Synthesis of Compounds 61, 67, and 75.  The synthesis of compounds 61, 67, 
and 75 (Figure 3.5) was accomplished utilizing a similar synthetic strategy described for 
compounds 58, 60, 65, 68, 69, and 74 (Figure 3.4).  Again Boc-Lys-Fmoc was utilized 
as the orthogonally protected amino acid.  The only difference between the synthesis of 
these compounds (Figure 3.5) and the previous set (Figure 3.4) is that no R2 acylation 
is performed in this set, 3.29 (Figure 3.5) versus 3.24 (Figure 3.4). 
Synthesis of Compounds 84 to 89.  The synthesis of compounds 84 to 89 
(Figure 3.6) was accomplished utilizing a slightly different procedure than the other 
analogs in this chapter.  The synthesis did not utilize an orthogonally protected amino 
acid, instead it utilized a Boc protected amino acid, either norleucine (84, 86, 88, 89) or 
! 130 
glycine (85 and 87) was incorporated in the R1 functionality.  This was accomplished 
using a 6 fold excess of the amino acid preactivated with a 6 fold excess of DIC and 
HOBt in 0.1M DMF.  After Boc removal with 55%TFA/DCM the R2 carboxylic acid is 
coupled using a 10 fold excess with DIC and HOBt in 0.1M DMF as described 
previously.  Following acylation the reduction, cyclization, and cleavage procedures are 
the same as utilized for all the other analogs in this chapter. 
HPLC Purification (Compounds 55 to 89). All purifications were performed on 
a Shimadzu Prominence preparative HPLC system, consisting of LC-8A binary solvent 
pumps, a SCL-10A system controller, a SIL-10AP auto sampler, and a FRC-10A 
fraction collector. A Shimadzu SPD-20A UV detector was used for detection. The 
wavelength was set at 214 nm during analysis. Chromatographic separations were 
obtained using a Phenomenex Luna C18 preparative column (5 µm, 150 mm × 21.5 mm 
i.d.). The column was protected by a Phenomenex C18 column guard (5 µm, 15 mm × 
21.2 mm i.d.). Prominence prep software was used to set all detection and collection 
parameters. The mobile phases for HPLC purification were HPLC grade obtained from 
Sigma-Aldrich and Fisher Scientific. The mobile phase consisted of a mixture of 
acetonitrile/ water (both with 0.1% formic acid). The initial setting for separation was 2% 
acetonitrile, which was held for 2 min, then the gradient was linearly increased to 20% 
acetonitrile over 4 min. The gradient was then linearly increased to 55% acetonitrile 
over 36 min. The HPLC system was set to automatically flush and re-equilibrate the 
column after each run for a total of four column volumes. The total flow rate was set to 
12 mL/min, and the total injection volume was set to 3900 µL. The fraction collector was 
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set to collect from 6 to 40 min. The corresponding fractions were then combined and 
lyophilized. 
LCMS Analysis of Purified Material. Purity and identity of compounds was 
verified using a Shimadzu 2010 LCMS system, consisting of a LC-20AD binary solvent 
pumps, a DGU-20A degasser unit, a CTO-20A column oven, and a SIL-20A HT auto 
sampler. A Shimadzu SPD-M20A diode array detector was used for detections. A full 
spectra range of 190−600 nm was obtained during analysis. Chromatographic 
separations were obtained using a Phenomenex Luna C18 analytical column (5 µm, 50 
mm × 4.6 mm i.d.). The column was protected by a Phenomenex C18 column guard (5 
µm, 4 × 3.0 mm i.d.). All equipment was controlled and integrated by Shimadzu LCMS 
solutions software version 3. Mobile phases for LCMS analysis were HPLC grade or 
LCMS grade obtained from Sigma-Aldrich and Fisher Scientific. The mobile phases 
consisted of a mixture of LCMS grade acetonitrile/water (both with 0.1% formic acid for 
a pH of 2.7). The initial setting for analysis was 5% acetonitrile (v/v), then linearly 
increased to 95% acetonitrile over 6 min. The gradient was then held at 95% acetonitrile 
for 2 min before being linearly decreased to 5% over 0.1 min and held until stop for an 
additional 1.9 min. The total run time was equal to 12 min, and the total flow rate was 
0.5 mL/min. The column oven and flow cell temperature for the diode array detector was 
30 °C. The auto sampler temperature was held at 15 °C, and 5 µL was injected for 
analysis. 
NMR and LCMS Analysis of Purified Compounds. 1H NMR spectra were 
obtained utilizing the Bruker 400 Ascend (400 MHz). NMR chemical shifts were reported 
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in δ (ppm) using the δ 7.26 signal of CDCl3 or the δ 2.50 signal of DMSO-d6 (1H NMR) 
as the internal standard. 
 (S)-1-(4-((R)-3-(4-cyclohexylbutyl)-2-iminoimidazolidin-4-yl)butyl)-4-
(cyclohexylmethyl)-3-heptylimidazolidin-2-imine (55) Using the synthetic approach 
described in Figure 3.2 compound 55 was synthesized using the following reagents: 
cyclohexanebutyric acid (R1), Boc-L-cyclohexylalanine (R2), and heptanoic acid (R3). 
Final crude product was purified by HPLC as described above. 1H NMR (400 MHz, 
CDCl3): δ 8.64 (br s, 1 H) 8.26 (br s, 1 H) 3.76 - 3.92 (m, 2 H) 3.59 - 3.76 (m, 4 H) 3.49 
(br s, 2 H) 3.42 (br s, 1 H) 3.14 (t, 3 H) 1.49 - 1.77 (m, 18 H) 1.31 - 1.40 (m, 8 H) 1.24 - 
1.30 (m, 8 H) 1.16 - 1.24 (m, 8 H) 0.92 - 1.16 (m, 3 H) 0.88 (t, 3 H).  LCMS (ESI+) m/z 
calcd for C34H64N6 [M + H]+: 557.52, found 557.30. LCMS retention time (214 nm): 
3.876 min. 
(S)-1-(4-((S)-3-(4-cyclohexylbutyl)-2-iminoimidazolidin-4-yl)butyl)-4-
(cyclohexylmethyl)imidazolidin-2-imine (56) Using the synthetic approach described in 
Figure 3.3 compound 56 was synthesized using the following reagents: 
cyclohexanebutyric Acid (R1), Boc-L-cyclohexylalanine (R2). Final crude product was 
purified by HPLC as described above. 1H NMR (400 MHz, CDCl3): δ 8.60 (br s, 2 H) 
8.44 (br s, 1H) 4.02 (br s, 1 H) 3.88 (br s, 1 H) 3.65 (br s, 2 H) 3.52 (br s, 2 H) 3.38 (br s, 
2 H) 3.14 (br s, 2 H) 2.25 (br s, 2 H) 1.93 (br s, 1 H) 1.60 - 1.76 (m, 10 H) 1.53 (br s, 3 
H) 1.23 - 1.42 (m, 8 H) 1.19 (br s, 8 H) 0.78 - 1.00 (m, 4 H).  LCMS (ESI+) m/z calcd for 
C27H50N6 [M + H]+: 459.41, found 459.30. LCMS retention time (214 nm): 4.169 min. 
(S)-1-(4-(3-(4-cyclohexylbutyl)-2-iminoimidazolidin-4-yl)butyl)-3-
heptylimidazolidin-2-imine (57) Using the synthetic approach described in Figure 3.1 
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compound 57 was synthesized using the following reagents: cyclohexanebutyric acid 
(R1), Boc-glycine (R2), and heptanoic acid (R3). Final crude product was purified by 
HPLC as described above. 1H NMR (400 MHz, CDCl3): δ 8.62 (br s, 2 H) 3.87 (br s, 1 
H) 3.70 (t, 1 H) 3.58 (br s, 4 H) 3.48 (br s, 3 H) 3.36 (br s, 1 H) 3.01 - 3.25 (m, 2 H) 1.48 
-1.71 (m, 13 H) 1.23 - 1.45 (m, 12 H) 1.19 (br s, 6 H) 1.11 (br s, 1 H) 0.88 (br s, 5 H).  
LCMS (ESI+) m/z calcd for C27H52N6 [M + H]+: 461.43, found 461.60. LCMS retention 
time (214 nm): 4.174 min.  
(S)-4-(cyclohexylmethyl)-3-heptyl-1-(4-((S)-2-iminoimidazolidin-4-
yl)butyl)imidazolidin-2-imine (58) Using the synthetic approach described in Figure 3.4 
compound 58 was synthesized using the following reagents: Fmoc-L-cyclohexylalanine 
(R1) and heptanoic acid (R2). Final crude product was purified by HPLC as described 
above. 1H NMR (400 MHz, CDCl3): δ 8.62 (br s, 2 H) 3.84 (br s, 1 H) 3.62 - 3.80 (m, 3 
H) 3.54 (br s, 1 H) 3.49 (br s, 1 H) 3.29 (br s, 1 H) 3.16 (br s, 2 H) 2.99 (br s, 2 H) 2.61 
(br s, 1 H) 1.73 (d, 3 H) 1.66 (s, 3 H) 1.63 (s, 4 H) 1.24 - 1.44 (m, 11 H) 1.13 - 1.24 (m, 4 
H) 0.91 - 1.10 (m, 2 H) 0.88 (t, 3 H).  LCMS (ESI+) m/z calcd for C24H46N6 [M + H]+: 
419.38, found 419.20. LCMS retention time (214 nm): 4.107 min. 
(S)-1-(4-cyclohexylbutyl)-5-(4-(2-iminoimidazolidin-1-yl)butyl)imidazolidin-2-imine 
(59). Using the synthetic approach described in Figure 3.3 compound 59 was 
synthesized using the following reagents: cyclohexanebutyric Acid (R1), Boc-glycine 
(R2).  Final crude product was purified by HPLC as described above. 1H NMR (400 
MHz, CDCl3): δ 8.83 (br s, 1 H) 8.58 (br s, 1 H), 8.42 (br s, 1 H) 3.89 (br s, 1 H) 3.66 - 
3.77 (m, 1 H) 3.61 (d, 3 H) 3.48 (br s, 1 H) 3.34 - 3.43 (m, 1 H) 3.09 (br s, 1 H) 2.28 - 
2.57 (m, 2 H) 1.66 (s, 4 H) 1.69 (s, 4 H) 1.43 - 1.61 (m, 4 H) 1.30 (br s, 4 H) 1.19 (br s, 4 
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H) 1.11 (br s, 1 H) 0.86 (br s, 3 H).  LCMS (ESI+) m/z calcd for C20H38N6 [M + H]+: 
363.32, found 363.15. LCMS retention time (214 nm): 3.560 min.  
(S)-1-heptyl-3-(4-(2-iminoimidazolidin-4-yl)butyl)imidazolidin-2-imine (60) 
Using the synthetic approach described in Figure 3.4 compound 60 was synthesized 
using the following reagents: Fmoc-glycine (R1), and heptanoic acid (R2). Final crude 
product was purified by HPLC as described above. 1H NMR (400 MHz, CDCl3): δ 8.60 
(br s, 2 H) 3.78 (br s, 1 H) 3.61 - 3.75 (m, 1 H) 3.58 (br s, 3 H) 3.47 (br s, 1 H) 3.42 (br 
s, 2 H) 3.29 (br s, 1 H) 3.14 (br s, 1 H) 2.96 (br s, 2 H) 1.76 (br s, 1 H) 1.46 - 1.68 (m, 6 
H) 1.21 - 1.38 (m, 8 H) 0.88 (t, 3 H). LCMS (ESI+) m/z calcd for C17H34N6 [M + H]+: 
323.28, found 323.05. LCMS retention time (214 nm): 3.249 min.   
(S)-1,4'-(butane-1,4-diyl)diimidazolidin-2-imine  (61) Using the synthetic approach 
described in Figure 3.5 compound 61 was synthesized using the following reagents: 
Fmoc-glycine (R1). Final crude product was purified by HPLC as described above. 
LCMS (ESI+) m/z calcd for C10H20N6 [M + H]+: 225.17, found 225.00. LCMS retention 
time (214 nm): 1.522 min.   
(4S)-3-(2-([1,1'-biphenyl]-4-yl)ethyl)-1-(4-((4R)-3-(2-((1S,3S)-adamantan-1-
yl)ethyl)-2-iminoimidazolidin-4-yl)butyl)-4-butylimidazolidin-2-imine  (62) Using the 
synthetic approach described in Figure 3.2 compound 62 was synthesized using the 
following reagents: 1-adamantaneacetic acid (R1), Boc-L-norleucine (R2), and 4-
biphenylacetic acid (R3). Final crude product was purified by HPLC as described above. 
1H NMR (400 MHz, CDCl3): δ 8.70 (br s, 2 H) 7.52 - 7.59 (m, 3 H) 7.43 (br s, 3 H) 7.35 
(br s, 2 H) 7.28 (br s, 1 H) 3.99 (br s, 1 H) 3.86 (br s, 1 H) 3.63 - 3.76 (m, 1 H) 3.58 (d, 1 
H) 3.39 - 3.54 (m, 4 H) 3.33 (br s, 1 H) 3.07 (br s, 2 H) 2.76 - 3.02 (m, 2 H) 1.96 (br s, 3 
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H) 1.57 - 1.73 (m, 9 H) 1.53 (br s, 8 H) 1.30 (br s, 8 H) 1.16 (br s, 2 H) 0.89 (br s, 3 H).  
LCMS (ESI+) m/z calcd for C40H58N6 [M + H]+: 622.48, found 622.50. LCMS retention 
time (214 nm): 4.445 min.    
 (4S)-1-(4-((4S)-3-(2-((1S,3R)-adamantan-1-yl)ethyl)-2-iminoimidazolidin-4-
yl)butyl)-4-butylimidazolidin-2-imine (63) Using the synthetic approach described in 
Figure 3.3 compound 63 was synthesized using the following reagents: 1-
adamantaneacetic Acid (R1) and Boc-L-norleucine (R2).  Final crude product was 
purified by HPLC as described above. 1H NMR (400 MHz, CDCl3): δ 8.09 (br s, 1 H) 
7.79 (br s, 1 H) 3.91 (br s, 2 H) 3.68 (br s, 2 H) 3.61 (br s, 1 H) 3.42 (br s, 2 H) 3.18 (br 
s, 2 H) 3.07 (br s, 1 H) 2.84 (br s, 2 H) 1.91 - 2.01 (m, 4 H) 1.58 - 1.72 (m, 8 H) 1.52 (br 
s, 6 H) 1.33 (br s, 7 H) 0.90 (t, 3 H). LCMS (ESI+) m/z calcd for C26H46N6 [M + H]+: 
443.38, found 443.15. LCMS retention time (214 nm): 4.013 min.    
 1-(2-([1,1'-biphenyl]-4-yl)ethyl)-3-(4-((4S)-3-(2-((1S,3R)-adamantan-1-yl)ethyl)-2-
iminoimidazolidin-4-yl)butyl)imidazolidin-2-imine (64) Using the synthetic approach 
described in Figure 3.1 compound 64 was synthesized using the following reagents: 1-
adamantaneacetic acid (R1), Boc-glycine (R2), and 4-biphenylacetic acid (R3). Final 
crude product was purified by HPLC as described above. 1H NMR (400 MHz, CDCl3): δ 
8.50 (s, 1 H) 7.62 (d, 2 H) 7.66 (d, 2 H) 7.25 - 7.49 (m, 5 H) 3.74 - 4.02 (m, 1 H) 3.40 - 
3.67 (m, 8 H) 3.28 (br s, 3 H) 3.11 - 3.24 (m, 2 H) 3.01 (t, 1 H) 2.88 (br s, 2 H) 2.68 (br 
s, 1 H) 1.93 (br s, 4 H) 1.55 - 1.77 (m, 7 H) 1.51 (br s, 6 H) 1.35 (t, 2 H) 1.04 - 1.26 (m, 2 
H). LCMS (ESI+) m/z calcd for C36H50N6 [M + H]+: 567.41, found 567.25. LCMS 
retention time (214 nm): 4.281 min.       
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(S)-3-(2-(biphenyl-4-yl)ethyl)-4-butyl-1-(4-((S)-2-iminoimidazolidin-4-
yl)butyl)imidazolidin-2-imine (65) Using the synthetic approach described in Figure 3.4 
compound 65 was synthesized using the following reagents: Fmoc-L-norleucine (R1) 
and 4-biphenylacetic acid (R2). Final crude product was purified by HPLC as described 
above. 1H NMR (400 MHz, CDCl3): δ 8.59 (br s, 2 H) 7.51 - 7.59 (m, 5 H) 7.31 - 7.38 (m, 
4 H) 3.69 - 3.83 (m, 1 H) 3.55 (br s, 4 H) 3.39 - 3.51 (m, 1 H) 3.35 (br s, 1 H) 3.12 (br s, 
2 H) 2.93 (br s, 1 H) 2.04 (br s, 4 H) 1.61 (br. s., 4 H) 1.38 (br s, 4 H) 1.16 (br s, 2 H) 
0.89 (br s, 3 H). LCMS (ESI+) m/z calcd for C28H40N6 [M + H]+: 461.33, found 461.15. 
LCMS retention time (214 nm): 3.895 min.       
(5S)-1-(2-((1S,3R)-adamantan-1-yl)ethyl)-5-(4-(2-iminoimidazolidin-1-
yl)butyl)imidazolidin-2-imine (66) Using the synthetic approach described in Figure 3.3 
compound 66 was synthesized using the following reagents: 1-adamantaneacetic acid 
(R1) and Boc-glycine (R2).  Final crude product was purified by HPLC as described 
above. 1H NMR (400 MHz, CDCl3): δ 8.60 (br s, 3 H) 3.89 (br s, 1 H) 3.60 (d, 4 H) 3.46 
(br s, 1 H) 3.35 (br s, 2 H) 3.05 (br s, 1 H) 2.25 (br s, 2 H) 1.95 (br s, 4 H) 1.48 - 1.73 
(m, 14 H) 1.30 (br s, 5 H). LCMS (ESI+) m/z calcd for C22H38N6 [M + H]+: 387.32, found 
387.15. LCMS retention time (214 nm): 3.576 min.       
(S)-4-butyl-1-(4-((S)-2-iminoimidazolidin-4-yl)butyl)imidazolidin-2-imine (67) 
Using the synthetic approach described in Figure 3.5 compound 67 was synthesized 
using the following reagents: Fmoc-L-norleucine (R1).  Final crude product was purified 
by HPLC as described above. 1H NMR (400 MHz, CDCl3): δ 8.58 (br s, 1 H) 8.51 (br s, 
1 H) 8.07 (br s, 1 H) 3.59 - 3.83 (m, 2 H) 3.40 (br s, 1 H) 3.32 (br s, 1 H) 3.16 (br s, 2 H) 
2.96 (br s, 2 H) 1.93 (br s, 1 H) 1.80 (br s, 2 H) 1.73 (br s, 2 H) 1.62 (br s, 3 H) 1.37 (br 
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s, 2 H) 1.29 (br s, 2 H) 0.91 (t, 3 H).  LCMS (ESI+) m/z calcd for C14H28N6 [M + H]+: 
281.24, found 280.95. LCMS retention time (214 nm): 2.759 min.   
(S)-1-(2-(biphenyl-4-yl)ethyl)-3-(4-(2-iminoimidazolidin-4-yl)butyl)imidazolidin-2-
imine (68) Using the synthetic approach described in Figure 3.4 compound 68 was 
synthesized using the following reagents: Fmoc-glycine (R1) and 4-biphenylacetic acid 
(R2).  Final crude product was purified by HPLC as described above. 1H NMR (400 
MHz, CDCl3):  δ 8.51 (br s, 1 H) 8.28 (br s, 1 H) 7.55 (m, 2 H) 7.36 - 7.47 (m, 3 H) 7.31 
(d, 2 H) 7.26 (br s, 2 H) 3.82 (br s, 1 H) 3.71 (d, 2 H) 3.47 (br s, 4 H) 3.33 (br s, 2 H) 
3.19 (br s, 1 H) 2.94 - 3.09 (m, 3 H) 2.89 (br s, 1 H) 2.06 (br s, 1 H) 1.73 (br s, 1 H) 1.59 
(br s, 2 H) 1.35 (br s, 1 H). LCMS (ESI+) m/z calcd for C24H32N6 [M + H]+: 405.27, found 
405.00. LCMS retention time (214 nm): 3.460 min.         
(S)-1-(4-(2-iminoimidazolidin-4-yl)butyl)-3-phenethylimidazolidin-2-imine 
(69) Using the synthetic approach described in Figure 3.4 compound 69 was 
synthesized using the following reagents: Fmoc-glycine (R1) and phenylacetic acid (R2).  
Final crude product was purified by HPLC as described above. 1H NMR (400 MHz, 
CDCl3):   δ 8.48 (br s, 2 H) 7.32 (br s, 5 H) 3.71 - 3.99 (m, 1 H) 3.42 - 3.68 (m, 6 H) 3.26 
- 3.42 (m, 3 H) 2.77 - 2.92 (m, 3 H) 2.68 (br s, 1 H) 1.73 (br s, 2 H) 1.51 (br s, 2 H) 1.21 
(br s, 1 H).  LCMS (ESI+) m/z calcd for C18H28N6 [M + H]+: 329.24, found 329.05. LCMS 
retention time (214 nm): 2.844 min.          
(S)-4-butyl-3-(4-cyclohexylbutyl)-1-(4-((R)-2-imino-3-(4-
(trifluoromethyl)phenethyl)imidazolidin-4-yl)butyl)imidazolidin-2-imine (70) Using the 
synthetic approach described in Figure 3.2 compound 70 was synthesized using the 
following reagents: (α-α-α-trifluoro-m-tolyl)acetic acid (R1), Boc-L-norleucine (R2), and 
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cyclohexanebutyric acid (R3). Final crude product was purified by HPLC as described 
above. 1H NMR (400 MHz, CDCl3):  δ  9.13 (br s, 1 H) 8.67 (br s, 1 H) 7.57 (br s, 2 H) 
7.39 - 7.53 (m, 2 H) 3.91 - 4.10 (m, 1 H) 3.67 - 3.85 (m, 2 H) 3.52 -3.66 (m, 2 H) 3.48 (d, 
2 H) 3.30 - 3.44 (m, 3 H) 3.26 (br s, 1 H) 3.15 (t, 2 H) 2.97 (br s, 1 H) 1.75 (br s, 2 H) 
1.58 - 1.72 (m, 6 H) 1.54 (br s, 4 H) 1.31 - 1.51 (m, 6 H) 1.15 - 1.30 (m, 8 H) 1.11 (br s, 
2 H) 0.78 - 0.99 (m, 3 H).  LCMS (ESI+) m/z calcd for C33H53F3N6 [M + H]+: 591.43, 
found 591.60. LCMS retention time (214 nm): 4.619 min.   
(S)-1-heptyl-3-(4-(2-imino-3-(4-(trifluoromethyl)phenethyl)imidazolidin-4-
yl)butyl)imidazolidin-2-imine (71) Using the synthetic approach described in Figure 3.1 
compound 71 was synthesized using the following reagents: (α-α-α-trifluoro-m-
tolyl)acetic acid (R1), Boc-glycine (R2), and heptanoic acid (R3). Final crude product was 
purified by HPLC as described above. 1H NMR (400 MHz, CDCl3): δ 8.62 (br s, 2 H) 
7.53 (br s, 2 H) 7.36 - 7.49 (m, 2 H) 3.94 (br s, 1 H) 3.56 (br s, 5 H) 3.40 (br s, 4 H) 3.25 
(br s, 1 H) 2.94 (br s, 2 H) 2.61 (br s, 2 H) 1.55 (br s, 6 H) 1.26 (s, 4 H) 1.29 (s, 6 H) 
0.86 (br s, 3 H). LCMS (ESI+) m/z calcd for C26H41N6 [M + H]+: 495.33, found 495.25. 
LCMS retention time (214 nm): 3.896 min.   
(S)-5-(4-(2-iminoimidazolidin-1-yl)butyl)-1-(4-
(trifluoromethyl)phenethyl)imidazolidin-2-imine (72) Using the synthetic approach 
described in Figure 3.3 compound 72 was synthesized using the following reagents: (α-
α-α-trifluoro-m-tolyl)acetic acid (R1) and Boc-glycine (R2). Final crude product was 
purified by HPLC as described above. 1H NMR (400 MHz, CDCl3): δ 8.43 (br s, 2 H) 
7.76 (br s, 2 H) 7.42 - 7.69 (m, 2 H) 3.79 - 4.06 (m, 1 H) 3.44 - 3.72 (m, 5 H) 3.37 (br s, 
4 H) 3.12 - 3.31 (m, 2 H) 2.99 (br s, 1 H) 2.78 - 2.93 (m, 1 H) 2.68 (br s, 1 H) 1.75 (br s, 
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1 H) 1.52 (br s, 2 H) 1.21 (br s, 1 H).  LCMS (ESI+) m/z calcd for C19H27F3N6 [M + H]+: 
397.23 found 397.05. LCMS retention time (214 nm): 3.081 min.    
(S)-4-butyl-1-(4-((S)-2-imino-3-(4-(trifluoromethyl)phenethyl)imidazolidin-4-
yl)butyl)imidazolidin-2-imine (73) Using the synthetic approach described in Figure 3.3 
compound 73 was synthesized using the following reagents: (α-α-α-trifluoro-m-
tolyl)acetic acid (R1) and Boc-L-norleucine (R2). Final crude product was purified by 
HPLC as described above. 1H NMR (400 MHz, CDCl3):  δ 8.78 (br s, 2 H) 8.58 (br s, 2 
H) 7.40 - 7.52 (m, 4 H) 3.91 - 4.01 (m, 1 H) 3.88 (br s, 1 H) 3.49 - 3.65 (m, 2 H) 3.31 - 
3.45 (m, 2 H) 3.27 (br s, 1 H) 3.13 (br s, 1 H) 2.74 - 3.02 (m, 2 H) 1.60 (br s, 4 H) 1.52 
(br s, 2 H) 1.29 - 1.41 (m, 4 H) 1.25 (br s, 4 H) 0.90 (br s, 3 H). LCMS (ESI+) m/z calcd 
for C23H35F3N6 [M + H]+: 453.29, found 453.20. LCMS retention time (214 nm): 3.642 
min.   
(S)-4-butyl-3-heptyl-1-(4-((S)-2-iminoimidazolidin-4-yl)butyl)imidazolidin-2-imine 
(74) Using the synthetic approach described in Figure 3.4 compound 74 was 
synthesized using the following reagents: Fmoc-L-norleucine (R1) and heptanoic acid 
(R2). Final crude product was purified by HPLC as described above. 1H NMR (400 MHz, 
CDCl3):  δ 8.63 (br s, 2 H) 3.79 (br s, 2 H) 3.60 - 3.75 (m, 3 H) 3.40 - 3.58 (m, 2 H) 3.29 
(br s, 1 H) 3.18 (br s, 2 H) 2.98 (br s, 3 H) 1.75 (br s, 2 H) 1.42 - 1.66 (m, 5 H) 1.20 - 
1.42 (m, 12 H) 0.93 (br s, 3 H) 0.88 (br s, 3 H). LCMS (ESI+) m/z calcd for C21H42N6 [M 
+ H]+: 379.35 found 379.15. LCMS retention time (214 nm): 3.843 min.   
(S)-4-butyl-1-(4-((S)-2-iminoimidazolidin-4-yl)butyl)imidazolidin-2-imine (75) 
Using the synthetic approach described in Figure 3.5 compound 75 was synthesized 
using the following reagents: Fmoc-L-norleucine (R1).   Final crude product was purified 
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by HPLC as described above. 1H NMR (400 MHz, CDCl3): δ 8.60 (br s, 2 H) 8.54 (br s, 
1 H) 3.59 - 3.83 (m, 2 H) 3.40 (br s, 2 H) 3.32 (br s, 1 H) 3.16 (br s, 1 H) 2.96 (br s, 2 H) 
1.93 (br s, 2 H) 1.80 (br s, 2 H) 1.73 (br s, 2 H) 1.62 (br s, 2 H) 1.33 (br s, 4 H) 0.91 (br 
s, 3 H).  LCMS (ESI+) m/z calcd for C14H28N6 [M + H]+: 281.24, found 280.95. LCMS 
retention time (214 nm): 2.759 min.   
(S)-5-(4-(2-iminoimidazolidin-1-yl)butyl)-1-(2-methylphenethyl)imidazolidin-2-
imine (76) Using the synthetic approach described in Figure 3.3 compound 76 was 
synthesized using the following reagents: o-tolylacetic Acid (R1) and Boc-glycine (R2). 
Final crude product was purified by HPLC as described above. 1H NMR (400 MHz, 
CDCl3):  δ 8.76 (br s, 1 H) 8.02 (br s, 1 H) 7.32 - 7.53 (m, 1 H) 7.03 - 7.26 (m, 3 H) 3.65 
(br s, 2 H) 3.51 (br s, 2 H) 3.32 (br s, 1 H) 2.95 (br s, 1 H) 2.36 (s, 3 H) 2.02 (br s, 1 H) 
1.61 (br s, 5 H) 1.29 (br s, 2 H) 1.20 (br s, 2 H) 0.90 (br s, 1 H).  LCMS (ESI+) m/z calcd 
for C19H28N6 [M + H]+: 341.24 found 343.05. LCMS retention time (214 nm): 2.869 min  
(S)-5-(4-(2-iminoimidazolidin-1-yl)butyl)-1-(3-methylphenethyl)imidazolidin-2-
imine (77) Using the synthetic approach described in Figure 3.3 compound 77 was 
synthesized using the following reagents: m-tolylacetic Acid (R1) and Boc-glycine (R2). 
Final crude product was purified by HPLC as described above. 1H NMR (400 MHz, 
DMSO-d6): δ 9.14 (br s, 1 H) 8.91 (br s, 1 H) 8.43 (br s, 1 H) 7.03 - 7.26 (m, 4 H) 3.75 - 
4.02 (m, 1 H) 3.75 - 4.02 (m, 1 H) 3.43 - 3.70 (m, 5 H) 3.36 (br s, 3 H) 3.09 - 3.31 (m, 3 
H) 2.78 – 2.87 (m, 1 H) 2.30 (s, 3 H) 1.72 (br s, 1 H) 1.51 (br s, 2 H) 1.20 (br s, 1 H).   
LCMS (ESI+) m/z calcd for C19H28N6 [M + H]+: 341.24 found 341.00. LCMS retention 
time (214 nm): 2.906 min  
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(S)-5-(4-(2-iminoimidazolidin-1-yl)butyl)-1-(4-methylphenethyl)imidazolidin-2-
imine (78) Using the synthetic approach described in Figure 3.3 compound 78 was 
synthesized using the following reagents: p-tolylacetic acid (R1) and Boc-glycine (R2). 
Final crude product was purified by HPLC as described above. 1H NMR (400 MHz, 
CDCl3): δ 8.77 (br s, 1 H) 8.43 (br s, 1 H) 6.93 - 7.19 (m, 4 H) 3.69 (br s, 2 H) 3.60 (br s, 
2 H) 3.50 (br s, 2 H) 3.33 (br s, 5 H) 2.27 - 2.37 (m, 3 H) 1.64 (br s, 4 H) 1.28 (br s, 2 H). 
LCMS (ESI+) m/z calcd for C19H28N6 [M + H]+: 341.24 found 341.00. LCMS retention 
time (214 nm): 2.926 min.  
(S)-5-(4-(2-iminoimidazolidin-1-yl)butyl)-1-phenethylimidazolidin-2-imine 
(79) Using the synthetic approach described in Figure 3.3 compound 79 was 
synthesized using the following reagents: phenylacetic acid (R1) and Boc-glycine (R2). 
Final crude product was purified by HPLC as described above. 1H NMR (400 MHz, 
CDCl3): δ 8.43 (br s, 2 H) 7.32 (br s, 5 H) 3.70 (br s, 1 H) 3.59 (br s, 1 H) 3.39 (br s, 2 H) 
3.29 (br s, 3 H) 2.94 (br s, 2 H) 2.29 (br s, 2 H) 2.12 (br s, 2 H) 1.86 (br s, 2 H) 1.60 (br 
s, 2 H) 1.29 (br s, 1 H) 1.23 (br s, 1 H).  LCMS (ESI+) m/z calcd for C18H28N6 [M + H]+: 
329.24, found 329.05. LCMS retention time (214 nm): 2.175 min.   
(5S)-5-(4-(2-iminoimidazolidin-1-yl)butyl)-1-(2-(3-
methylcyclohexyl)ethyl)imidazolidin-2-imine (80) Using the synthetic approach 
described in Figure 3.3 compound 80 was synthesized using the following reagents: (3-
methylcyclohexyl)acetic acid (R1) and Boc-glycine (R2). Final crude product was purified 
by HPLC as described above. 1H NMR (400 MHz, CDCl3): δ 8.59 (br s, 1 H) 8.17 (br s, 
1 H) 3.51 - 3.74 (m, 5 H) 3.34 (br s, 3 H) 3.10 (br s, 3 H) 1.71 (br s, 10 H) 1.42 (br s, 2 
H) 1.34 (br s, 2 H) 1.07 - 1.30 (m, 2 H) 0.84 - 1.02 (m, 2 H) 0.80 (d, 3 H).  LCMS (ESI+) 
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m/z calcd for C19H36N6 [M + H]+: 349.30, found 349.05. LCMS retention time (214 nm): 
3.328 min.   
(S)-5-(4-(2-iminoimidazolidin-1-yl)butyl)-1-(2-(4-
methylcyclohexyl)ethyl)imidazolidin-2-imine (81) Using the synthetic approach 
described in Figure 3.3 compound 81 was synthesized using the following reagents: (4-
methylcyclohexyl)acetic acid (R1) and Boc-glycine (R2). Final crude product was purified 
by HPLC as described above. 1H NMR (400 MHz, CDCl3): δ 8.51 (br s, 1 H) 8.17 (br s, 
1 H) 3.52 - 3.72 (m, 5 H) 3.40 (br s, 3 H) 3.10 (br s, 3 H) 1.65 (br s, 10 H) 1.48 (br s, 3 
H) 1.36 (br s, 2 H) 1.26 (br s, 2 H) 1.21 (br s, 1 H) 0.89 (d, 3 H). LCMS (ESI+) m/z calcd 
for C19H36N6 [M + H]+: 349.30, found 349.05. LCMS retention time (214 nm): 3.332 min.    
(5S)-5-(4-(2-iminoimidazolidin-1-yl)butyl)-1-((2-
methylcyclohexyl)methyl)imidazolidin-2-imine (82) Using the synthetic approach 
described in Figure 3.3 compound 82 was synthesized using the following reagents: 2-
methyl-1-cyclohexanecarboxylic Acid (R1) and Boc-glycine (R2). Final crude product 
was purified by HPLC as described above. 1H NMR (400 MHz, CDCl3): δ 8.61 (br s, 1 
H) 8.16 (br s, 1 H) 3.46 - 3.73 (m, 5 H) 3.35 (br s, 3 H) 3.15 (br s, 3 H) 1.82 (br s, 2 H) 
1.60 (br s, 6 H) 1.49 (br s, 3 H) 1.37 (br s, 2 H) 1.26 (br s, 2 H) 1.21 (br s, 1 H) 0.91 (br 
s, 3 H).  LCMS (ESI+) m/z calcd for C18H34N6 [M + H]+: 335.28, found 335.05. LCMS 
retention time (214 nm): 3.020 min.     
(S)-5-(4-(2-iminoimidazolidin-1-yl)butyl)-1-((4-
methylcyclohexyl)methyl)imidazolidin-2-imine (83) Using the synthetic approach 
described in Figure 3.3 compound 83 was synthesized using the following reagents: 4-
methyl-1-cyclohexanecarboxylic acid (R1) and Boc-glycine (R2). Final crude product was 
! 143 
purified by HPLC as described above. 1H NMR (400 MHz, CDCl3): δ 8.55 (br s, 1 H) 
8.47 (br s, 1 H) 8.14 (br s, 1 H) 3.95 (br s, 2 H) 3.56 - 3.83 (m, 6 H) 3.49 (br s, 3 H) 2.08 
(br s, 2 H) 2.02 (br s, 1 H) 1.71 (br s, 4 H) 1.50 (br s, 3 H) 1.38 (br s, 3 H) 1.29 (br s, 2 
H) 0.95 (br s, 3 H).  LCMS (ESI+) m/z calcd for C18H34N6 [M + H]+: 335.28, found 
335.05. LCMS retention time (214 nm): 3.175 min.     
(S)-1-(2-(biphenyl-4-yl)ethyl)-5-butylimidazolidin-2-imine (84) Using the synthetic 
approach described in Figure 3.6 compound 84 was synthesized using the following 
reagents: Boc-L-norleucine (R1) and 4-biphenylacetic acid (R2). Final crude product was 
purified by HPLC as described above. 1H NMR (400 MHz, CDCl3): δ 8.58 (br s, 1 H) 
7.57 (br s, 5 H) 7.32 - 7.47 (m, 4 H) 3.93 - 4.02 (m, 1 H) 3.63 (br s, 2 H) 3.38 - 3.55 (m, 
2 H) 2.98 (br s, 2 H) 2.06 (br s, 2 H) 1.30 (br s, 2 H) 1.13 - 1.25 (m, 2 H) 0.90 (t, 3 H).  
LCMS (ESI+) m/z calcd for C21H27N3 [M + H]+: 322.22, found 321.95. LCMS retention 
time (214 nm): 4.631 min.      
1-(2-(biphenyl-4-yl)ethyl)imidazolidin-2-imine (85) Using the synthetic approach 
described in Figure 3.6 compound 85 was synthesized using the following reagents: 
Boc-glycine (R1) and 4-biphenylacetic Acid (R2). Final crude product was purified by 
HPLC as described above. 1H NMR (400 MHz, CDCl3): δ 8.52 (br s, 1 H) 7.58 (br s, 5 
H) 7.32 - 7.41 (m, 4 H) 3.74 (br s, 2 H) 3.58 (d, 2 H) 3.45 -3.52 (m, 2 H) 2.99 (br s, 2 H).  
LCMS (ESI+) m/z calcd for C17H19N3 [M + H]+: 266.16, found 265.95. LCMS retention 
time (214 nm): 4.088 min.       
(S)-5-butyl-1-phenethylimidazolidin-2-imine (86) Using the synthetic approach 
described in Figure 3.6 compound 86 was synthesized using the following reagents: 
Boc-L-norleucine (R1) and phenylacetic acid (R2). Final crude product was purified by 
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HPLC as described above. 1H NMR (400 MHz, DMSO-d6): δ 9.49 (br s, 1 H) 8.43 (br s, 
1 H) 7.32 (br s, 5 H) 3.79 (d, 2 H) 3.56 (t, 2 H) 3.27 - 3.44 (m, 2 H) 2.82 - 3.00 (m, 1 H) 
1.33 - 1.51 (m, 2 H) 1.10 - 1.33 (m, 4 H) 0.88 (t, 3 H).  LCMS (ESI+) m/z calcd for 
C15H23N3 [M + H]+: 246.19 found 245.95. LCMS retention time (214 nm): 4.061 min.       
1-phenethylimidazolidin-2-imine (87) Using the synthetic approach described in 
Figure 3.6 compound 87 was synthesized using the following reagents: Boc-glycine (R1) 
and phenylacetic acid (R2). Final crude product was purified by HPLC as described 
above. LCMS (ESI+) m/z calcd for C11H15N3 [M + H]+: 190.13, found 189.85. LCMS 
retention time (214 nm): 3.078 min. 
(5S)-1-(2-((1S,3R)-adamantan-1-yl)ethyl)-5-butylimidazolidin-2-imine (88) Using 
the synthetic approach described in Figure 3.6 compound 88 was synthesized using the 
following reagents: Boc-L-norleucine (R1) and 1-adamantaneacetic acid (R2). Final 
crude product was purified by HPLC as described above. 1H NMR (400 MHz, CDCl3): δ 
8.06 (br s, 1 H) 7.69 (br s, 1 H) 3.89 (br s, 1 H) 3.72 (t, 1 H) 3.45 - 3.65 (m, 1 H) 3.32 
(br. s., 1 H) 2.98 - 3.25 (m, 1 H) 2.10 (br s, 2 H) 2.00 (br s, 1 H) 1.61 - 1.82 (m, 8 H) 
1.48 - 1.61 (m, 7 H) 1.32 - 1.45 (m, 3 H) 1.28 (br s, 2 H) 0.95 (br s, 3 H).  LCMS (ESI+) 
m/z calcd for C19H33N3 [M + H]+: 304.27, found 304.45. LCMS retention time (214 nm): 
4.841 min.        
 (S)-5-butyl-1-((4-methylcyclohexyl)methyl)imidazolidin-2-imine (89) Using the 
synthetic approach described in Figure 3.6 compound 89 was synthesized using the 
following reagents: Boc-L-norleucine (R1) and 4-methyl-1-cyclohexanecarboxylic acid 
(R2). Final crude product was purified by HPLC as described above. 1H NMR (400 MHz, 
CDCl3):  δ 8.55 (br s, 1 H) 7.99 (br s, 1 H) 3.84 (br s, 1 H) 3.65 - 3.80 (m, 1 H) 3.48 - 
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3.62 (m, 1 H) 3.29 - 3.42 (m, 1 H) 2.88 - 3.08 (m, 1 H) 2.05 (br s, 1 H) 1.72 (br s, 4 H) 
1.51 (br s, 3 H) 1.33 - 1.48 (m, 5 H) 1.27 (d, 2 H) 0.99 - 1.20 (m, 1 H) 0.87 - 0.99 (m, 6 
H). LCMS (ESI+) m/z calcd for C15H29N3 [M + H]+: 252.24 found 252.0. LCMS retention 
time (214 nm): 4.469 min.        
 
High Content Screen with Infected Macrophage 
 J774 cells are seeded into black 384 well plates with an optically clear bottom 
and then axenic amastigotes are added at MOI 10:1 to establish infections. The plate 
wells are then washed with media to remove extracellular amastigotes and plates are 
incubated at 37 oC overnight. Serial dilutions of compound are prepared in a separate 
mother plate and then added to the test plate containing J774 macrophages infected 
with L. donovani. After 72 hr media is removed, the cells are fixed with 2% 
paraformaldehyde and then stained with 5 µM Draq5 (diluted in PBS) for 5 min. 
Following another plate wash high content imaging analysis on a Perkin Elmer Operetta 
is used to capture 6 images (100x) for each well and the images are analyzed with 
Harmony software (Perkin Elmer) to determine the number of amastigotes per 
macrophage and the data are fit to 4-parameter logistic dose response to calculate 
IC50s. Image analysis is based upon the different sizes of the Draq5 stained nuclei of 
J774 and amastigotes.   
 
L. donovani axenic amastigotes assay 
 L. donovani axenic amastigotes are seeded at a concentration of 106 
parasites/mL in 96-well plates in the presence or absence of compounds of interest.  
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Plates are incubated at 37 °C for 72 h, and then the commercially available CellTiter 
reagent (a water soluble tetrazolium dye from Promega) is added.  After a 3-4 h 
incubation period to allow for reduction of the dye, converting it from yellow to purple, 
the absorbance of each well is measured at 490 nm using the SpectraMax Plus 
microplate reader (Molecular Devices).  IC50 values are determined with the aid of a 
four-parameter, logistic dose response equation in the DataAspects Plate Manager 
software.7 
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Tables 
Table 3.1. Leishmania Scaffold Ranking Data. 
ID # of  Total # Core Scaffold 
CR6  
12.5 
µg/ml 
CS1 
12.5 
µg/ml 
IM 
IC50 
µg/ml 
SI Rank 
Lib1 110 45,864 
 
98% 89% 0.9 57.4 1 
Lib27 120 738,192 
 
26% -10% 1.2 41.9 27 
Lib19 96 31,320 
 
7% 12% 3.5 14.2 19 
Lib15 174 195,112 
 
6% 14% 4.8 10.4 15 
Lib32 400 10,800 
 
4% 10% 1.3 37.9 32 
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Table 3.1 (continued). Leishmania Scaffold Ranking Data. 
ID # of  Total # Core Scaffold 
CR6  
12.5 
µg/ml 
CS1 
12.5 
µg/ml 
IM 
IC50 
µg/ml 
SI Rank 
Lib9 96 31,320 
 
4% 10% 5.0 9.9 9 
Lib31 400 16,000 
 
2% 9% 2.3 21.6 31 
Lib20 96 31,320 
 
2% 23% 0.6 81.1 20 
Lib8 116 56,610 
 
1% -2% 3.5 14.1 8 
Lib3 110 45,864 
 
1% 12% 0.6 40.8 3 
Lib30 400 16,400 
 
-1% 13% 5.1 9.9 30 
Lib17 319 13,398 
 
-2% 6% 10.0 5.0 17 
Lib7 110 45,864 
 
-3% 12% 5.8 8.6 7 
Lib29 135 85,248 
 
-3% 18% 3.5 14.1 29 
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Table 3.1 (continued). Leishmania Scaffold Ranking Data. 
ID # of  Total # Core Scaffold 
CR6  
12.5 
µg/ml 
CS1 
12.5 
µg/ml 
IM 
IC50 
µg/ml 
SI Rank 
Lib10 120 738,192 
 
-3% -4% 10.0 5.0 10 
Lib28 96 31,320 
 
-4% -4% 3.6 14.1 28 
Lib23 110 45,864 
 
-4% 20% 3.7 13.6 23 
Lib22 96 31,320 
 
-5% -10% 10.0 5.0 22 
Lib11 125 72,283 
 
-5% 0% 5.2 9.6 11 
Lib5 116 56,610 
 
-5% 5% 2.0 25.4 5 
Lib13 116 56,610 
 
-5% 22% 5.1 9.7 13 
Lib4 116 56,610 
 
-6% -7% 10.0 5.0 4 
Lib21 120 738,192 
 
-7% -8% 0.6 81.6 21 
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Table 3.1 (continued). Leishmania Scaffold Ranking Data. 
ID # of  Total # Core Scaffold 
CR6  
12.5 
µg/ml 
CS1 
12.5 
µg/ml 
IM 
IC50 
µg/ml 
SI Rank 
Lib2 120 738,192 
 
-9% -5% 1.2 42.7 2 
Lib6 120 738,192 
 
-13% -6% 1.8 28.1 6 
Lib12 150 125,000 
 
-46% 7% 2.8 17.7 12 
Lib37 94 3,249 
 
NT NT 0.6 81.6 37 
Lib38 124 3,844 
 
NT NT 0.6 43.7 NT 
 
Data sorted by CR6 column.  “ID” corresponds to the numbers used throughout the chapter.  “# of” is the 
number of samples in the corresponding positional scanning library for a given scaffold. “Total #” is the 
total number of compounds in a given scaffold ranking sample. SI Is the IC50 uninfected macrophage 
(J774) divided by the IC50 for the infected macrophage.  The maximum dose tested was 50 µg/ml for the 
uninfected and 5 µg/ml for the infected. Rank is the order the samples appeared in the scaffold ranking 
table for ESKAPE (Table 2.1), so a sample with a rank of 1 possessed more potent broad spectrum 
activity then a sample ranked 2 or higher.  NT means not tested. 
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Table 3.2. Leishmania Lib1 R1.  
  
 
 
 
ID #! R1! a.a. i.m. E! S! K! A! P! E!
Lib1.001! hydrogen! -13% 2.5 ! ! ! ! ! !
Lib1.002! 2-phenylbutyl! 69% >10 ! ! ! ! ! !
Lib1.003! 3-phenylbutyl! 94% 1.2 ! ! ! ! ! !
Lib1.004! m-tolylethyl! 91% >10 ! ! ! ! ! !
Lib1.005! 2-(3-fluoro-phenyl)-ethyl! 42% >10 ! ! ! ! ! !
Lib1.006! 2-(3-bromo-phenyl)-ethyl! 86% 3.7 ! ! ! ! ! !
Lib1.007! 2-(3-trifluoromethyl-phenyl)-ethyl! 81% 0.7 ! ! ! ! ! !
Lib1.008! p-tolylethyl! 87% >10 ! ! ! ! ! !
Lib1.009! 2-(4-fluoro-phenyl)-ethyl! 14% 3.5 ! ! ! ! ! !
Lib1.010! 2-(3-methoxy-phenyl)-ethyl! -7% >10 ! ! ! ! ! !
Lib1.011! 2-(4-bromo-phenyl)-ethyl! 34% >10 ! ! ! ! ! !
Lib1.012! 2-(4-methoxy-phenyl)-ethyl! -10% 1.1 ! ! ! ! ! !
Lib1.013! 2-(4-ethoxy-phenyl)-ethyl! -3% 0.9 ! ! ! ! ! !
Lib1.014! 2-(4-Isobutyl-phenyl)-propyl! 99% 5.2 ! ! ! ! ! !
Lib1.015! 3,4-dichlorophenethyl! 66% >10 ! ! ! ! ! !
Lib1.016! 2-(3,5-bis-trifluoromethyl-phenyl)-ethyl! 37% 1.3 ! ! ! ! ! !
Lib1.017! 3-(3,4-dimethoxy-phenyl)-propyl! 5% >10 ! ! ! ! ! !
Lib1.018! phenethyl! 23% 5.2 ! ! ! ! ! !
Lib1.019! 3,4,5-trimethoxy-benzyl! -14% 5.1 ! ! ! ! ! !
Lib1.020! butyl! 4% 5.3 ! ! ! ! ! !
Lib1.021! heptyl! 100% 1.3 ! ! ! ! ! !
Lib1.022! isobutyl! -14% >10 ! ! ! ! ! !
Lib1.023! 2-methylbutyl! 10% 5.2 ! ! ! ! ! !
Lib1.024! 3-methylbutyl! 31% >10 ! ! ! ! ! !
Lib1.025! 3-methylpentyl! 91% >10 ! ! ! ! ! !
Lib1.026! 4-methylpentyl! 93% 0.9 ! ! ! ! ! !
Lib1.027! 4-methyl-benzyl! -17% 2.5 ! ! ! ! ! !
Lib1.028! cyclopently-methyl! 14% 1.7 ! ! ! ! ! !
Lib1.029! cyclohexyl-methyl! 61% 1.9 ! ! ! ! ! !
Lib1.030! cyclohexyl-ethyl! 99% 3.6 ! ! ! ! ! !
Lib1.031! cyclohexyl-butyl! 100% 0.6 ! ! ! ! ! !
Lib1.032! cycloheptyl-methyl! 63% 2.9 ! ! ! ! ! !
Lib1.033! 2-methylcyclopropyl-methyl! -4% 4.6 ! ! ! ! ! !
Lib1.034! cyclobutyl-methyl! 61% 1.2 ! ! ! ! ! !
Lib1.035! 3-cyclopentyl-propyl! 100% 1.2 ! ! ! ! ! !
Lib1.036! cyclohexyl-propyl! 100% >10 ! ! ! ! ! !
Lib1.037! 4-methyl-1-cyclohexyl-methyl! 100% 2.4 ! ! ! ! ! !
Lib1.038! 4-tert-butyl-cyclohexyl-methyl! 100% 1.6 ! ! ! ! ! !
Lib1.039! 2-biphenyl-4-yl-ethyl! 98% 1.2 ! ! ! ! ! !
Lib1.040! adamantan-1-yl-methyl! 63% >10 ! ! ! ! ! !
Lib1.041! adamantan-1-yl-ethyl! 99% 1.2 ! ! ! ! ! !
Lib1.042! 2-bicyclo[2.2.1]hept-2-yl-ethyl! 99% 0.5 ! ! ! ! ! !
 
a.a. Is the data from the 2.5ug/ml axenic amastigotes assay reported as % inhibition. i.m. is the 
IC50 data from the infect macrophage assay.  indicates a MIC ≤5 µg/ml,  a MIC 5-10 µg/ml, 
 a MIC 10-25 µg/ml, and  > 25 µg/ml from the ESKAPE assays (Chapter 2). 
!
! 152 
 
Table 3.3. Leishmania Lib1 R2.   
 
ID # R2 a.a. i.m. E S K A P E 
Lib1.043 S-methyl 91% >10       
Lib1.044 S-benzyl 99% >10       
Lib1.045 hydrogen 84% >10       
Lib1.046 S-2-butyl 100% 1.2       
Lib1.047 S-isobutyl 100% 5.1       
Lib1.048 R-hydroxymethyl -4% 5.8       
Lib1.049 (R,R)-1-hydroxyethyl 7% >10       
Lib1.050 S-isopropyl 65% >10       
Lib1.051 S-4-hydroxybenzyl -35% >10       
Lib1.052 R-methyl 79% >10       
Lib1.053 R-benzyl 96% >10       
Lib1.054 R-2-butyl 99% >10       
Lib1.055 R-isobutyl 97% >10       
Lib1.056 S-hydroxymethyl -18% >10       
Lib1.057 (S,S)-1-hydroxyethyl 3% >10       
Lib1.058 R-isopropyl 23% 5.3       
Lib1.059 R-4-hydroxybenzyl -18% 5.4       
Lib1.060 S-phenyl 29% >10       
Lib1.061 S-propyl 56% 5.2       
Lib1.062 R-propyl 98% 5.3       
Lib1.063 S-butyl 99% 4.5       
Lib1.064 R-butyl 100% 5.1       
Lib1.065 S-2-naphthylmethyl 95% >10       
Lib1.066 R-2-naphthylmethyl 26% 3.8       
Lib1.067 S-cyclohexylmethyl 99% >10       
Lib1.068 R-cyclohexylmethyl 100% 0.6       
!
a.a. Is the data from the 2.5ug/ml axenic amastigotes assay reported as % inhibition.  i.m. is the 
IC50 data from the infect macrophage assay.   indicates a MIC ≤5 µg/ml,  a MIC 5-10 µg/ml, 
 a MIC 10-25 µg/ml, and  > 25 µg/ml from the ESKAPE assays (Chapter 2). 
!
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Table 3.4. Leishmania Lib1 R3.  
 
ID # R3 a.a. i.m. E S K A P E 
Lib1.069 hydrogen -1% 5.4       
Lib1.070 2-phenylbutyl 38% >10       
Lib1.071 3-phenylbutyl 63% 3.6       
Lib1.072 m-tolylethyl 88% 0.6       
Lib1.073 2-(3-fluoro-phenyl)-ethyl 11% 1.3       
Lib1.074 2-(3-bromo-phenyl)-ethyl 11% 1.3       
Lib1.075 2-(3-trifluoromethyl-phenyl)-ethyl 25% 1.4       
Lib1.076 p-tolylethyl 57% 0.4       
Lib1.077 2-(4-fluoro-phenyl)-ethyl 11% 6.1       
Lib1.078 2-(3-methoxy-phenyl)-ethyl 9% 7.0       
Lib1.079 2-(4-bromo-phenyl)-ethyl 12% >10       
Lib1.080 2-(4-methoxy-phenyl)-ethyl 13% >10       
Lib1.081 2-(4-ethoxy-phenyl)-ethyl 21% 1.3       
Lib1.082 2-(4-Isobutyl-phenyl)-propyl 86% >10       
Lib1.083 3,4-dichlorophenethyl 3% 1.2       
Lib1.084 2-(3,5-bis-trifluoromethyl-phenyl)-ethyl 19% 1.3       
Lib1.085 3-(3,4-dimethoxy-phenyl)-propyl 1% 1.8       
Lib1.086 phenethyl 13% 4.8       
Lib1.087 3,4,5-trimethoxy-benzyl 2% 1.3       
Lib1.088 butyl 12% 0.7       
Lib1.089 heptyl 99% 5.1       
Lib1.090 isobutyl -17% 0.7       
Lib1.091 2-methylbutyl 7% 0.9       
Lib1.092 3-methylbutyl 7% 5.1       
Lib1.093 3-methylpentyl 58% 1.3       
Lib1.094 4-methylpentyl 79% 1.8       
Lib1.095 4-methyl-benzyl 10% 2.7       
Lib1.096 cyclopently-methyl 21% 1.7       
Lib1.097 cyclohexyl-methyl 15% 1.4       
Lib1.098 cyclohexyl-ethyl 92% >10       
Lib1.099 cyclohexyl-butyl 100% 4.9       
Lib1.100 cycloheptyl-methyl 15% 1.2       
Lib1.101 2-methylcyclopropyl-methyl -2% 1.4       
Lib1.102 cyclobutyl-methyl 9% 1.2       
Lib1.103 3-cyclopentyl-propyl 91% 1.3       
Lib1.104 cyclohexyl-propyl 94% 1.3       
Lib1.105 4-methyl-1-cyclohexyl-methyl 11% >10       
Lib1.106 4-tert-butyl-cyclohexyl-methyl 97% 3.5       
Lib1.107 2-biphenyl-4-yl-ethyl 42% >10       
Lib1.108 adamantan-1-yl-methyl 11% >10       
Lib1.109 adamantan-1-yl-ethyl 90% 0.7       
Lib1.110 2-bicyclo[2.2.1]hept-2-yl-ethyl 62% 2.7       
!
a.a. Is the data from the 2.5ug/ml axenic amastigotes assay reported as % inhibition. i.m. is the 
IC50 data from the infect macrophage assay.   indicates a MIC ≤5 µg/ml,  a MIC 5-10 µg/ml, 
 a MIC 10-25 µg/ml, and  > 25 µg/ml from the ESKAPE assays (Chapter 2). 
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Table 3.5. 27 Individual Compounds Made for ESKAPE and Tested for Anti-Leishmaniasis. 
 
ID R1 R2 R3 
a.a 
5 µM 
a.a 
2.5 µM 
i.m. 
IC50 
cyto 
IC50 
SI 
1 2-(3-trifluoromethyl-phenyl)-ethyl S-butyl heptyl 26% 9% 0.6 48 81 
2 2-(3-trifluoromethyl-phenyl)-ethyl S-butyl cyclohexyl-butyl 43% -5% >5 50 10 
3 2-(3-trifluoromethyl-phenyl)-ethyl S-butyl 2-biphenyl-4-yl-ethyl 100% 47% 0.3 28 89 
4 2-(3-trifluoromethyl-phenyl)-ethyl R-2-naphthylmethyl heptyl 100% 37% 3.5 50 14 
5 2-(3-trifluoromethyl-phenyl)-ethyl R-2-naphthylmethyl cyclohexyl-butyl 75% 6% 1.8 50 28 
6 2-(3-trifluoromethyl-phenyl)-ethyl R-2-naphthylmethyl 2-biphenyl-4-yl-ethyl -15% -13% 1.3 50 39 
7 2-(3-trifluoromethyl-phenyl)-ethyl S-cyclohexylmethyl heptyl 6% -3% >5 50 10 
8 2-(3-trifluoromethyl-phenyl)-ethyl S-cyclohexylmethyl cyclohexyl-butyl 94% -7% 1.8 26 14 
9 2-(3-trifluoromethyl-phenyl)-ethyl S-cyclohexylmethyl 2-biphenyl-4-yl-ethyl 97% 35% >5 46 9 
10 cyclohexyl-butyl S-butyl heptyl 98% 68% 1.3 16 12 
11 cyclohexyl-butyl S-butyl cyclohexyl-butyl 99% 71% >5 15 3 
12 cyclohexyl-butyl S-butyl 2-biphenyl-4-yl-ethyl 98% 78% 5.0 12 2 
13 cyclohexyl-butyl R-2-naphthylmethyl heptyl 97% 6% 1.3 50 38 
14 cyclohexyl-butyl R-2-naphthylmethyl cyclohexyl-butyl -6% -1% 0.9 50 56 
15 cyclohexyl-butyl R-2-naphthylmethyl 2-biphenyl-4-yl-ethyl -5% 15% >5 34 7 
16 cyclohexyl-butyl S-cyclohexylmethyl heptyl 95% 97% 0.7 25 36 
17 cyclohexyl-butyl S-cyclohexylmethyl cyclohexyl-butyl 95% 77% >5 24 5 
18 cyclohexyl-butyl S-cyclohexylmethyl 2-biphenyl-4-yl-ethyl 95% 70% 0.3 20 69 
19 adamantan-1-yl-ethyl S-butyl heptyl 94% 96% >5 32 6 
20 adamantan-1-yl-ethyl S-butyl cyclohexyl-butyl 8% 11% 0.6 27 41 
21 adamantan-1-yl-ethyl S-butyl 2-biphenyl-4-yl-ethyl -21% -27% 0.9 22 25 
22 adamantan-1-yl-ethyl R-2-naphthylmethyl heptyl -22% -31% 0.6 36 57 
23 adamantan-1-yl-ethyl R-2-naphthylmethyl cyclohexyl-butyl 99% 99% 2.6 32 13 
24 adamantan-1-yl-ethyl R-2-naphthylmethyl 2-biphenyl-4-yl-ethyl -46% -25% 1.7 41 25 
25 adamantan-1-yl-ethyl S-cyclohexylmethyl heptyl 85% 14% 2.5 26 11 
26 adamantan-1-yl-ethyl S-cyclohexylmethyl cyclohexyl-butyl 28% -4% >5 23 5 
27 adamantan-1-yl-ethyl S-cyclohexylmethyl 2-biphenyl-4-yl-ethyl 57% 14% 0.9 17 20 
!
a.a. Is the 5 and 2.5 µM axenic amastigotes assay reported as % inhibition. i.m. is the IC50 data 
from the infect macrophage assay.  cyto is the IC50 data from the infect macrophage assay. SI is 
the selectivity index, cyto IC50 divided by i.m IC50. Complete structures for all 27 compounds are 
shown in Figure 2.7. 
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Table 3.6. Analogs of 16 
!
!
ID i.m. IC50 
cyto 
IC50 
SI 25 µM 10 µM 5 µM 1 µM 
16 0.7 25 36 ESKAPE ESKAPE ESKAE SKAE 
55 8.9 50 6 ESKAPE ESKAPE ESKAE SKAE 
56 1.8 27 16 ESKA ESKA ES S 
57 3.5 6 2 S S S S 
58 2.5 50 20 S - - - 
59 5.2 24 5 - - - - 
60 10.0 13 1 - - - - 
61 4.8 50 10 - - - - 
!
a.a. Is the 5 and 2.5 µM axenic amastigotes assay reported as % inhibition. 
i.m. is the IC50 data from the infect macrophage assay.  
cyto is the IC50 data from the infect macrophage assay. 
SI is the selectivity index, cyto IC50 divided by i.m IC50. 
A microbroth dilution assay was performed to determine the MIC of each compound against the 
6 ESKAPE pathogens.  At each of the given doses tested a letter is provided for the pathogens 
inhibited.  
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Table 3.7. Analogs of 21 
!
ID i.m. IC50 
cyto 
IC50 
SI 25 µM 10 µM 5 µM 1 µM 
21 0.9 22 25 ESKAPE ESKAPE ESKAE ESKAE 
62 3.8 21 6 ESKAPE ESKAPE ESKAE SKE 
63 4.2 13 3 S S S - 
64 0.7 23 33 S S S S 
65 1.2 50 43 S - - - 
66 3.5 50 14 - - - - 
67 10.0 50 5 - - - - 
68 4.9 50 10 - - - - 
61 4.8 50 10 - - - - 
69 0.6 20 36 - - - - 
 
a.a. Is the 5 and 2.5 µM axenic amastigotes assay reported as % inhibition. i.m. is the IC50 data 
from the infect macrophage assay. cyto is the IC50 data from the infect macrophage assay. SI is 
the selectivity index, cyto IC50 divided by i.m IC50.  A microbroth dilution assay was performed to 
determine the MIC of each compound against the 6 ESKAPE pathogens.  At each of the given 
doses tested a letter is provided for the pathogens inhibited.  
!
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Table 3.8. Analogs of 1, 2, and 3 
!
ID i.m. IC50 
cyto 
IC50 
SI 25 µM 10 µM 5 µM 1 µM 
1 0.6 48 81 ESKAPE ESKAPE ESKAPE - 
2 5.0 50 10 ESKAPE ESKAPE ESKAPE - 
3 0.3 28 88 ESKAPE ESKAPE ESKAPE - 
70 0.6 50 79 ESKAPE ESKAPE ESKAPE SKE 
71 2.5 9 4 S - - - 
72 0.9 7 9 - - - - 
73 3.5 11 3 - - - - 
74 1.3 22 17 - - - - 
75 5.0 50 10 - - - - 
61 4.8 50 10 - - - - 
 
a.a. Is the 5 and 2.5 µM axenic amastigotes assay reported as % inhibition. i.m. is the IC50 data 
from the infect macrophage assay.  cyto is the IC50 data from the infect macrophage assay. SI is 
the selectivity index, cyto IC50 divided by i.m IC50.  A microbroth dilution assay was performed to 
determine the MIC of each compound against the 6 ESKAPE pathogens.  At each of the given 
doses tested a letter is provided for the pathogens inhibited.  
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Table 3.9. Analogs of 72 
!
!
ID i.m. IC50 
cyto 
IC50 
SI 25 µM 10 µM 5 µM 1 µM 
72 0.9 7 9 - - - - 
76 3.5 50 14 - - - - 
77 0.9 50 56 - - - - 
78 3.9 22 6 - - - - 
79 1.2 16 13 - - - - 
80 1.8 19 10 - - - - 
81 0.6 17 28 - - - - 
82 5.4 14 3 - - - - 
83 4.4 6 1 - - - - 
 
a.a. Is the 5 and 2.5 µM axenic amastigotes assay reported as % inhibition. 
i.m. is the IC50 data from the infect macrophage assay.  
cyto is the IC50 data from the infect macrophage assay. 
SI is the selectivity index, cyto IC50 divided by i.m IC50 
A microbroth dilution assay was performed to determine the MIC of each compound against the 
6 ESKAPE pathogens.  At each of the given doses tested a letter is provided for the pathogens 
inhibited.  
!
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Table 3.10. Monocyclic Analogs 
!
!
ID i.m. IC50 
cyto 
IC50 
SI 25µM 10µM 5µM 1µM 
21 0.9 22 25 ESKAPE ESKAPE ESKAE ESKAE 
84 2.4 15 6 ESKA S S - 
85 4.8 15 3 S - - - 
86 0.6 25 42 - - - - 
87 10.0 8 1 - - - - 
88 4.7 12 3 ESKA S S - 
89 0.6 6 10 - - - - 
 
a.a. Is the 5 and 2.5 µM axenic amastigotes assay reported as % inhibition. 
i.m. is the IC50 data from the infect macrophage assay.  
cyto is the IC50 data from the infect macrophage assay. 
SI is the selectivity index, cyto IC50 divided by i.m IC50 
A microbroth dilution assay was performed to determine the MIC of each compound against the 
6 ESKAPE pathogens.  At each of the given doses tested a letter is provided for the pathogens 
inhibited.  
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Figures 
 
 
Figure 3.1. Synthesis of Compounds 57, 64, and 71.   
a) 5% DIEA/DCM b) Fmoc-Lys(Boc), DIC, HOBt, DMF c) 20% Piperidine/DMF d) R1-
COOH, DIC, HOBt, DMF e) 55% TFA/DCM; 5% DIEA/DCM f) Boc-AA(R2)-OH, DIC, 
HOBt, DMF g) R3-COOH, DIC, HOBt, DMF h) Borane-THF 65 oC 96 hr; Piperazine 65 
oC, 24 hr i) Cyanogen bromide, DCM j) HF 0 oC 1.5 hr. 
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Figure 3.2. Synthesis of Compounds 55, 62, and 70.   
a) 5% DIEA/DCM b) Fmoc-D-lys(Boc), DIC, HOBt, DMF c) 20% Piperidine/DMF d) R1-
COOH, DIC, HOBt, DMF e) 55% TFA/DCM; 5% DIEA/DCM f) Boc-AA(R2)-OH, DIC, 
HOBt, DMF g) R3-COOH, DIC, HOBt, DMF h) Borane-THF 65 oC 96 hr; Piperazine 65 
oC, 24 hr i) Cyanogen bromide, DCM j) HF 0 oC 1.5 hr. 
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Figure 3.3. Synthesis of Compounds 56, 59, 63, 66, 72, 73, and 76 to 83. 
a) 5% DIEA/DCM b) Fmoc-Lys(Boc), DIC, HOBt, DMF c) 20% Piperidine/DMF d) R1-
COOH, DIC, HOBt, DMF e) 55% TFA/DCM; 5%DIEA/DCM f) Boc-AA(R2)-OH, DIC, 
HOBt, DMF g) Borane-THF 65 oC 96 hr; Piperazine 65 oC, 24 hr h) Cyanogen bromide, 
DCM i) HF 0 oC 1.5 hr 
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Figure 3.4. Synthesis of Compounds 58, 60, 65, 68, 69, and 74. 
a) 5% DIEA/DCM b) Boc-Lys(Fmoc), DIC, HOBt, DMF c) 20% Piperidine/DMF d) Boc-
AA(R1)-OH, DIC, HOBt, DMF e) R2-COOH, DIC, HOBt, DMF f) 55% TFA/DCM; 5% 
DIEA/DCM g) Borane-THF 65 oC 96 hr; Piperazine 65 oC, 24 hr h) Cyanogen bromide, 
DCM  i) HF 0 oC 1.5 hr  
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Figure 3.5. Synthesis of Compounds 61, 67, and 75. 
a) 5% DIEA/DCM b) Boc-Lys(Fmoc), DIC, HOBt, DMF c) 20% Piperidine/DMF d) Boc-
AA(R1)-OH, DIC, HOBt, DMF e) 55% TFA/DCM; 5% DIEA/DCM f) Borane-THF 65 oC 
96 hr; Piperazine 65 oC, 24 hr g) Cyanogen bromide, DCM  h) HF 0 oC 1.5 hr  
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Figure 3.6. Synthesis of Compounds 84 to 89.   
a) 5% DIEA/DCM b) Boc-AA(R1)-OH, DIC, HOBt, DMF c) 55% TFA/DCM; 5% 
DIEA/DCM d) R2-COOH, DIC, HOBt, DMF e) Borane-THF 65 oC 96 hr; Piperazine 65 
oC, 24 hr f) Cyanogen bromide, DCM  g) HF 0 oC 1.5 hr  
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CHAPTER FOUR: 
SYSTEMATICALLY FORMATTED MIXTURE BASED LIBRARIES – AUTO-
PALMITOYLATION 
 
Introduction  
 Palmitoylation is the post-translational process by which a fatty acid, palmitic 
acid, is covalently coupled onto a cysteine residue of a protein. A family of protein acyl 
transferases (PATs) catalyze the palmitoylation of proteins through a two step 
process.1-2 The first step in the process, auto-palmitoylation, involves the transfer of a 
palmitoyl moiety from palmitoyl-CoA to the PAT generating the PAT-palmitoyl 
intermediate.  During the second step the palmitoyl moiety is transferred to the cysteine 
residue of the protein substrate.1,3 
Palmitoylation plays a role in cellular processes such as signal transduction, 
protein turnover, and cell-cell interaction.  The addition of a palmitate to a protein 
enhances the protein’s membrane affinity, mediates protein-protein interactions, 
trafficking, stability, and aggregation state.4 Disruption of the palmitoylation process has 
been linked to cardiovascular disease, neurological disorders, and some cancers.4,5 
While it is potentially an attractive target for drug development there are currently no 
therapeutics that target palmitoylation specifically.  Additionally, there is only a limited 
set of tool compounds available all of which exhibit low affinity and lack specificity.  Of 
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these compounds, 2-bromopalmitic acid (2-BP) is the primary compound utilized in 
inhibition studies despite its lack of specificity.6,7 
Dr. Robert Deschenes’ group has developed a high-throughput screening assay 
for quantifying auto-palmitoylation.8 The assay was utilized to screen systematically 
formatted mixture based libraries in order to identify novel inhibitors of palmitoylation.  
Starting with a scaffold ranking library9,10 50 different scaffolds encompassing over 5 
million individual compounds were screened using just 50 samples.  From this initial 
screen a bis-piperazine scaffold was selected for positional scanning library screening.  
Utilizing a positional scanning library of 110 samples, 45,864 individual bis-piperazine 
analogs were assessed using the HTS assay in order to build an SAR profile around the 
bis-piperazine scaffold and select individual compounds likely to inhibit auto-
palmitoylation.  54 compounds (48 predicted to inhibit and 6 predicted to produce less 
inhibition) were synthesized and evaluated for inhibition of auto-palmitoylation.  Upon 
confirmation of their inhibitory ability a sub-set of compounds were selected for further 
characterization including evaluation of inhibition of the auto-palmitoylation activity in a 
yeast Ras PAT, Erf2 model.   
 
Scaffold Ranking 
In order to prioritize the screening of positional scanning libraries a scaffold 
ranking library was assembled (Table 4.1) in a similar manner to that as described in 
Chapters 2 and 3. Each of the 50 mixture samples shown in Table 4.1 contains an 
equal molar mixture of every compound available for a given scaffold.  For example, the 
scaffold ranking sample Lib3 contains an equal molar mixture of 45,864 individual bis-
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piperazine analogs (Table 4.1).  As described in Chapters 1, 2, 3 and elsewhere,9,10 
these scaffold ranking samples can be prepared as synthetic mixtures or by pooling 
together aliquots of each sample in a given positional scanning library.  
The 50 scaffold ranking samples shown in Table 4.1 were screened in an assay 
that monitors the rate of auto-palmitoylation by measuring the production of coenzyme 
A (CoASH) generated from the reduction of palmitoyl-CoA.8  In this assay the rate in 
reduction of auto-palmitoylation is determined by measuring the relative amount of 
NADH, a fluorescent compound, produced in the assay (Figure 4.1). All 50 samples 
were screened at 100 µg/ml and the average velocity of Erf2 auto-palmitoylation is 
presented as a fraction of the vehicle control (1% DMF), Table 4.1. (Note all samples 
were also examined for fluorescence that would interfere with the assay; none of the 
samples interfered.) No effect on Erf2 auto-palmitoylation is assigned the arbitrary value 
of 1 and samples that resulted in a reduction in Erf2 auto-palmitoylation of 3 standard 
deviations or greater were considered hits.  The four samples that met this criterion 
were Lib35, Lib39, Lib3, and Lib41.  Of note 3 of these 4 samples (Lib39, Lib3, and 
Lib41) contain a piperazine as a significant portion of their respective scaffold.  As in 
Chapters 2 and 3 the libraries from libraries series of scaffolds Lib1, Lib3, Lib7, Lib12, 
and Lib23 were included in the scaffold ranking screen (Table 4.1 and 4.2).  The 
importance of the piperazine scaffold relative the cyclic thiourea, diketopiperazine, cyclic 
guanidine, or linear polyamine scaffold for auto-palmitoylation is seen by comparing 
these libraries from libraries samples (Table 4.2). 
The four samples Lib35, Lib39, Lib3, and Lib41 that resulted in a reduction in 
Erf2 auto-palmitoylation of 3 standard deviations or greater at the 100 µg/ml dose were 
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screened at 200 µg/ml, 100 µg/ml, and 50 µg/ml.  Sample Lib3 reproducibly reduced 
auto-palmitoylation in a dose dependent fashion to the greatest extent and was 
therefore prioritized for screening as a positional scanning library. 
 
Positional Scanning 
Positional scanning library Lib3 was synthesized using the synthesis scheme 
shown in Chapter 2 (Figure 2.1) as well as in Chapter 1 (Figures 1.3 and 1.4).  As 
described in Chapter 1, 110 different mixture samples were synthesized using the 
reagents listed in Table 1.3, 1.4, and 1.5.  After the synthesis was completed, 110 
different mixture samples of bis-piperazine analogs were obtained (Table 4.3, 4.4, and 
4.5).   
The first 42 samples, Table 4.3, were systematically formatted by R1 functionality.  
For example, sample Lib3.020 contained the 1,092 bis-piperazines incorporating a butyl 
in the R1 position.  The 1,092 comes from the combination of 26 different R2 
functionalities and 42 different R3 functionalities (26 x 42 = 1,092).  Similarly, sample 
Lib3.021 contained the 1,092 bis-piperazines possessing a heptyl in the R1 position.  In 
total, each of the first 42 samples (Lib3.001 to Lib3.042) contained a unique set of 
1,092 analogs organized by their R1 functionality.  In this way, the 45,864 bis-piperazine 
analogs contained in the Lib3 scaffold ranking sample were systematically arranged 
into 42 samples by R1 functionality (42 x 1,092 = 45,864). 
The next set of 26 samples, Table 4.4, were systematically formatted by R2 
functionality.  For example, sample Lib3.043 contained all 1,764 (42 R1 x 42 R3 = 
1,764) bis-piperazines that have S-methyl in the R2 position and sample Lib3.044 
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contained all 1,764 analogs that have S-benzyl fixed in the R2 position.  In this way, the 
entire set of 45,864 bis-piperazines was formatted by R2 functionality into 26 mixtures, 
each containing 1,764 compounds. 
Finally the last set of 42 samples, Table 4.5, were formatted by R3 functionality.  
Each sample contained 1,092 analogs uniquely fixed with a given R3 functionality.  In 
total, the 110 samples (Tables 4.3, 4.4, and 4.5) contained all 45,864 bis-piperazines 
formatted three separate ways. 
Positional Scanning Library Lib3 was screened in the auto-palmitoylation assay 
at 100 µg/ml.  The results for the positional scanning library screen are reported as 
percent inhibition relative to vehicle control (Table 4.3, 4.4, and 4.5).  Several samples 
in each of the sublibraries produced on average >20% inhibition and most of these 
contain the functionalities that were selected for the synthesis of individual compounds 
(bolded functionalities in Tables 4.3, 4.4, and 4.5).   Of note, none of the samples fixed 
with a linear aliphatic functionality in any of the three sublibraries produced significant 
reproducible inhibition.  Aromatic functionalities were clearly favored in the R2 position 
with little specificity for stereochemistry (Table 4.4).   The R1 and R3 mixture samples 
(Tables 4.3 and 4.5 respectively) demonstrated similar inhibition profiles likely due to 
the somewhat symmetrical nature of the Lib3 scaffold.  
Based on the positional scanning Lib3 data (Tables 4.3, 4.4, and 4.5) 48 
individual compounds were selected for synthesis (Compounds 90 to 137 Table 4.6 and 
Figure 4.2).  These 48 compounds were synthesized by combining the R group 
functionalities that produced significant inhibition in the Lib3 screen.  4 different R1 
groups ((1-phenyl-cyclopropyl)-methyl, 2-(4-isobutyl-phenyl)-propyl, 2-(3,5-bis-
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trifluoromethyl-phenyl)-ethyl, and 4-tert-butyl-cyclohexyl-methyl), 4 different R2 groups 
(S-4-hydroxybenzyl, S-phenyl, S-2-naphthylmethyl, and R-2-naphthylmethyl), and 3 
different R3 groups (2-(4-isobutyl-phenyl)-propyl, 2-(3,5-bis-trifluoromethyl-phenyl)-ethyl, 
and adamantan-1-yl-methyl)) were used to make compounds 90 to 137.    
 
Individual Compounds 
Compounds 90 to 137 were synthesized by incorporating 4 different 
functionalities in the R1 and R2 and 3 different functionalities in the R3 positions resulting 
in 48 structural analogs (Table 4.6 and Figure 4.2).  In addition to these 48 compounds 
6 additional analogs that were predicted to produce less inhibition based on the Lib3 
screening data were also included as negative controls (Compounds 138 to 143 Table 
4.6 and Figure 4.2).  All 54 compounds were screened at 100 µM in the auto-
palmitoylation assay and the relative velocity of Erf2 auto-palmitoylation is shown in 
Table 4.6 and graphed in Figure 4.3. 
From the screening of the individual compounds several SAR trends can be 
identified.  For example it is clear that for the 4 different analog series defined by R1 (90 
to 101, 102 to 113, 114 to 125, and 126 to 137 respectively) the set with (1-phenyl-
cyclopropyl)-methyl fixed in the R1 position (90 to 101) produced the least active 
analogs.   Interestingly while the use of 2-(4-isobutyl-phenyl)-propyl in the R1 position 
provided for a number of active analogs (102 to 113) it should be noted that it is critical 
that the correct R2 and R3 functionalities were utilized.  This is evidenced by the lack of 
activity with compounds 138 and 139.  Compounds 138 and 139 contain R2 and R3 
functionalities that did not demonstrated any appreciable activity in the Lib3 data 
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(Tables 4.4 and 4.5 respectively).  Compounds 138 to 143 were tested to help validate 
the SAR predicted from the screening of the positional scanning library Lib3; each of 
these 6 compounds contains at least 2 non-optimal functionalities and were therefore 
predicted to be less active than the other 48 individual compounds.   
The screening data for the individual compounds (Table 4.6, Figure 4.3) also 
confirms that there is no apparent preference for absolute stereochemistry.  Both the R 
and S version of the 2-napthylmethyl functionality were incorporated into the set of 
compounds, providing a set of diastereomers such as 108 to 110 versus 111 to 113 that 
possessed similar activity (ie 108 to 111).  This trend was also seen in the Lib3 
screening data (Table 4.3). 
Finally the individual compound screening data also provided a set of active 
analogs that had the same R1 and R3 functionality such as 102, 108, and 111 with 2-(4-
isobutyl-phenyl)-propyl and 115 and 118 with 2-(3,5-bis-trifluoromethyl-phenyl)-ethyl.  
This trend was also seen in the Lib3 screening data as noted by the similar activity 
profiles for samples fixed with the same functionality in R1 (Table 4.2) as in R3 (Table 
4.4).  This is likely due to the somewhat symmetric geometry of the scaffold. 
The set of individual compounds screened demonstrated that while the core bis-
piperazine scaffold plays a role in the activity of the compounds it is also critical that the 
core scaffold is decorated with the correct R group functionalities.  This was most 
evidenced by the lack of activity of the negative controls, 138 to 143.  Based on the 
accumulated data the top 10 individual compounds (102, 103, 108, 111, 114, 116, 117, 
119, 123, and 132), that were ≥8 standard deviations from vehicle control, were 
selected for additional analysis. 
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Further Characterization 
The 10 individual compounds, 102, 103, 108, 111, 114, 116, 117, 119, 123, and 
132, were further characterized by Dr. Robert Deschenes’ group and the results have 
been submitted and recently accepted for publication in Combinatorial Chemistry & High 
Throughput Screening.11 Some of the results from the published work will be briefly 
summarized.   
Confirm Inhibition of Auto-palmitoylation.  A gel-based reaction12 was 
performed in order to confirm that the individual compounds were inhibiting the auto-
palmitoylation step and not producing a false positive in the HTS assay due to targeting 
hydrolysis of the enzyme.  The results from the gel-based reaction confirmed that all ten 
compounds did in fact inhibit auto-palmitoylation to either an equal or greater extent 
than the positive control 2-BP (~34-72 µM for the ten compounds identified in this study, 
and 79 µM for 2-BP). 
Competitive Inhibition of Erf2 Auto-palmitoylation.  Compounds 102 and 111 
were utilized for inhibition mechanism studies.  Utilizing a Michaelis-Menten approach it 
was determined that both compound 102 and 111 act predominantly through a 
competitive inhibition mechanism, while 2-BP has been demonstrated to act as an 
uncompetitve or mixed inhibitor of Erf2 auto-palmitoylation.8  Therefore the compounds 
in this study represent a new class of palmitoylation inhibitors that utilize a different 
mode of action from the most commonly used palmitoylation inhibitor, 2-BP. 
Inhibition of Ras-Dependent Growth in a Palmitoylation-Sensitive S. 
cerevisiae Strain.  The 10 individual compounds, 102, 103, 108, 111, 114, 116, 117, 
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119, 123, and 132, were all screened to see how well they inhibited the growth of a 
strain of S. cerevisiae that is dependent upon Ras2 palmitoylation for viability, 
RJY1942.13 The growth rates of the sensitive strain, RJY1942, were also compared 
against the growth rates of a wild type strain treated with the same respective 
compounds.  Compounds 102, 103, 114, 116, 117, and 123 all had EC50 values of 
between 3-5 µM against the sensitive strain while compounds 111, 132 and 2-BP all 
had EC50 values between 20-40 µM.  Additionally compounds 102, 103, 108, 111, 114, 
116, 117, 119, 123, and 132 all demonstrated selectivity to inhibit the sensitive yeast 
strain over the wild type strain. 
 
Conclusion and Future Studies 
After testing 50 different scaffold ranking samples, the piperazine moiety was 
identified as an important component in scaffolds that inhibited auto-palmitoylation 
(Table 4.1).  From the set of piperazine containing scaffold ranking samples positional 
scanning library Lib3 was selected for screening (Table 4.1).  From the screening of 
Lib3 in the HTS auto-palmitoylation assay (Tables 4.2 to 4.4) a SAR profile was 
developed that was utilized to identify the individual compounds that were most likely to 
be active in the auto-palmitoylation assay.  Based on this analysis a set of 48 individual 
bis-piperazines (from the 45,864 total compounds in Lib3) were selected for synthesis 
and subsequent screening.  In addition to the 48 predicted active individual compounds 
a subset of 6 structural analogs predicted to be less active were also screened in the 
HTS assay.  The screening of the individual compounds confirmed the SAR profile 
generated from the positional scanning library screening. 10 of the individual 
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compounds were studied in further detail.  These additional studies demonstrated that 
the compounds are inhibiting the auto-palmitoylation step and likely doing it through a 
competitive mechanism rather than an uncompetitve or mixed mechanism like 2-BP has 
been shown to do.  Finally 6 of the compounds, 102, 103, 114, 116, 117, and 123, 
inhibited the growth of a S. cerevisiae strain that is dependent upon Ras2 palmitoylation 
for viability at 10% of the concentration required for 2-BP.   These compounds were also 
shown to selectively inhibit the growth of a Ras2 sensitive strain over a wild type strain 
further demonstrating their utility as Ras2 auto-palymitoylation inhibitor tool compounds.  
While it is not reasonable to think that any of the top 10 compounds identified in 
this study in their current form will become therapeutic agents, it is reasonable to 
assume they will serve as useful tool compounds and as potential starting points for 
future medicinal chemistry studies.  Additionally this study demonstrates the usefulness 
of utilizing systematically formatted mixtures in order to rapidly and judiciously identify 
hit compounds and build SAR profiles.  In this study a total of only 214 samples (50 
scaffold ranking samples, 110 positional scanning samples, 54 individual compounds) 
were utilized to survey 50 different scaffolds comprised of over 5 million individual 
compounds, demonstrating that through the use of a limited number of samples a 
significant amount of novel SAR data can be generated.   
 
Experimental  
 The following information regarding the synthesis, purification, and 
characterization of individual compounds as well as relevant assay information is also 
reported in the manuscript that was recently published in Combinatorial Chemistry & 
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High Throughput Screening.11 The information provided below is reproduced with little 
modification from what appears in the submitted manuscript. 
  
Synthesis and Characterization of Bis-piperazines 
Lib3 as well as the individual compounds (90-143) were synthesized following 
the same synthetic scheme (Figure 4.4).14,15  Utilizing the “tea-bag” methodology16 100 
mg of p-methylbenzhydrylamine (MBHA) resin (1.1mmol/g, 100-200 mesh) was sealed 
in a mesh “tea-bag,” neutralized with 5% diisopropylethylamine (DIEA) in 
dichloromethane (DCM), and subsequently swelled with additional DCM washes.  
Fmoc-L-Lys(Boc)-OH was coupled in dimethylformamide (0.1M DMF) for 120 minutes in 
the presence of diisopropylcarbodiimide (DIC, 6 equiv.) and 1-hydroxybenzotriazole 
hydrate (HOBt, 6 equiv.) (4.2, Figure 4.4).  The coupling solution was removed and the 
tea-bag was washed with three rounds of DMF (1 min each wash).  The Fmoc 
protecting group was removed with 20% piperidine in DMF for 20 minutes, followed by 
two rounds of DMF washes (1 min each). The R1 carboxylic acids was coupled (10 
equiv) in the presence of DIC (10 equiv) and HOBt (10 equiv) in DMF (0.1M) for 120 
minutes (4.3, Figure 4.4).  The coupling solution was removed and the tea-bag was 
washed with three rounds of DMF (1 min each wash). Following acylation the Boc group 
is removed using 55%TFA in DCM (30 minutes).  The free amine is then neutralized 
with 5% DIEA/DCM and the R2 amino acid is coupled using a 6 fold excess of the Boc 
protected acid, DIC, and HOBT in 0.1M DMF (120 minutes).   The coupling solution was 
removed and the tea-bag was washed with three rounds of DMF (1 min each wash). 
The Boc group was removed with 55% TFA/DCM for 30 minutes and subsequently 
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neutralized with 5% DIEA/DCM (3 times 2 min each wash).   Carboxylic acids (R3) were 
coupled using (10 equiv) in the presence of DIC (10 equiv) and HOBt (10 equiv) in DMF 
(0.1 M) for 120 minutes (4.5, Figure 4.4). The coupling solution was removed and the 
tea-bag was washed with three rounds of DMF (1 min each wash), two rounds of DCM 
(1 min each), and then allowed to dry.  All coupling reactions were monitored for 
completion by Ninhydrin test.  The reduction was performed in a 4000 mL Wilmad 
LabGlass vessel under nitrogen.  1.0M Tetrahydrofuran (THF) borane complex solution 
was used in 40 fold excess for each amide bond.  The vessel was heated to 65 °C and 
maintained at this temperature for 96 hours.  The solution was then removed and the 
bags were washed with THF and methanol (MeOH).  Once completely dry, the bags 
were treated overnight with piperidine at 65 °C and washed several times with DMF, 
DCM, and methanol (4.6, Figure 4.4).  As previously reported the reduction of 
polyamides with borane is free of racemization.17-18  Before proceeding, completion of 
reduction was monitored by LCMS analysis of a control compound (4.6, Figure 4.4) that 
was cleaved from the solid support (HF, anisole, 0 °C 7 hr).  Cyclization was performed 
with a 5 fold excess (for each cyclization) of oxalyldiimidazole in a 0.1 M anhydrous 
DMF solution overnight.  Following the cyclization, the bags were rinsed with DMF and 
DCM (3 times 1 min each) , the resulting diketopiperarzines were reduced down to their 
corresponding piperazines (4.7, Figure 4.4) using the same borane reduction procedure 
as above.  The final bis-piperazine was cleaved from the resin with HF in the presence 
of anisole in an ice bath at 0 °C for 7 hours (4.7, Figure 4.4).  After removal of the HF by 
gaseous N2 the products are then extracted from the vessels with 95% acetic acid in 
water, transferred to scintillation vials, frozen and lyophilized.  The compounds are then 
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reconstituted in 50% acetonitrile and water, frozen and lyophilized three more times.  
For the initial HTS screening (Table 4.6 and graphed in Figure 4.3) the individual 
compounds are tested as crude material in case the activity is driven by some side 
reaction that was also present in the original positional scanning library.  After this initial 
screening compounds, 102, 103, 108, 111, 114, 116, 117, 119, 123, and 132, were 
selected for purification and NMR characterization; the purified samples were retested 
in the original HTS assay to confirm activity and then utilized in all subsequent 
experiments.   
 LCMS Analysis. The purity and identity of all individual compounds (crude and 
pure) was verified using a Shimadzu 2010 LCMS system, consisting of a LC-20AD 
binary solvent pumps, a DGU-20A degasser unit, a CTO-20A column oven, and a SIL-
20A HT auto sampler. A Shimadzu SPD-M20A diode array detector was used for 
detections. A full spectra range of 190-600nm was obtained during analysis. 
Chromatographic separations were obtained using a Phenomenex Luna C18 analytical 
column (5µm, 50 x 4.6mm i.d.). The column was protected by a Phenomenex C18 
column guard (5µm, 4 x 3.0mm i.d.). All equipment was controlled and integrated by 
Shimadzu LCMS solutions software version 3.  Mobile phases for LCMS analysis were 
HPLC grade or LCMS grade obtained from Sigma Aldrich and Fisher Scientific. The 
mobile phases consisted of a mixture LCMS grade acetonitrile/water (both with 0.1% 
formic acid adjusted for a pH of 2.7).  The initial setting for analysis was set at 5% 
acetonitrile (v/v), then was linearly increased to 95% acetonitrile over 6 minutes. The 
gradient was then held at 95% acetonitrile for 2 minutes and then linearly decreased to 
5% over 0.10 minutes and held until stop for an additional 1.90 minutes. The total run 
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time was equal to 12 minutes. The total flow rate was set to 0.5 mL/minute. The column 
oven and flow cell temperature for the diode array detector was set at 30 °C. The auto 
sampler temperature was held at 15 °C. 5 µL was injected for analysis.   
 HPLC Purification. All purification was performed on a Shimadzu Prominence 
preparative HPLC system, consisting of LC-8A binary solvent pumps, a SCL-10A 
system controller, a SIL-10AP auto sampler, and a FRC-10A fraction collector. A 
Shimadzu SPD-20A UV detector was used for detection. The wavelength was set at 
214 nm during analysis. Chromatographic separations were obtained using a 
Phenomenex Luna C18 preparative column (5 µm, 150 x 21.5 mm i.d.). The column 
was protected by a Phenomenex C18 column guard (5 µm, 15 x 21.2 mm i.d.). 
Prominence prep software was used to set all detection and collection parameters. The 
mobile phases for HPLC purification were HPLC grade obtained from Sigma Aldrich and 
Fisher Scientific. The mobile phase consisted of a mixture of acetonitrile/water (both 
with 0.1% formic acid). The initial setting for separation was set at 2% acetonitrile, which 
was held for 2 minutes, then the gradient was linearly increased to 20% acetonitrile over 
4 minutes. The gradient was then linearly increased to 55% acetonitrile over 36 
minutes. The HPLC system was set to automatically flush and re-equilibrate the column 
after each run for a total of 4 column volumes. The total flow rate was set to 12 mL/min 
and the total injection volume was set to 3900 µL. The fraction collector was set to 
collect from 6 to 40 minutes. The corresponding fraction were then combined and 
lyophilized. 
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  NMR Analysis of Purified Compounds. The 1H spectra were obtained utilizing 
the Bruker 400 Ascend (400 MHz).  NMR chemical shifts were reported in δ (ppm) using 
the δ 7.26 signal of CDCl3 (1H NMR). 
4-(((2S)-1-(2-(4-isobutylphenyl)propyl)-4-(4-((S)-1-((1-
phenylcyclopropyl)methyl)piperazin-2-yl)butyl)piperazin-2-yl)methyl)phenol (Compound 
90). Using the synthetic approach described in Figure 4.4 for the synthesis of compound 
90 was accomplished using the following reagents: 1-phenyl-1-cyclopropanecarboxylic 
acid (R1), Boc-L-Tyr(BrZ) (R2), 4-isobutyl-alpha-methylphenylacetic acid (R3).  LCMS 
(ESI+) m/z calcd for C45H60N4O [M + H]+: 637.48, found 637.15 (RT= 4.209 min) 84.3% 
purity (UV 214 nM). 
4-(((S)-1-(3,5-bis(trifluoromethyl)phenethyl)-4-(4-((S)-1-((1-
phenylcyclopropyl)methyl)piperazin-2-yl)butyl)piperazin-2-yl)methyl)phenol (Compound 
91). Using the synthetic approach described in Figure 4.4 the synthesis of compound 91 
was accomplished using the following reagents: 1-phenyl-1-cyclopropanecarboxylic acid 
(R1), Boc-L-Tyr(BrZ) (R2), 3,5-bis(trifluoromethyl)-phenylacetic acid (R3).  LCMS (ESI+) 
m/z calcd for C39H48F6N4O [M + H]+: 703.37, found 703.05 (RT= 4.048 min) 84.4% 
purity (UV 214 nM). 
4-(((S)-1-(adamantan-1-ylmethyl)-4-(4-((S)-1-((1-
phenylcyclopropyl)methyl)piperazin-2-yl)butyl)piperazin-2-yl)methyl)phenol (Compound 
92). Using the synthetic approach described in Figure 4.4 the synthesis of compound 92 
was accomplished using the following reagents: 1-phenyl-1-cyclopropanecarboxylic acid 
(R1), Boc-L-Tyr(BrZ) (R2), 1-adamantanecarboxylic acid (R3).  LCMS (ESI+) m/z calcd 
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for C40H58N4O [M + H]+: 611.46, found 611.15 (RT= 4.061 min) 83.9% purity (UV 214 
nM). 
(2S)-1-(2-(4-isobutylphenyl)propyl)-2-phenyl-4-(4-((S)-1-((1-
phenylcyclopropyl)methyl)piperazin-2-yl)butyl)piperazine (Compound 93). Using the 
synthetic approach described in Figure 4.4 the synthesis of compound 93 was 
accomplished using the following reagents: 1-phenyl-1-cyclopropanecarboxylic acid 
(R1), Boc-L-phenylglycine (R2), 4-isobutyl-alpha-methylphenylacetic acid (R3).  LCMS 
(ESI+) m/z calcd for C41H58N4 [M + H]+:  607.47, found 607.25 (RT= 4.458 min) 80.1% 
purity (UV 214 nM). 
(S)-1-(3,5-bis(trifluoromethyl)phenethyl)-2-phenyl-4-(4-((S)-1-((1-
phenylcyclopropyl)methyl)piperazin-2-yl)butyl)piperazine (Compound 94). Using the 
synthetic approach described in Figure 4.4 the synthesis of compound 94 was 
accomplished using the following reagents: 1-phenyl-1-cyclopropanecarboxylic acid 
(R1), Boc-L-phenylglycine (R2), 3,5-bis(trifluoromethyl)-phenylacetic acid (R3).  LCMS 
(ESI+) m/z calcd for C38H48F6N4 [M + H]+:  673.36, found 673.15 (RT= 4.286 min) 
75.5% purity (UV 214 nM). 
(S)-1-(adamantan-1-ylmethyl)-2-phenyl-4-(4-((S)-1-((1-
phenylcyclopropyl)methyl)piperazin-2-yl)butyl)piperazine (Compound 95). Using the 
synthetic approach described in Figure 4.4 the synthesis of compound 95 was 
accomplished using the following reagents: 1-phenyl-1-cyclopropanecarboxylic acid 
(R1), Boc-L-phenylglycine (R2), 1-adamantanecarboxylic acid (R3).  LCMS (ESI+) m/z 
calcd for C39H56N4 [M + H]+:  581.45, found 581.15 (RT= 4.256 min) 79.1% purity (UV 
214 nM). 
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(2S)-1-(2-(4-isobutylphenyl)propyl)-2-(naphthalen-2-ylmethyl)-4-(4-((S)-1-((1-
phenylcyclopropyl)methyl)piperazin-2-yl)butyl)piperazine (Compound 96). Using the 
synthetic approach described in Figure 4.4 the synthesis of compound 96 was 
accomplished using the following reagents: 1-phenyl-1-cyclopropanecarboxylic acid 
(R1), Boc-3-(2-naphthyl)-L-alanine (R2), 4-isobutyl-alpha-methylphenylacetic acid (R3).  
LCMS (ESI+) m/z calcd for C46H62N4 [M + H]+:  671.50, found 671.30 (RT= 4.611 min) 
85.9% purity (UV 214 nM). 
(S)-1-(3,5-bis(trifluoromethyl)phenethyl)-2-(naphthalen-2-ylmethyl)-4-(4-((S)-1-
((1-phenylcyclopropyl)methyl)piperazin-2-yl)butyl)piperazine (Compound 97). Using the 
synthetic approach described in Figure 4.4 the synthesis of compound 97 was 
accomplished using the following reagents: 1-phenyl-1-cyclopropanecarboxylic acid 
(R1), Boc-3-(2-naphthyl)-L-alanine (R2), 3,5-bis(trifluoromethyl)-phenylacetic acid (R3).  
LCMS (ESI+) m/z calcd for C43H50F6N4 [M + H]+: 737.39, found 737.25 (RT= 4.454 min) 
76.2% purity (UV 214 nM). 
(S)-1-(adamantan-1-ylmethyl)-2-(naphthalen-2-ylmethyl)-4-(4-((S)-1-((1-
phenylcyclopropyl)methyl)piperazin-2-yl)butyl)piperazine (Compound 98). Using the 
synthetic approach described in Figure 4.4 the synthesis of compound 98 was 
accomplished using the following reagents: 1-phenyl-1-cyclopropanecarboxylic acid 
(R1), Boc-3-(2-naphthyl)-L-alanine (R2), 1-adamantanecarboxylic acid (R3).  LCMS 
(ESI+) m/z calcd for C44H60N4 [M + H]+: 645.48, found 645.15 (RT= 4.547 min) 71.1% 
purity (UV 214 nM). 
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(2R)-1-(2-(4-isobutylphenyl)propyl)-2-(naphthalen-2-ylmethyl)-4-(4-((S)-1-((1-
phenylcyclopropyl)methyl)piperazin-2-yl)butyl)piperazine (Compound 99). Using the 
synthetic approach described in Figure 4.4 the synthesis of compound 99 was 
accomplished using the following reagents: 1-phenyl-1-cyclopropanecarboxylic acid 
(R1), Boc-3-(2-naphthyl)-D-alanine (R2), 4-isobutyl-alpha-methylphenylacetic acid (R3).  
LCMS (ESI+) m/z calcd for C46H62N4 [M + H]+: 671.50, found 671.30 (RT= 4.623 min) 
79.8% purity (UV 214 nM). 
(R)-1-(3,5-bis(trifluoromethyl)phenethyl)-2-(naphthalen-2-ylmethyl)-4-(4-((S)-1-
((1-phenylcyclopropyl)methyl)piperazin-2-yl)butyl)piperazine (Compound 100). Using 
the synthetic approach described in Figure 4.4 the synthesis of compound 100 was 
accomplished using the following reagents: 1-phenyl-1-cyclopropanecarboxylic acid 
(R1), Boc-3-(2-naphthyl)-D-alanine (R2), 3,5-bis(trifluoromethyl)-phenylacetic acid (R3).  
LCMS (ESI+) m/z calcd for C43H50F6N4 [M + H]+: 737.39, found 737.25 (RT= 4.455 min) 
78.2% purity (UV 214 nM). 
(R)-1-(adamantan-1-ylmethyl)-2-(naphthalen-2-ylmethyl)-4-(4-((S)-1-((1-
phenylcyclopropyl)methyl)piperazin-2-yl)butyl)piperazine (Compound 101). Using the 
synthetic approach described in Figure 4.4 the synthesis of compound 101 was 
accomplished using the following reagents: 1-phenyl-1-cyclopropanecarboxylic acid 
(R1), Boc-3-(2-naphthyl)-D-alanine (R2), 1-adamantanecarboxylic acid (R3).  LCMS 
(ESI+) m/z calcd for C44H60N4 [M + H]+: 645.48, found 645.25 (RT= 4.521 min) 77.0% 
purity (UV 214 nM). 
4-(((2S)-1-(2-(4-isobutylphenyl)propyl)-4-(4-((2S)-1-(2-(4-
isobutylphenyl)propyl)piperazin-2-yl)butyl)piperazin-2-yl)methyl)phenol (Compound 
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102). Using the synthetic approach described in Figure 4.4 the synthesis of compound 
102 was accomplished using the following reagents: 4-isobutyl-alpha-
methylphenylacetic acid (R1), Boc-L-Tyr(BrZ) (R2), 4-isobutyl-alpha-methylphenylacetic 
acid (R3).  LCMS (ESI+) m/z calcd for C45H68N4O [M + H]+: 681.54, found 681.50 (RT= 
4.494 min) 80.1% purity (UV 214 nM).  Final crude product was purified by HPLC as 
described above. 1H NMR (400 MHz, CDCl3): δ 7.08 - 7.16 (m, 4 H) 7.05 (br s, 4 H) 
6.92 (br s, 2 H) 6.80 (br s, 2 H) 2.98 (br s, 8 H) 2.64 - 2.84 (m, 5 H) 2.58 (br s, 4 H) 2.45 
(t, 6 H) 2.32 (d, 2 H) 2.01 (br s, 1 H) 1.86 (br s, 2 H) 1.52 (br s, 2 H) 1.42 (br s, 2 H) 1.36 
(br s, 2 H) 1.30 (br s, 4 H) 1.12 - 1.26 (m, 4 H) 1.01 (br s, 1 H) 0.91 (br s, 12 H). Pure 
LCMS (ESI+) m/z calcd for C45H68N4O [M + H]+:  681.54, found 681.25 (RT= 4.558 min) 
100% purity (UV 214 nM).  
4-(((2S)-1-(3,5-bis(trifluoromethyl)phenethyl)-4-(4-((2S)-1-(2-(4-
isobutylphenyl)propyl)piperazin-2-yl)butyl)piperazin-2-yl)methyl)phenol (Compound 
103). Using the synthetic approach described in Figure 4.4 the synthesis of compound 
103 was accomplished using the following reagents: 4-isobutyl-alpha-
methylphenylacetic acid (R1), Boc-L-Tyr(BrZ) (R2), 3,5-bis(trifluoromethyl)-phenylacetic 
acid (R3). LCMS (ESI+) m/z calcd for C42H56F6N4O: 747.44, found 747.35 (RT= 4.380 
min) 79.3% purity (UV 214 nM). Final crude product was purified by HPLC as described 
above. 1H NMR (400 MHz, CDCl3): δ ppm 7.75 (br s, 1 H) 7.65 (br s, 2 H) 7.00 - 7.08 
(m, 4 H) 6.95 (br s, 2 H) 6.81 (br s, 2 H) 3.07 (br s, 5 H) 2.93 (br s, 8 H) 2.76 (br s, 4 H) 
2.65 (br s, 4 H) 2.43 (d, 4 H) 2.36 (br s, 2 H) 2.19 (br s, 1 H) 2.01 (br s, 1 H) 1.84 (br s, 1 
H) 1.47 (br s, 2 H) 1.39 (br s, 1 H) 1.27 (br s, 1 H) 1.22 (br s, 3 H) 1.05 (br s, 1 H) 0.90 
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(d, 6 H). Pure LCMS (ESI+) m/z calcd for C42H56F6N4O [M + H]+: 747.44, found 747.20 
(RT= 4.374 min) 100% purity (UV 214 nM). 
4-(((2S)-1-(adamantan-1-ylmethyl)-4-(4-((2S)-1-(2-(4-
isobutylphenyl)propyl)piperazin-2-yl)butyl)piperazin-2-yl)methyl)phenol (Compound 
104). Using the synthetic approach described in Figure 4.4 the synthesis of compound 
104 was accomplished using the following reagents: 4-isobutyl-alpha-
methylphenylacetic acid (R1), Boc-L-Tyr(BrZ) (R2), 1-adamantanecarboxylic acid (R3).  
LCMS (ESI+) m/z calcd for C43H66N4O [M + H]+: 655.52, found 655.30 (RT= 4.483 min) 
91.2% purity (UV 214 nM). 
(2S)-1-(2-(4-isobutylphenyl)propyl)-4-(4-((2S)-1-(2-(4-
isobutylphenyl)propyl)piperazin-2-yl)butyl)-2-phenylpiperazine (Compound 105). Using 
the synthetic approach described in Figure 4.4 the synthesis of compound 105 was 
accomplished using the following reagents: 4-isobutyl-alpha-methylphenylacetic acid 
(R1), Boc-L-phenylglycine (R2), 4-isobutyl-alpha-methylphenylacetic acid (R3).  LCMS 
(ESI+) m/z calcd for C44H66N4 [M + H]+: 651.53, found 651.35 (RT= 4.845 min) 86.2% 
purity (UV 214 nM). 
(2S)-1-(3,5-bis(trifluoromethyl)phenethyl)-4-(4-((2S)-1-(2-(4-
isobutylphenyl)propyl)piperazin-2-yl)butyl)-2-phenylpiperazine (Compound 106). Using 
the synthetic approach described in Figure 4.4 the synthesis of compound 106 was 
accomplished using the following reagents: 4-isobutyl-alpha-methylphenylacetic acid 
(R1), Boc-L-phenylglycine (R2), 3,5-bis(trifluoromethyl)-phenylacetic acid (R3).  LCMS 
(ESI+) m/z calcd for C38H48F6N4 [M + H]+: 717.43, found 717.15 (RT= 4.664 min) 83.1% 
purity (UV 214 nM). 
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(2S)-1-(adamantan-1-ylmethyl)-4-(4-((2S)-1-(2-(4-
isobutylphenyl)propyl)piperazin-2-yl)butyl)-2-phenylpiperazine (Compound 107). Using 
the synthetic approach described in Figure 4.4 the synthesis of compound 107 was 
accomplished using the following reagents: 4-isobutyl-alpha-methylphenylacetic acid 
(R1), Boc-L-phenylglycine (R2), 1-adamantanecarboxylic acid (R3).  LCMS (ESI+) m/z 
calcd for C39H56N4 [M + H]+: 625.51 found 620.20 (RT= 4.712 min) 81.0% purity (UV 
214 nM). 
(2S)-1-(2-(4-isobutylphenyl)propyl)-4-(4-((2S)-1-(2-(4-
isobutylphenyl)propyl)piperazin-2-yl)butyl)-2-(naphthalen-2-ylmethyl)piperazine 
(Compound 108). Using the synthetic approach described in Figure 4.4 the synthesis of 
compound 108 was accomplished using the following reagents: 4-isobutyl-alpha-
methylphenylacetic acid (R1), Boc-3-(2-naphthyl)-L-alanine (R2), 4-isobutyl-alpha-
methylphenylacetic acid (R3). LCMS (ESI+) m/z calcd for C49H70N4 [M + H]+: 715.56, 
found 715.30 (RT= 4.925 min) 80.8% purity (UV 214 nM).  Final crude product was 
purified by HPLC as described above. 1H NMR (400 MHz, CDCl3): δ ppm 7.78 (br s, 3 
H) 7.61 (br s, 1 H) 7.44 (br s, 2 H) 7.29 (br s, 1 H) 6.99 - 7.20 (m, 8 H) 4.16 (br s, 1 H) 
3.09 - 3.34 (m, 1 H) 3.00 (d, 4 H) 2.91 (br s, 2 H) 2.84 (br s, 2 H) 2.78 (br s, 3 H) 2.58 
(d, 2 H) 2.45 (dd, 7 H) 2.28 (br s, 4 H) 2.20 (br s, 2 H) 1.97 (br s, 1 H) 1.86 (dd, 2 H) 
1.60 (br s, 1 H) 1.18 - 1.46 (m, 9 H) 1.15 (br s, 2 H) 0.70 - 0.95 (m, 12 H). Pure LCMS 
(ESI+) m/z calcd for C49H70N4 [M + H]+: 715.56, found 715.30 (RT= 4.966 min) 100% 
purity (UV 214 nM).   
(2S)-1-(3,5-bis(trifluoromethyl)phenethyl)-4-(4-((2S)-1-(2-(4-
isobutylphenyl)propyl)piperazin-2-yl)butyl)-2-(naphthalen-2-ylmethyl)piperazine 
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(Compound 109). Using the synthetic approach described in Figure 4.4 the synthesis of 
compound 109 was accomplished using the following reagents: 4-isobutyl-alpha-
methylphenylacetic acid (R1), Boc-3-(2-naphthyl)-L-alanine (R2), 3,5-bis(trifluoromethyl)-
phenylacetic acid (R3).  LCMS (ESI+) m/z calcd for C46H58F6N4 [M + H]+: 781.46, found 
781.10 (RT= 4.816 min) 92.2% purity (UV 214 nM). 
(2S)-1-(adamantan-1-ylmethyl)-4-(4-((2S)-1-(2-(4-
isobutylphenyl)propyl)piperazin-2-yl)butyl)-2-(naphthalen-2-ylmethyl)piperazine 
(Compound 110). Using the synthetic approach described in Figure 4.4 the synthesis of 
compound 110 was accomplished using the following reagents: 4-isobutyl-alpha-
methylphenylacetic acid (R1), Boc-3-(2-naphthyl)-L-alanine (R2), 1-
adamantanecarboxylic acid (R3).  LCMS (ESI+) m/z calcd for C47H68N4 [M + H]+: 689.54 
found 689.40 (RT= 4.948 min) 82.6% purity (UV 214 nM). 
 (2R)-1-(2-(4-isobutylphenyl)propyl)-4-(4-((2S)-1-(2-(4-
isobutylphenyl)propyl)piperazin-2-yl)butyl)-2-(naphthalen-2-ylmethyl)piperazine 
(Compound 111). Using the synthetic approach described in Figure 4.4 the synthesis of 
compound 111 was accomplished using the following reagents: 4-isobutyl-alpha-
methylphenylacetic acid (R1), Boc-3-(2-naphthyl)-D-alanine (R2), 4-isobutyl-alpha-
methylphenylacetic acid (R3).  LCMS (ESI+) m/z calcd for C49H70N4 [M + H]+: 715.56, 
found 715.20 (RT= 4.921 min) 83.4% purity (UV 214 nM).  Final crude product was 
purified by HPLC as described above. 1H NMR (400 MHz, CDCl3): δ ppm 7.71 - 7.85 
(m, 3 H) 7.60 (br s, 1 H) 7.44 (br s, 2 H) 7.28 - 7.35 (m, 1 H) 7.01 - 7.26 (m, 8 H) 3.19 
(d, 1 H) 2.94 - 3.07 (m, 3 H) 2.89 (d, 3 H) 2.82 (br s, 3 H) 2.60 - 2.74 (m, 2 H) 2.55 (br s, 
1 H) 2.24 - 2.50 (m, 10 H) 2.19 (br s, 2 H) 1.97 (br s, 2 H) 1.74 - 1.92 (m, 2 H) 1.34 (d, 8 
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H) 1.22 (br s, 4 H) 1.13 (br s, 2 H) 0.91 (br s, 12 H). Pure LCMS (ESI+) m/z calcd for 
C49H70N4 [M + H]+: 715.56, found 715.20 (RT= 4.942 min) 100% purity (UV 214 nM)  
(2R)-1-(3,5-bis(trifluoromethyl)phenethyl)-4-(4-((2S)-1-(2-(4-
isobutylphenyl)propyl)piperazin-2-yl)butyl)-2-(naphthalen-2-ylmethyl)piperazine 
(Compound 112). Using the synthetic approach described in Figure 4.4 the synthesis of 
compound 112 was accomplished using the following reagents: 4-isobutyl-alpha-
methylphenylacetic acid (R1), Boc-3-(2-naphthyl)-D-alanine (R2), 3,5-bis(trifluoromethyl)-
phenylacetic acid (R3).  LCMS (ESI+) m/z calcd for C46H58F6N4: [M + H]+: 781.46, found 
781.15 (RT= 4.813min) 92.1% purity (UV 214nM). 
(2R)-1-(adamantan-1-ylmethyl)-4-(4-((2S)-1-(2-(4-
isobutylphenyl)propyl)piperazin-2-yl)butyl)-2-(naphthalen-2-ylmethyl)piperazine 
(Compound 113). Using the synthetic approach described in Figure 4.4 the synthesis of 
compound 113 was accomplished using the following reagents: 4-isobutyl-alpha-
methylphenylacetic acid (R1), Boc-3-(2-naphthyl)-D-alanine (R2), 1-
adamantanecarboxylic acid (R3).  LCMS (ESI+) m/z calcd for C47H68N4 [M + H]+: 689.54 
found 689.40 (RT= 4.925 min) 85.8% purity (UV 214 nM). 
4-(((2S)-4-(4-((S)-1-(3,5-bis(trifluoromethyl)phenethyl)piperazin-2-yl)butyl)-1-(2-
(4-isobutylphenyl)propyl)piperazin-2-yl)methyl)phenol (Compound 114). Using the 
synthetic approach described in Figure 4.4 the synthesis of compound 114 was 
accomplished using the following reagents: 3,5-bis(trifluoromethyl)-phenylacetic acid 
(R1), Boc-L-Tyr(BrZ) (R2), 4-isobutyl-alpha-methylphenylacetic acid (R3). LCMS (ESI+) 
m/z calcd for C42H56F6N4O [M + H]+:  747.44, found 747.35 (RT= 4.453min) 86.4% 
purity (UV 214nM). Final crude product was purified by HPLC as described above. 1H 
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NMR (400 MHz, CDCl3): δ ppm 7.74 (br s, 2 H) 7.62 (br s, 1 H) 7.29 (s, 2 H) 7.07 - 7.26 
(m, 4 H) 6.82 (d, 2 H) 3.19 (br s, 2 H) 3.10 (br s, 2 H) 3.00 (br s, 5 H) 2.84 (br s, 5 H) 
2.70 (br s, 4 H) 2.62 (br s, 3 H) 2.46 (d, 3 H) 2.19 (br s, 2 H) 2.02 (br s, 2 H) 1.86 (br s, 1 
H) 1.56 (br s, 2 H) 1.43 (br s, 2H) 1.30 (br s, 3 H) 1.17 (d, 1 H) 1.10 (br s, 2 H) 0.91 (d, 6 
H). Pure LCMS (ESI+) m/z calcd for C42H56F6N4O [M + H]+: 747.44, found 747.10 (RT= 
4.468 min) 100% purity (UV 214 nM). 
4-(((S)-1-(3,5-bis(trifluoromethyl)phenethyl)-4-(4-((S)-1-(3,5-
bis(trifluoromethyl)phenethyl)piperazin-2-yl)butyl)piperazin-2-yl)methyl)phenol 
(Compound 115). Using the synthetic approach described in Figure 4.4 the synthesis of 
compound 115 was accomplished using the following reagents: 3,5-bis-(trifluoromethyl)-
phenylacetic acid (R1), Boc-L-Tyr(BrZ) (R2), 3,5-bis(trifluoromethyl)-phenylacetic acid 
(R3). LCMS (ESI+) m/z calcd for C39H44F12N4O [M + H]+: 813.33, found 813.00 (RT= 
4.378 min) 88.1% purity (UV 214 nM). 
4-(((S)-1-(adamantan-1-ylmethyl)-4-(4-((S)-1-(3,5-
bis(trifluoromethyl)phenethyl)piperazin-2-yl)butyl)piperazin-2-yl)methyl)phenol - 
(Compound 116)  Using the synthetic approach described in Figure 4.4 the synthesis of 
compound 116 was accomplished using the following reagents: 3,5-bis-(trifluoromethyl)-
phenylacetic acid (R1), Boc-L-Tyr(BrZ) (R2), 1-adamantanecarboxylic acid (R3).  LCMS 
(ESI+) m/z calcd for C40H54F6N4O [M + H]+: 721.42, found 721.15 (RT= 4.341 min) 
85.6% purity (UV 214 nM). Final crude product was purified by HPLC as described 
above. 1H NMR (400 MHz, CDCl3): δ ppm 7.83 (br s, 1 H) 7.73 (br s, 1 H) 7.63 (br s, 1 
H) 7.00 (br s, 2 H) 6.83 (d, 2 H) 3.17 (br s, 1 H) 2.91 - 3.13 (m, 5 H) 2.84 (br s, 5 H) 2.54 
- 2.77 (m, 7 H) 2.40 (br s, 2 H) 2.10 (br s, 1 H) 1.99 (d, 4 H) 1.69 - 1.85 (m, 5 H) 1.64 (d, 
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4 H) 1.50 (br s, 8 H) 1.28 (br s, 2 H) 1.13 (br s, 2 H). Pure LCMS (ESI+) m/z calcd for 
C40H54F6N4O [M + H]+: 721.42, found 721.15 (RT= 4.383 min) 100% purity (UV 214 
nM). 
(2S)-4-(4-((S)-1-(3,5-bis(trifluoromethyl)phenethyl)piperazin-2-yl)butyl)-1-(2-(4-
isobutylphenyl)propyl)-2-phenylpiperazine (Compound 117). Using the synthetic 
approach described in Figure 4.4 the synthesis of compound 117 was accomplished 
using the following reagents: 3,5-bis(trifluoromethyl)-phenylacetic acid (R1), Boc-L-
phenylglycine (R2), 4-isobutyl-alpha-methylphenylacetic acid (R3).  Final crude product 
was purified by HPLC as described above. LCMS (ESI+) Calcd for C41H54F6N4 [M + H]+: 
717.43, found 717.30 (RT= 4.689 min) 80.5% purity (UV 214 nM). 1H NMR (400 MHz, 
CDCl3): δ ppm 7.74 (br s, 1 H) 7.65 (br s, 2 H) 7.28 - 7.40 (m, 2 H) 7.12 - 7.26 (m, 2 H) 
6.85 - 7.07 (m, 5 H) 3.43 - 3.66 (m, 1 H) 3.36 (br. s., 1 H) 3.30 (d, 1 H) 3.22 (d, 1 H) 
3.15 (br s, 1 H) 3.02 (br s, 2 H) 2.83 - 2.96 (m, 6 H) 2.78 (d, 1 H) 2.53 - 2.72 (m, 2 H) 
2.36 - 2.52 (m, 4 H) 2.26 - 2.36 (m, 2 H) 2.21 (br s, 1 H) 1.98 - 2.16 (m, 2 H) 1.76 - 1.96 
(m, 2 H) 1.48 (br s, 3 H) 1.36 (br s, 1 H) 1.27 (br s, 1 H) 1.20 (d, 2 H) 1.08 (d, 2 H) 0.88 
(d, 6 H). LCMS (ESI+) m/z calcd for C41H54F6N4 [M + H]+: 717.43, found 717.15 (RT= 
4.695 min) 100% purity (UV 214 nM). 
 (S)-1-(3,5-bis(trifluoromethyl)phenethyl)-4-(4-((S)-1-(3,5-
bis(trifluoromethyl)phenethyl)piperazin-2-yl)butyl)-2-phenylpiperazine (Compound 118). 
Using the synthetic approach described in Figure 4.4 the synthesis of compound 118 
was accomplished using the following reagents: 3,5-bis-(trifluoromethyl)-phenylacetic 
acid (R1), Boc-L-phenylglycine (R2), 3,5-bis-(trifluoromethyl)-phenylacetic acid (R3). 
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LCMS (ESI+) m/z calcd for C39H44F12N4O [M + H]+: 783.32, found 783.15 (RT= 4.673 
min) 87.3% purity (UV 214 nM). 
(S)-1-(adamantan-1-ylmethyl)-4-(4-((S)-1-(3,5-
bis(trifluoromethyl)phenethyl)piperazin-2-yl)butyl)-2-phenylpiperazine (Compound 119).  
Using the synthetic approach described in Figure 4.4 the synthesis of compound 119 
was accomplished using the following reagents: 3,5-bis(trifluoromethyl)-phenylacetic 
acid (R1), Boc-L-phenylglycine (R2), 1-adamantanecarboxylic acid (R3).  LCMS (ESI+) 
m/z calcd for C39H52F6N4 [M + H]+: 691.41, found 691.30 (RT= 4.511 min) 81.3% purity 
(UV 214 nM).  Final crude product was purified by HPLC as described above. 1H NMR 
(400 MHz, CDCl3): δ ppm 7.74 (br s, 1 H) 7.66 (br s, 2 H) 7.35 (br s, 2 H) 7.28 - 7.32 (m, 
3 H) 3.49 - 3.76 (m, 3 H) 3.34 - 3.49 (m, 1 H) 3.15 - 3.33 (m, 2 H) 3.03 (d, J=10.64 Hz, 2 
H) 2.78 - 2.96 (m, 6 H) 2.59 - 2.73 (m, 2 H) 2.48 - 2.58 (m, 1 H) 2.45 (br s, 1 H) 2.28 - 
2.43 (m, 2 H) 2.20 (t, 1 H) 2.10 (d, 1 H) 1.87 (br s, 3 H) 1.71 (br s, 1 H) 1.64 (d, 3 H) 
1.55 (d, 4 H) 1.35 - 1.51 (m, 6 H) 1.25 (s, 3 H) 1.23 (s, 2 H). Pure LCMS (ESI+) m/z 
calcd for C39H52F6N4 [M + H]+: 691.41, found 691.10 (RT= 4.546 min) 100% purity (UV 
214 nM). 
(2S)-4-(4-((S)-1-(3,5-bis(trifluoromethyl)phenethyl)piperazin-2-yl)butyl)-1-(2-(4-
isobutylphenyl)propyl)-2-(naphthalen-2-ylmethyl)piperazin (Compound 120). Using the 
synthetic approach described in Figure 4.4 the synthesis of compound 120 was 
accomplished using the following reagents: 3,5-bis(trifluoromethyl)-phenylacetic acid 
(R1), Boc-3-(2-naphthyl)-L-alanine (R2), 4-isobutyl-alpha-methylphenylacetic acid (R3).  
LCMS (ESI+) m/z calcd for C46H58F6N4 [M + H]+: 780.46, found 781.15 (RT= 4.924 min) 
81.9% purity (UV 214 nM). 
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(S)-1-(3,5-bis(trifluoromethyl)phenethyl)-4-(4-((S)-1-(3,5-
bis(trifluoromethyl)phenethyl)piperazin-2-yl)butyl)-2-(naphthalen-2-ylmethyl)piperazine 
(Compound 121). Using the synthetic approach described in Figure 4.4 the synthesis of 
compound 121 was accomplished using the following reagents: 3,5-bis(trifluoromethyl)-
phenylacetic acid (R1), Boc-3-(2-naphthyl)-L-alanine (R2), 3,5-bis(trifluoromethyl)-
phenylacetic acid (R3).  LCMS (ESI+) m/z calcd for C43H46F12N4 [M + H]+: 847.35, found 
847.00 (RT= 4.733 min) 80.4% purity (UV 214 nM). 
(S)-1-(adamantan-1-ylmethyl)-4-(4-((S)-1-(3,5-
bis(trifluoromethyl)phenethyl)piperazin-2-yl)butyl)-2-(naphthalen-2-ylmethyl)piperazine 
(Compound 122). Using the synthetic approach described in Figure 4.4 the synthesis of 
compound 122 was accomplished using the following reagents: 3,5-bis-(trifluoromethyl)-
phenylacetic acid (R1), Boc-3-(2-naphthyl)-L-alanine (R2), 1-adamantanecarboxylic acid 
(R3).  LCMS (ESI+) m/z calcd for C44H56F6N4 [M + H]+: 755.44, found 755.20 (RT= 
4.839 min) 85.9% purity (UV 214 nM). 
(2R)-4-(4-((S)-1-(3,5-bis(trifluoromethyl)phenethyl)piperazin-2-yl)butyl)-1-(2-(4-
isobutylphenyl)propyl)-2-(naphthalen-2-ylmethyl)piperazine (Compound 123). Using the 
synthetic approach described in Figure 4.4 the synthesis of compound 123 was 
accomplished using the following reagents: 3,5-bis(trifluoromethyl)-phenylacetic acid 
(R1), Boc-3-(2-naphthyl)-D-alanine (R2), 4-isobutyl-alpha-methylphenylacetic acid (R3). 
LCMS (ESI+) m/z calcd for C46H58F6N4 [M + H]+: 781.46, found 781.15 (RT= 4.827 min) 
83.6% purity (UV 214 nM). Final crude product was purified by HPLC as described 
above. 1H NMR (400 MHz, CDCl3): δ ppm 7.71 - 7.82 (m, 4 H) 7.59 (s, 1 H) 7.63 (s, 2 
H) 7.43 (br s, 2 H) 7.28 (br s, 1 H) 7.07 - 7.20 (m, 4 H) 3.54 (br s, 2 H) 3.33 (br s, 1 H) 
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3.19 (d, 1 H) 3.01 (br s, 3 H) 2.89 (br s, 4 H) 2.83 (br s, 4 H) 2.61 (br s, 2 H) 2.56 (br s, 2 
H) 2.40 - 2.52 (m, 5 H) 2.36 (br s, 1 H) 2.26 (br s, 1 H) 2.19 (br s, 2 H) 1.88 (d, 1 H) 1.39 
(br s, 3 H) 1.27 - 1.37 (m, 4 H) 1.23 (br s, 1 H) 1.16 (br s., 1 H) 0.92 (br s, 6 H). Pure 
LCMS (ESI+) m/z calcd for C46H58F6N4 [M + H]+: 781.46, found 781.15 (RT= 4.868 min) 
100% purity (UV 214 nM). 
 (R)-1-(3,5-bis(trifluoromethyl)phenethyl)-4-(4-((S)-1-(3,5-
bis(trifluoromethyl)phenethyl)piperazin-2-yl)butyl)-2-(naphthalen-2-ylmethyl)piperazine 
(Compound 124). Using the synthetic approach described in Figure 4.4 the synthesis of 
compound 124 was accomplished using the following reagents: 3,5-bis(trifluoromethyl)-
phenylacetic acid (R1), Boc-3-(2-naphthyl)-D-alanine (R2), 3,5-bis(trifluoromethyl)-
phenylacetic acid (R3).  LCMS (ESI+) m/z calcd for C43H46F12N4 [M + H]+: 847.35, found 
846.90 (RT= 4.740 min) 82.4% purity (UV 214 nM). 
(R)-1-(adamantan-1-ylmethyl)-4-(4-((S)-1-(3,5-
bis(trifluoromethyl)phenethyl)piperazin-2-yl)butyl)-2-(naphthalen-2-ylmethyl)piperazine 
(Compound 125). Using the synthetic approach described in Figure 4.4 the synthesis of 
compound 125 was accomplished using the following reagents: 3,5-bis-(trifluoromethyl)-
phenylacetic acid (R1), Boc-3-(2-naphthyl)-D-alanine (R2), 1-adamantanecarboxylic acid 
(R3).  LCMS (ESI+) m/z calcd for C44H56F6N4 [M + H]+: 755.44, found 755.10 (RT= 
4.818 min) 85.1% purity (UV 214 nM). 
4-(((2S)-4-(4-((S)-1-((4-(tert-butyl)cyclohexyl)methyl)piperazin-2-yl)butyl)-1-(2-(4-
isobutylphenyl)propyl)piperazin-2-yl)methyl)phenol (Compound 126). Using the 
synthetic approach described in Figure 4.4 the synthesis of compound 126 was 
accomplished using the following reagents: 4-tert-butyl-cyclohexanecarboxylic acid (R1), 
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Boc-L-Tyr(BrZ) (R2), 4-isobutyl-alpha-methylphenylacetic acid (R3).  LCMS (ESI+) m/z 
calcd for C43H70N4O [M + H]+: 659.55, found 659.30 (RT= 4.436 min) 92.8% purity (UV 
214 nM). 
4-(((S)-1-(3,5-bis(trifluoromethyl)phenethyl)-4-(4-((S)-1-((4-(tert-
butyl)cyclohexyl)methyl)piperazin-2-yl)butyl)piperazin-2-yl)methyl)phenol (Compound 
127). Using the synthetic approach described in Figure 4.4 the synthesis of compound 
127 was accomplished using the following reagents: 4-tert-butyl-cyclohexanecarboxylic 
acid (R1), Boc-L-Tyr(BrZ) (R2), 3,5-bis(trifluoromethyl)-phenylacetic acid (R3).  LCMS 
(ESI+) m/z calcd for C40H58F6N4O [M + H]+: 725.45, found 725.30 (RT= 4.285 min) 
94.2% purity (UV 214 nM). 
4-(((S)-1-(adamantan-1-ylmethyl)-4-(4-((S)-1-((4-(tert-
butyl)cyclohexyl)methyl)piperazin-2-yl)butyl)piperazin-2-yl)methyl)phenol (Compound 
128). Using the synthetic approach described in Figure 4.4 the synthesis of compound 
128 was accomplished using the following reagents: 4-tert-butyl-cyclohexanecarboxylic 
acid (R1), Boc-L-Tyr(BrZ) (R2), 1-adamantanecarboxylic acid (R3).  LCMS (ESI+) m/z 
calcd C41H68N4O [M + H]+: 633.54, found 633.30 (RT= 4.355 min) 97.2% purity (UV 214 
nM). 
(2S)-4-(4-((S)-1-((4-(tert-butyl)cyclohexyl)methyl)piperazin-2-yl)butyl)-1-(2-(4-
isobutylphenyl)propyl)-2-phenylpiperazine (Compound 129). Using the synthetic 
approach described in Figure 4.4 the synthesis of compound 129 was accomplished 
using the following reagents: 4-tert-butyl-cyclohexanecarboxylic acid (R1), Boc-L-
Tyr(BrZ) (R2), 4-isobutyl-alpha-methylphenylacetic acid (R3).  LCMS (ESI+) m/z calcd 
C42H68N4 [M + H]+: 629.54, found 629.30 (RT= 4.744 min) 93.3% purity (UV 214 nM). 
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(S)-1-(3,5-bis(trifluoromethyl)phenethyl)-4-(4-((S)-1-((4-(tert-
butyl)cyclohexyl)methyl)piperazin-2-yl)butyl)-2-phenylpiperazine (Compound 130). 
Using the synthetic approach described in Figure 4.4 the synthesis of compound 130 
was accomplished using the following reagents: 4-tert-butyl-cyclohexanecarboxylic acid 
(R1), Boc-L-Tyr(BrZ) (R2), 3,5-bis(trifluoromethyl)-phenylacetic acid (R3).  LCMS (ESI+) 
m/z calcd for C49H56F6N4 [M + H]+: 695.44, found 695.10 (RT= 4.545 min) 90.5% purity 
(UV 214 nM). 
(S)-1-(adamantan-1-ylmethyl)-4-(4-((S)-1-((4-(tert-
butyl)cyclohexyl)methyl)piperazin-2-yl)butyl)-2-phenylpiperazine (Compound 131). 
Using the synthetic approach described in Figure 4.4 the synthesis of compound 131 
was accomplished using the following reagents: 4-tert-butyl-cyclohexanecarboxylic acid 
(R1), Boc-L-Tyr(BrZ) (R2), 1-adamantanecarboxylic acid (R3).  LCMS (ESI+) m/z calcd 
for C40H66N4 [M + H]+: 603.53, found 60.35 (RT= 4.549 min) 92.0% purity (UV 214 nM). 
(2S)-4-(4-((S)-1-((4-(tert-butyl)cyclohexyl)methyl)piperazin-2-yl)butyl)-1-(2-(4-
isobutylphenyl)propyl)-2-(naphthalen-2-ylmethyl)piperazine (Compound 132). Using the 
synthetic approach described in Figure 4.4 the synthesis of compound 132 was 
accomplished using the following reagents: 4-tert-butyl-cyclohexanecarboxylic acid (R1), 
Boc-3-(2-naphthyl)-L-alanine (R2), 4-isobutyl-alpha-methylphenylacetic acid (R3). LCMS 
(ESI+) m/z calcd for C47H72N4 [M + H]+: 694.58, found 694.50 (RT= 4.808 min) 80.7% 
purity (UV 214 nM). Final crude product was purified by HPLC as described above. 1H 
NMR (400 MHz, CDCl3): δ ppm 7.71 - 7.84 (m, 3 H) 7.60 (br s, 1 H) 7.45 (br s, 2 H) 7.29 
(br s, 1 H) 7.02 - 7.26 (m, 4 H) 3.18 (d, 1 H) 3.04 (br s, 2 H) 2.97 (br s, 2 H) 2.91 (br s, 3 
H) 2.83 (br s, 1 H) 2.73 (d, 2 H) 2.52 - 2.67 (m, 2 H) 2.48 (br s, 3 H) 2.41 (br s, 2 H) 2.31 
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(br s, 2 H) 2.22 (br s, 2 H) 1.91 - 2.09 (m, 2 H) 1.88 (d, 1 H) 1.75 (d, 2 H) 1.60 (d, 1 H) 
1.50 (br s, 4 H) 1.43 (br s, 4 H) 1.26 - 1.38 (m, 7 H) 1.21 (br. s., 3 H) 0.89 - 1.06 (m, 6 
H) 0.65 - 0.89 (m, 9 H). Pure LCMS (ESI+) m/z calcd for C47H72N4 [M + H]+: 694.58, 
found 694.40 (RT= 4.820 min) 100% purity (UV 214 nM).  
(S)-1-(3,5-bis(trifluoromethyl)phenethyl)-4-(4-((S)-1-((4-(tert-
butyl)cyclohexyl)methyl)piperazin-2-yl)butyl)-2-(naphthalen-2-ylmethyl)piperazine 
(Compound 133). Using the synthetic approach described in Figure 4.4 the synthesis of 
compound 133 was accomplished using the following reagents: 4-tert-butyl-
cyclohexanecarboxylic acid (R1), Boc-3-(2-naphthyl)-L-alanine (R2), 3,5-
bis(trifluoromethyl)-phenylacetic acid (R3).  LCMS (ESI+) m/z calcd for C44H60F6N4 [M + 
H]+: 759.47, found 759.10 (RT= 4.702 min) 94.6% purity (UV 214 nM). 
(S)-1-(adamantan-1-ylmethyl)-4-(4-((S)-1-((4-(tert-
butyl)cyclohexyl)methyl)piperazin-2-yl)butyl)-2-(naphthalen-2-ylmethyl)piperazine 
(Compound 134). Using the synthetic approach described in Figure 4.4 the synthesis of 
compound 134 was accomplished using the following reagents: 4-tert-butyl-
cyclohexanecarboxylic acid (R1), Boc-3-(2-naphthyl)-L-alanine (R2), 1-
adamantanecarboxylic acid (R3).  LCMS (ESI+) m/z calcd for C45H70N4 [M + H]+: 
667.56, found 667.40 (RT= 4.802 min) 78.5% purity (UV 214 nM). 
(2R)-4-(4-((S)-1-((4-(tert-butyl)cyclohexyl)methyl)piperazin-2-yl)butyl)-1-(2-(4-
isobutylphenyl)propyl)-2-(naphthalen-2-ylmethyl)piperazine (Compound 135). Using the 
synthetic approach described in Figure 4.4 the synthesis of compound 135 was 
accomplished using the following reagents: 4-tert-butyl-cyclohexanecarboxylic acid (R1), 
Boc-3-(2-naphthyl)-D-alanine (R2), 4-isobutyl-alpha-methylphenylacetic acid (R3). LCMS 
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(ESI+) m/z calcd for C47H72N4 [M + H]+: 694.58, found 693.45 (RT= 4.911 min) 88.3% 
purity (UV 214 nM). 
(R)-1-(3,5-bis(trifluoromethyl)phenethyl)-4-(4-((S)-1-((4-(tert-
butyl)cyclohexyl)methyl)piperazin-2-yl)butyl)-2-(naphthalen-2-ylmethyl)piperazine 
(Compound 136). Using the synthetic approach described in Figure 4.4 the synthesis of 
compound 136 was accomplished using the following reagents: 4-tert-butyl-
cyclohexanecarboxylic acid (R1), Boc-3-(2-naphthyl)-D-alanine (R2), 3,5-
bis(trifluoromethyl)-phenylacetic acid (R3).  LCMS (ESI+) m/z calcd for C44H60F6N4 [M + 
H]+: 759.47, found 759.25 (RT= 4.715 min) 93.6% purity (UV 214 nM). 
(R)-1-(adamantan-1-ylmethyl)-4-(4-((S)-1-((4-(tert-
butyl)cyclohexyl)methyl)piperazin-2-yl)butyl)-2-(naphthalen-2-ylmethyl)piperazine 
(Compound 137). Using the synthetic approach described in Figure 4.4 the synthesis of 
compound 137 was accomplished using the following reagents: 4-tert-butyl-
cyclohexanecarboxylic acid (R1), Boc-3-(2-naphthyl)-D-alanine (R2), 1-
adamantanecarboxylic acid (R3).  LCMS (ESI+) m/z calcd for C45H70N4 [M + H]+: 
667.56, found 667.25 (RT= 4.824 min) 89.3% purity (UV 214 nM). 
(2R)-1-(3-cyclopentylpropyl)-4-(4-((2S)-1-(2-(4-isobutylphenyl)propyl)piperazin-2-
yl)butyl)-2-propylpiperazine (Compound 138). Using the synthetic approach described in 
Figure 4.4 the synthesis of compound 138 was accomplished using the following 
reagents: 4-isobutyl-alpha-methylphenylacetic acid (R1), Boc-D-norvaline (R2), 3-
Cyclopentylpropionic Acid (R3).  LCMS (ESI+) m/z calcd for C36H64N4 [M + H]+: 553.51, 
found 553.30 (RT= 4.156 min) 83.2% purity (UV 214 nM). 
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(2R)-1-(2-cyclohexylethyl)-4-(4-((2S)-1-(2-(4-isobutylphenyl)propyl)piperazin-2-
yl)butyl)-2-propylpiperazine (Compound 139). Using the synthetic approach described in 
Figure 4.4 the synthesis of compound 139 was accomplished using the following 
reagents: 4-isobutyl-alpha-methylphenylacetic acid (R1), Boc-D-norvaline (R2), 
Cyclohexylacetic Acid (R3).  LCMS (ESI+) m/z calcd for C36H64N4 [M + H]+: 553.51, 
found 553.35 (RT= 4.131 min) 81.7% purity (UV 214 nM). 
(S)-2-butyl-4-(4-((S)-1-(4-cyclohexylbutyl)piperazin-2-yl)butyl)-1-(4-
ethoxyphenethyl)piperazine (Compound 140). Using the synthetic approach described 
in Figure 4.4 the synthesis of compound 140 was accomplished using the following 
reagents: cyclohexanebutyric acid (R1), Boc-L-norleucine (R2), 4-ethoxyphenylacetic 
acid (R3).  LCMS (ESI+) m/z calcd for C36H64N4O [M + H]+: 570.51, found 570.35 (RT= 
3.930 min) 90.7% purity (UV 214 nM). 
(S)-2-butyl-4-(4-((S)-1-(4-cyclohexylbutyl)piperazin-2-yl)butyl)-1-(3-
methylphenethyl)piperazine (Compound 141). Using the synthetic approach described 
in Figure 4.4 the synthesis of compound 141 was accomplished using the following 
reagents: cyclohexanebutyric acid (R1), Boc-L-norleucine (R2), m-tolylacetic acid (R3).  
LCMS (ESI+) m/z calcd for C35H62N4 [M + H]+: 539.50, found 539.35 (RT= 3.945 min) 
88.9% purity (UV 214 nM). 
(S)-4-(4-((S)-1-(4-cyclohexylbutyl)piperazin-2-yl)butyl)-2-(cyclohexylmethyl)-1-(4-
ethoxyphenethyl)piperazine (Compound 142). Using the synthetic approach described 
in Figure 4.4 the synthesis of compound 142 was accomplished using the following 
reagents: cyclohexanebutyric acid (R1), Boc-L-cyclohexylalanine (R2), 4-
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ethoxyphenylacetic acid (R3).  LCMS (ESI+) m/z calcd for C39H68N4O [M + H]+: 609.54, 
found 609.40 (RT= 4.100 min) 90.3% purity (UV 214 nM). 
(S)-4-(4-((S)-1-(4-cyclohexylbutyl)piperazin-2-yl)butyl)-2-(cyclohexylmethyl)-1-(4-
ethoxyphenethyl)piperazine (Compound 143). Using the synthetic approach described 
in Figure 4.4 the synthesis of compound 143 was accomplished using the following 
reagents: 2-norbornaneacetic acid (R1), Boc-L-cyclohexylalanine (R2), m-tolylacetic acid 
(R3).  LCMS (ESI+) m/z calcd for C39H68N4 [M + H]+: 564.50, found 564.35 (RT= 3.896 
min) 86.3% purity (UV 214 nM). 
 
Strains, Media, and Yeast Techniques  
Yeast growth media were prepared as described previously.19  Cells were grown 
in synthetic complete (SC) medium or YPD (1% yeast extract, 2% peptone, and 2% 
glucose) medium.19  Induction of GAL1, 10 promoters were achieved by adding 4% 
galactose to SC medium.  Yeast transformations were performed using the lithium 
acetate procedure.20 Three yeast strains were used for this study: RJY1941 (S288C) 
MATα leu2-3,112 ura3-52 ade2 ade8 lys2 ras1::HIS3 Ras2(CS-ext) erf2∆::KANr 
erg6∆::TRP1 [YCp52-RAS2], RJY1942 (S288C) MATα leu2-3,112 ura3-52 ade2 ade8 
lys2 ras1::HIS3 Ras2(CS-ext) erf2∆::KANr erg6∆::TRP1 [YCp52] and RJY1842 (MATa/α 
ade2-1/ade2-1 leu2-3,112/leu2-3,112 ura3-52/ura3-52 trp1-1/trp1-1 his3-11,15/his3-
11,15 can1-100/can1-100 GAL+/GAL+ psi+/psi+ erf4∆::NATr/erf4∆::NATr13. 
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Protein Purification 
Strain RJY1842 was transformed with pESC(-Leu)-6xHIS-Erf2-(Flag)-Erf4 and 
grown in SC(-Leu) medium containing 2% (v/v) ethanol/ 2% (v/v) glycerol at 30 ˚C with 
shaking and grown to 2 x 107 cells/ml.  50 mls (1x109 cells) were added to 1 liter of 
YEP medium supplemented with 4% galactose for induction.  Cells were induced with 
shaking (230 RPM) for 18h (30˚C) and then harvested by centrifugation at 3000 xg for 
15 minutes. The resulting pellet was resuspended in breaking buffer (50 mM Tris-Cl pH 
8, 500 ml NaCl, 1mM EDTA, 1mM DTT, 1xPIC, 8 µl/ml saturated PMSF/isopropyl 
alcohol), and the cells were lysed using glass beads (400-600 mesh, Sigma) for 40 
minutes with 1 min pulses (1 minute cooling).  The resulting extract was spun at 3000 
xg for 15 minutes to remove cellular debris and unbroken cells, followed by a crude 
membrane fraction (P13) by centrifugation (13,000 xg) for 0.5 hours at 4 ˚C.   The 
supernatant was discarded and the pellet was resuspended in Tris buffered saline, pH 
8, with the aid of a Dounce homogenizer.  The resulting extract was adjusted to a final 
concentration of 1% Triton-X100.  To solubilize the membranes, the extract was 
incubated at 4 ˚C (1.5 h).  Insoluble material was then removed by centrifugation 
(13,000 xg) for 0.5 hours at 4 ˚C.  The supernatant was incubated with Ni-NTA resin at 
4 ˚C for 1 h.  The resin was washed 3x with Solution W (50mM Tris-HCl, pH 8, 150mM 
NaCl and 1% Triton-X100). The protein was eluted with 50mM Tris-HCl, pH8, 150mM 
NaCl, 1% Triton-X100, 5% glycerol and 250mM imidazole.  Eluates were desalted and 
concentrated using  (50mM Tris-Cl, pH 8, 150mM NaCl, 1% Triton-X100 and 5% 
glycerol.  Fractions containing 6xHis-Erf2/FLAG-Erf4 were pooled to obtain 
approximately 0.2 mg of purified Ras PAT per liter of culture as determined by SDS-
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PAGE against a standard curve of bovine serum albumin.  The complexes were divided 
into 50 µL aliquots and frozen at -80 ˚C until use. 
 
Coupled PAT Assay 
The HTS of protein palmitoylation was recently described8, but was adjusted for 
this study.  The production of NADH was monitored with a Biotek Mx fluorimeter (Biotek, 
Winooski, VT) using 340 nm excitation/ 465 nm emission.  The 50 µl reaction contained 
2 mM 2-Oxoglutarate (α-ketoglutamic acid), 0.25 mM NAD+, 0.2 mM Thiamine 
Pyrophosphate, 0.5 µg of purified 6xHIS-Erf2/FLAG-Erf4, 1 mM EDTA, 1 mM 
dithiothreitol, 32 mU 2-oxogluarate dehydrogenase (α-ketoglutarate dehydrogenase), 50 
mM sodium phosphate, pH 6.8, and 0 - 100 µM inhibitor in 5% DMF.  The reaction was 
initiated by the addition of 40 µM palmitoyl-CoA and monitored for 30 mins at 30 ˚C.  
The first 10mins of the reaction was analyzed to determine the initial rates of CoASH 
release.  The PAT specific activity was determined from a standard curve of NADH 
production with different CoASH amounts.  In these reactions, CoASH was added to the 
standard PAT reaction mixture (without Erf2/Erf4 complex or palmitoyl-CoA) and the 
reaction was allowed to proceed to equilibrium before fluorescence was measured. 
 
BODIPY®-C12:0 Auto-palmitoylation Assay 
BODIPY®-C12:0-CoA (40 µM final, unless specified otherwise) was added to a 
50 µl reaction containing approximately 0.5 µg enzyme (6xHIS-Erf2/FLAG-Erf4) and 
100 µM inhibitors in 5% DMF in 50mM sodium phosphate buffer, pH 6.8.  The reactions 
were incubated 10 min with inhibitor, and then the reaction was initiated with the 
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addition of BODIPY®-C12:0-CoA, and incubated 15 mins at 30 ˚C.  The reaction was 
terminated by the addition of 5x non-reducing protein loading buffer.  Each reaction was 
heated at 65 ˚C for three min and then subjected to SDS-PAGE (12%).  The gel was 
washed three times in ddH2O and visualized on the Typhoon 9410 Variable Mode 
Imager (GE Healthcare, Piscataway, NJ) for BODIPY® fluorescence (ex. 488 nm / em. 
532 nm) to visualize co-migration of the BODIPY® signal with 6xHIS-Erf2/FLAG-Erf4.  
The amount of 6xHIS-Erf2/FLAG-Erf4 was determined empirically using SDS-
PAGE/western blot analysis under reducing conditions against a standard curve of 
bovine serum albumin. 
 
Growth Inhibition Assay 
The in vivo effect of the inhibitors on Ras2 palmitoylation was investigated by 
comparing the growth of S. cerevisiae strains previously described for our 
complementation assay.13  Briefly, the cells contain a defective allele of RAS2 that is 
balanced by an episomal copy of RAS2 linked to URA3.  Under these conditions, the 
yeast strain cannot grow unless the episomal copy of RAS2 is palmitoylated.  Varying 
concentrations of the inhibitors were added to 200 µl volumes of the yeast cells at an 
OD600 between 0.8 and 1.2 in a 96-well plate format.  The OD600 was observed every 
30 minutes for 24 hours and EC50 values were determined by graphing rate of growth 
against concentration of inhibitor for each inhibitor. 
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Yeast Cell Spot Assay  
Following 24 hour incubation with varying concentrations of the inhibitors in 1% 
DMF, S. cerevisiae strains RJY1941 and RJY1942 were then diluted 1/100, and spotted 
onto SC-URA plates with 2% glucose.  Cytotoxicity data was obtained by detecting the 
colony growth, following 48 hours incubation at 30 ˚C, with white light detection on the 
Bio-Rad Molecular Imager® ChemiDocTM XRS+ (Hercules, CA) and performing 
densitometry with Bio-Rad ImageLabTM software (Hercules, CA).  Triplicate reactions 
were plated in triplicate.  Values were normalized to vehicle control (1% DMF) for each 
plate, and then the averages of each reaction was compared for statistical analysis. 
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Tables 
Table 4.1. Scaffold Ranking Inhibition of Auto-palmitoylation. 
ID # of sample Total # Core Scaffold 100 µg/ml 
Lib35 127 3,990 
 
0.30 
Lib39 99 2,340 
 
0.38 
Lib3 110 45,864 
 
0.38 
Lib41 99 2,340  
 
0.50 
Lib37 94 3,249 
 
0.58 
Lib34 156 134,560 
 
0.60 
Lib30 400 16,400 
 
0.70 
Lib28 96 31,320 
 
0.77 
Lib42 83 17,340 
 
0.77 
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Table 4.1 (continued). Scaffold Ranking Inhibition of Auto-palmitoylation. 
ID # of sample Total # Core Scaffold 100 µg/ml 
Lib11 125 72,283 
 
0.78 
Lib43 116 56,610 
 
0.78 
Lib6 120 738,192 
 
0.79 
Lib44 188 4,879,681 
 
0.80 
Lib26 150 125,000 
 
0.80 
Lib45 124 3,844 
 
 
0.81 
Lib24 94 3,249 
 
0.81 
Lib25 107 45,288 
 
0.90 
 
 
 
 207 
Table 4.1 (continued). Scaffold Ranking Inhibition of Auto-palmitoylation. 
ID # of sample Total # Core Scaffold 100 µg/ml 
Lib15 174 195,112 
 
0.91 
Lib13 116 56,610 
 
0.92 
Lib22 96 31,320 
 
0.94 
Lib47 124 3,844 
 
0.96 
Lib14 83 17,340 
 
0.98 
Lib49 99 2,340 
 
0.99 
Lib12 110 45,864 
 
0.99 
Lib7 110 45,864 
 
1.00 
Lib50 228 399,776 
 
1.00 
Lib27 120 738,192 
 
1.00 
Lib18 83 17,340 
 
1.00 
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Table 4.1 (continued). Scaffold Ranking Inhibition of Auto-palmitoylation. 
ID # of sample Total # Core Scaffold 100 µg/ml 
Lib23 110 45,864 
 
1.11 
Lib4 116 56,610 
 
1.13 
Lib51 83 17,340 
 
1.15 
Lib52 66 2,016 
 
1.18 
Lib53 86 1,303,210 
 
1.19 
Lib1 110 45,864 
 
1.90 
Lib32 400 10,800 
 
1.20 
Lib5 116 56,610 
 
1.21 
Lib21 120 738,192 
 
1.22 
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Table 4.1 (continued). Scaffold Ranking Inhibition of Auto-palmitoylation. 
ID # of sample Total # Core Scaffold 100 µg/ml 
Lib55 264 18,974,736 
 
1.37 
Lib31 400 16,000 
 
1.38 
Lib56 140 4,900 
 
1.40 
Lib19 96 31,320 
 
1.41 
Lib10 120 738,192 
 
1.43 
Lib2 120 738,192 
 
1.58 
Lib20 96 31,320 
 
1.58 
Lib9 96 31,320 
 
1.59 
Lib8 116 56,610 
 
1.70 
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Table 4.1 (continued). Scaffold Ranking Inhibition of Auto-palmitoylation. 
ID # of sample Total # Core Scaffold 100 µg/ml 
Lib29 135 85,248 
 
1.80 
 
“ID” corresponds to the numbers used throughout the chapter.  “# of sample” is the number of 
samples in the corresponding positional scanning library for a given scaffold. “Total #” is the 
total number of compounds in a given scaffold ranking sample.  The scaffold ranking library 
screen of 50 scaffolds was screened at 100 µg/ml, and the average velocity (Avg Vel) of Erf2 
auto-palmitoylation of three reactions is presented as a fraction of vehicle control (1% DMF).  
The velocity of Erf2 auto-palmitoylation was detected as an increase in fluorescence over time.  
No effect on Erf2 autoplamitoylation would fall at 1 arbitrary unit.  Scaffolds that resulted in a 
reduction in Erf2 auto-palmitoylation 3 standard deviations (<0.56) were considered hits of this 
assay. A heat inactivated Erf2 (Boiled; 0.18) and a catalytically inactive mutant of Erf2 (C203S; 
0.21) represent baseline activity in this assay.  100 µM 2-BP (0.42) is a control for inhibition of 
Erf2 auto-palmitoylation. Table sorted by Avg Vel at 100 µg/ml. 
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Table 4.2. Scaffold Ranking Inhibition of Auto-palmitoylation – Libraries from Libraries. 
 
ID # of sample Total # Core Scaffold Avg Vel  100 µg/ml 
Lib3 110 45,864 
 
0.38 
Lib12 110 45,864 
 
0.99 
Lib7 110 45,864 
 
1.00 
Lib23 110 45,864 
 
1.11 
Lib1 110 45,864 
 
1.90 
 
“ID” corresponds to the numbers used throughout the chapter.  “# of sample” is the 
number of samples in the corresponding positional scanning library for a given scaffold. 
“Total #” is the total number of compounds in a given scaffold ranking sample.  The 
libraries from libraries scaffold ranking library samples were screened at 100 µg/ml, and 
the average velocity (Avg Vel) of Erf2 auto-palmitoylation of three reactions is presented 
as a fraction of vehicle control (1% DMF).  The velocity of Erf2 auto-palmitoylation was 
detected as an increase in fluorescence over time.  No effect on Erf2 autoplamitoylation 
would fall at 1 arbitrary unit.  Scaffolds that resulted in a reduction in Erf2 auto-
palmitoylation 3 standard deviations (<0.56) were considered hits of this assay. A heat 
inactivated Erf2 (Boiled; 0.18) and a catalytically inactive mutant of Erf2 (C203S; 0.21) 
represent baseline activity in this assay.  100 µM 2-BP (0.42) is a control for inhibition of 
Erf2 auto-palmitoylation.  Table sorted by Avg Vel at 100 µg/ml. 
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Table 4.3. Inhibition of Auto-palmitoylation Lib3 R1.   
 
ID # R1 100 µg/ml 
Lib3.001 (1-phenyl-cyclopropyl)-methyl 16% 21% 27% 
Lib3.002 2-phenylbutyl -2% -1% 5% 
Lib3.003 3-phenylbutyl 7% 8% 18% 
Lib3.004 m-tolylethyl 3% 8% 9% 
Lib3.005 2-(3-fluoro-phenyl)-ethyl 2% 6% 7% 
Lib3.006 2-(3-bromo-phenyl)-ethyl 12% 14% 15% 
Lib3.007 2-(3-trifluoromethyl-phenyl)-ethyl 14% 16% 17% 
Lib3.008 p-tolylethyl 1% 4% 6% 
Lib3.009 2-(4-fluoro-phenyl)-ethyl -3% 2% 4% 
Lib3.010 2-(3-methoxy-phenyl)-ethyl 0% 8% 13% 
Lib3.011 2-(4-bromo-phenyl)-ethyl 16% 18% 23% 
Lib3.012 2-(4-methoxy-phenyl)-ethyl 8% 8% 10% 
Lib3.013 2-(4-ethoxy-phenyl)-ethyl 4% 12% 16% 
Lib3.014 2-(4-Isobutyl-phenyl)-propyl 26% 32% 37% 
Lib3.015 3,4-dichlorophenethyl 8% 15% 19% 
Lib3.016 2-(3,5-bis-trifluoromethyl-phenyl)-ethyl 12% 23% 26% 
Lib3.017 3-(3,4-dimethoxy-phenyl)-propyl -2% 10% 15% 
Lib3.018 phenethyl 5% 12% 13% 
Lib3.019 3,4,5-trimethoxy-benzyl 3% 10% 11% 
Lib3.020 butyl -8% -6% 11% 
Lib3.021 heptyl -2% 8% 11% 
Lib3.022 isobutyl -1% 2% 6% 
Lib3.023 2-methylbutyl -5% 0% 3% 
Lib3.024 3-methylbutyl -6% 1% 2% 
Lib3.025 3-methylpentyl -3% 2% 3% 
Lib3.026 4-methylpentyl -2% 5% 6% 
Lib3.027 4-methyl-benzyl 10% 14% 17% 
Lib3.028 cyclopently-methyl -5% 6% 10% 
Lib3.029 cyclohexyl-methyl -1% 1% 6% 
Lib3.030 cyclohexyl-ethyl 1% 6% 10% 
Lib3.031 cyclohexyl-butyl 9% 15% 17% 
Lib3.032 cycloheptyl-methyl 1% 5% 9% 
Lib3.033 2-methylcyclopropyl-methyl -4% 8% 25% 
Lib3.034 cyclobutyl-methyl -10% 6% 20% 
Lib3.035 3-cyclopentyl-propyl 9% 11% 17% 
Lib3.036 cyclohexyl-propyl 3% 11% 12% 
Lib3.037 4-methyl-1-cyclohexyl-methyl 0% 6% 13% 
Lib3.038 4-tert-butyl-cyclohexyl-methyl 18% 23% 24% 
Lib3.039! 2-biphenyl-4-yl-ethyl! 21% 27% 30%!
Lib3.040! adamantan-1-yl-methyl! 8% 16% 18%!
Lib3.041! adamantan-1-yl-ethyl! 5% 15% 18%!
Lib3.042! 2-bicyclo[2.2.1]hept-2-yl-ethyl! -1% 8% 17%!
 
“ID” corresponds to the numbers used throughout the chapter.  The functionality of the fixed position is 
provided.  The data is reported as percent inhibition relative to vehicle control for the auto-palmitoylation 
HTS assay.  
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Table 4.3. Inhibition of Auto-palmitoylation Lib3 R2.   
 
ID # R2 100µg/ml 
Lib3.043 S-methyl 0% 3% 10% 
Lib3.044 S-benzyl 15% 22% 23% 
Lib3.045 hydrogen -5% 3% 9% 
Lib3.046 S-2-butyl 2% 11% 12% 
Lib3.047 S-isobutyl -1% 10% 12% 
Lib3.048 R-hydroxymethyl -9% 1% 5% 
Lib3.049 (R,R)-1-hydroxyethyl 1% 2% 14% 
Lib3.050 S-isopropyl 3% 8% 13% 
Lib3.051 S-4-hydroxybenzyl 24% 25% 27% 
Lib3.052 R-methyl 0% 1% 4% 
Lib3.053 R-benzyl 13% 16% 24% 
Lib3.054 R-2-butyl -4% 5% 6% 
Lib3.055 R-isobutyl 0% 4% 8% 
Lib3.056 S-hydroxymethyl 3% 8% 11% 
Lib3.057 (S,S)-1-hydroxyethyl -11% 2% 7% 
Lib3.058 R-isopropyl -7% 1% 5% 
Lib3.059 R-4-hydroxybenzyl 13% 18% 19% 
Lib3.060 S-phenyl 13% 21% 24% 
Lib3.061 S-propyl -3% 9% 10% 
Lib3.062 R-propyl -12% -2% 0% 
Lib3.063 S-butyl -1% 7% 13% 
Lib3.064 R-butyl -7% 2% 3% 
Lib3.065 S-2-naphthylmethyl 31% 32% 39% 
Lib3.066 R-2-naphthylmethyl 32% 37% 40% 
Lib3.067 S-cyclohexylmethyl 15% 16% 21% 
Lib3.068 R-cyclohexylmethyl 10% 13% 16% 
!
“ID” corresponds to the numbers used throughout the chapter.  The functionality of the fixed 
position is provided.  The data is reported as percent inhibition relative to vehicle control for the 
auto-palmitoylation HTS assay. 
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Table 4.5. Inhibition of Auto-palmitoylation Lib3 R3.  
 
 
ID # R3 100µg/ml 
Lib3.069 (1-phenyl-cyclopropyl)-methyl -2% 2% 9% 
Lib3.070 2-phenylbutyl 5% 9% 12% 
Lib3.071 3-phenylbutyl -1% 8% 8% 
Lib3.072 m-tolylethyl -5% 7% 12% 
Lib3.073 2-(3-fluoro-phenyl)-ethyl 0% 2% 7% 
Lib3.074 2-(3-bromo-phenyl)-ethyl 10% 12% 20% 
Lib3.075 2-(3-trifluoromethyl-phenyl)-ethyl 16% 20% 21% 
Lib3.076 p-tolylethyl 2% 3% 5% 
Lib3.077 2-(4-fluoro-phenyl)-ethyl 0% 4% 10% 
Lib3.078 2-(3-methoxy-phenyl)-ethyl 2% 5% 13% 
Lib3.079 2-(4-bromo-phenyl)-ethyl 1% 8% 9% 
Lib3.080 2-(4-methoxy-phenyl)-ethyl -4% 1% 3% 
Lib3.081 2-(4-ethoxy-phenyl)-ethyl -2% 3% 8% 
Lib3.082 2-(4-Isobutyl-phenyl)-propyl 19% 26% 28% 
Lib3.083 3,4-dichlorophenethyl 8% 8% 10% 
Lib3.084 2-(3,5-bis-trifluoromethyl-phenyl)-ethyl 13% 24% 29% 
Lib3.085 3-(3,4-dimethoxy-phenyl)-propyl -5% 0% 12% 
Lib3.086 phenethyl 3% 6% 7% 
Lib3.087 3,4,5-trimethoxy-benzyl 0% 1% 3% 
Lib3.088 butyl 0% 1% 1% 
Lib3.089 heptyl 0% 0% 2% 
Lib3.090 isobutyl -6% -6% -3% 
Lib3.091 2-methylbutyl -5% -3% -1% 
Lib3.092 3-methylbutyl -6% -1% 0% 
Lib3.093 3-methylpentyl -6% -1% 3% 
Lib3.094 4-methylpentyl -2% 0% 4% 
Lib3.095 4-methyl-benzyl 4% 6% 13% 
Lib3.096 cyclopently-methyl 0% 1% 5% 
Lib3.097 cyclohexyl-methyl 0% 3% 5% 
Lib3.098 cyclohexyl-ethyl 1% 5% 8% 
Lib3.099 cyclohexyl-butyl 11% 11% 14% 
Lib3.100 cycloheptyl-methyl 7% 7% 10% 
Lib3.101 2-methylcyclopropyl-methyl -3% 0% 8% 
Lib3.102 cyclobutyl-methyl -5% 5% 7% 
Lib3.103 3-cyclopentyl-propyl 2% 11% 16% 
Lib3.104 cyclohexyl-propyl 3% 7% 14% 
Lib3.105 4-methyl-1-cyclohexyl-methyl 3% 4% 7% 
Lib3.106 4-tert-butyl-cyclohexyl-methyl 8% 12% 15% 
Lib3.107 2-biphenyl-4-yl-ethyl 18% 24% 31% 
Lib3.108 adamantan-1-yl-methyl 19% 25% 26% 
Lib3.109 adamantan-1-yl-ethyl 11% 13% 21% 
Lib3.110 2-bicyclo[2.2.1]hept-2-yl-ethyl 2% 3% 10% 
 
“ID” corresponds to the numbers used throughout the chapter.  The functionality of the fixed position is 
provided.  The data is reported as percent inhibition relative to vehicle control for the auto-palmitoylation 
HTS assay.  
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Table 4.6. Inhibition of Auto-palmitoylation Individual Compounds.  
 
Controls AVG STD 
1%DMF Solvent Control 0.94 1.01 
50 µM 2BP 0.53 0.69 
No Enzyme 0.06 0.03 
No Palm-CoA -0.01 0.00 
   
ID # R1 R2 R3 AVG STD 
90 (1-phenyl-cyclopropyl)-methyl S-4-hydroxybenzyl 2-(4-isobutyl-phenyl)-propyl 0.41 0.03 
91 (1-phenyl-cyclopropyl)-methyl S-4-hydroxybenzyl 2-(3,5-bis-trifluoromethyl-phenyl)-ethyl 0.59 0.03 
92 (1-phenyl-cyclopropyl)-methyl S-4-hydroxybenzyl adamantan-1-yl-methyl 0.47 0.03 
93 (1-phenyl-cyclopropyl)-methyl S-phenyl 2-(4-isobutyl-phenyl)-propyl 0.50 0.05 
94 (1-phenyl-cyclopropyl)-methyl S-phenyl 2-(3,5-bis-trifluoromethyl-phenyl)-ethyl 0.64 0.06 
95 (1-phenyl-cyclopropyl)-methyl S-phenyl adamantan-1-yl-methyl 0.64 0.04 
96 (1-phenyl-cyclopropyl)-methyl S-2-naphthylmethyl 2-(4-isobutyl-phenyl)-propyl 0.65 0.09 
97 (1-phenyl-cyclopropyl)-methyl S-2-naphthylmethyl 2-(3,5-bis-trifluoromethyl-phenyl)-ethyl 0.79 0.09 
98 (1-phenyl-cyclopropyl)-methyl S-2-naphthylmethyl adamantan-1-yl-methyl 0.70 0.07 
99 (1-phenyl-cyclopropyl)-methyl R-2-naphthylmethyl 2-(4-isobutyl-phenyl)-propyl 0.60 0.07 
100 (1-phenyl-cyclopropyl)-methyl R-2-naphthylmethyl 2-(3,5-bis-trifluoromethyl-phenyl)-ethyl 0.58 0.06 
101 (1-phenyl-cyclopropyl)-methyl R-2-naphthylmethyl adamantan-1-yl-methyl 0.74 0.07 
102 2-(4-isobutyl-phenyl)-propyl S-4-hydroxybenzyl 2-(4-isobutyl-phenyl)-propyl 0.36 0.02 
103 2-(4-isobutyl-phenyl)-propyl S-4-hydroxybenzyl 2-(3,5-bis-trifluoromethyl-phenyl)-ethyl 0.37 0.05 
104 2-(4-isobutyl-phenyl)-propyl S-4-hydroxybenzyl adamantan-1-yl-methyl 0.41 0.05 
105 2-(4-isobutyl-phenyl)-propyl S-phenyl 2-(4-isobutyl-phenyl)-propyl 0.41 0.03 
106 2-(4-isobutyl-phenyl)-propyl S-phenyl 2-(3,5-bis-trifluoromethyl-phenyl)-ethyl 0.39 0.03 
107 2-(4-isobutyl-phenyl)-propyl S-phenyl adamantan-1-yl-methyl 0.45 0.01 
108 2-(4-isobutyl-phenyl)-propyl S-2-naphthylmethyl 2-(4-isobutyl-phenyl)-propyl 0.36 0.06 
109 2-(4-isobutyl-phenyl)-propyl S-2-naphthylmethyl 2-(3,5-bis-trifluoromethyl-phenyl)-ethyl 0.40 0.00 
110 2-(4-isobutyl-phenyl)-propyl S-2-naphthylmethyl adamantan-1-yl-methyl 0.45 0.01 
111 2-(4-isobutyl-phenyl)-propyl R-2-naphthylmethyl 2-(4-isobutyl-phenyl)-propyl 0.34 0.01 
112 2-(4-isobutyl-phenyl)-propyl R-2-naphthylmethyl 2-(3,5-bis-trifluoromethyl-phenyl)-ethyl 0.40 0.04 
113 2-(4-isobutyl-phenyl)-propyl R-2-naphthylmethyl adamantan-1-yl-methyl 0.49 0.03 
114 2-(3,5-bis-trifluoromethyl-phenyl)-ethyl S-4-hydroxybenzyl 2-(4-isobutyl-phenyl)-propyl 0.29 0.05 
115 2-(3,5-bis-trifluoromethyl-phenyl)-ethyl S-4-hydroxybenzyl 2-(3,5-bis-trifluoromethyl-phenyl)-ethyl 0.39 0.04 
116 2-(3,5-bis-trifluoromethyl-phenyl)-ethyl S-4-hydroxybenzyl adamantan-1-yl-methyl 0.34 0.02 
117 2-(3,5-bis-trifluoromethyl-phenyl)-ethyl S-phenyl 2-(4-isobutyl-phenyl)-propyl 0.34 0.03 
118 2-(3,5-bis-trifluoromethyl-phenyl)-ethyl S-phenyl 2-(3,5-bis-trifluoromethyl-phenyl)-ethyl 0.38 0.01 
119 2-(3,5-bis-trifluoromethyl-phenyl)-ethyl S-phenyl adamantan-1-yl-methyl 0.37 0.04 
120 2-(3,5-bis-trifluoromethyl-phenyl)-ethyl S-2-naphthylmethyl 2-(4-isobutyl-phenyl)-propyl 0.37 0.02 
121 2-(3,5-bis-trifluoromethyl-phenyl)-ethyl S-2-naphthylmethyl 2-(3,5-bis-trifluoromethyl-phenyl)-ethyl 0.43 0.01 
122 2-(3,5-bis-trifluoromethyl-phenyl)-ethyl S-2-naphthylmethyl adamantan-1-yl-methyl 0.49 0.06 
123 2-(3,5-bis-trifluoromethyl-phenyl)-ethyl R-2-naphthylmethyl 2-(4-isobutyl-phenyl)-propyl 0.37 0.08 
124 2-(3,5-bis-trifluoromethyl-phenyl)-ethyl R-2-naphthylmethyl 2-(3,5-bis-trifluoromethyl-phenyl)-ethyl 0.45 0.03 
125 2-(3,5-bis-trifluoromethyl-phenyl)-ethyl R-2-naphthylmethyl adamantan-1-yl-methyl 0.46 0.04 
126 4-tert-butyl-cyclohexyl-methyl S-4-hydroxybenzyl 2-(4-isobutyl-phenyl)-propyl 0.38 0.03 
127 4-tert-butyl-cyclohexyl-methyl S-4-hydroxybenzyl 2-(3,5-bis-trifluoromethyl-phenyl)-ethyl 0.41 0.07 
128 4-tert-butyl-cyclohexyl-methyl S-4-hydroxybenzyl adamantan-1-yl-methyl 0.47 0.07 
129 4-tert-butyl-cyclohexyl-methyl S-phenyl 2-(4-isobutyl-phenyl)-propyl 0.40 0.03 
130 4-tert-butyl-cyclohexyl-methyl S-phenyl 2-(3,5-bis-trifluoromethyl-phenyl)-ethyl 0.50 0.08 
131 4-tert-butyl-cyclohexyl-methyl S-phenyl adamantan-1-yl-methyl 0.55 0.03 
132 4-tert-butyl-cyclohexyl-methyl S-2-naphthylmethyl 2-(4-isobutyl-phenyl)-propyl 0.33 0.05 
133 4-tert-butyl-cyclohexyl-methyl S-2-naphthylmethyl 2-(3,5-bis-trifluoromethyl-phenyl)-ethyl 0.73 0.05 
134 4-tert-butyl-cyclohexyl-methyl S-2-naphthylmethyl adamantan-1-yl-methyl 0.62 0.04 
135 4-tert-butyl-cyclohexyl-methyl R-2-naphthylmethyl 2-(4-isobutyl-phenyl)-propyl 0.48 0.03 
136 4-tert-butyl-cyclohexyl-methyl R-2-naphthylmethyl 2-(3,5-bis-trifluoromethyl-phenyl)-ethyl 0.48 0.03 
137 4-tert-butyl-cyclohexyl-methyl R-2-naphthylmethyl adamantan-1-yl-methyl 0.55 0.03 
138 2-(4-isobutyl-phenyl)-propyl R-propyl 3-cyclopentyl-propyl 1.02 0.06 
139 2-(4-isobutyl-phenyl)-propyl R-propyl cyclohexyl-methyl 0.99 0.07 
140 cyclohexyl-butyl S-butyl 2-(4-ethoxy-phenyl)-ethyl 0.90 0.06 
141 cyclohexyl-butyl S-butyl m-tolylethyl 0.85 0.04 
142 cyclohexyl-butyl S-cyclohexylmethyl 2-(4-ethoxy-phenyl)-ethyl 0.61 0.05 
143 2-bicyclo[2.2.1]hept-2-yl-ethyl S-cyclohexylmethyl m-tolylethyl 0.98 0.03 
 
Percent inhibition relative to vehicle control for the auto-palmitoylation HTS assay (n=3).  
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Figures 
!
  
 
Figure 4.1. Fluorescence-based Coupled Assay Measuring Inhibition of Auto-
palmitoylation 
During the auto-palmitoylation step coenzyme A (CoASH) is produced (left half of 
figure).  The CoASH is utilized in the conversion of α-ketoglutarate to succinyl-CoA.  
During this conversion the fluorescent NADH is produced through the reduction of NAD+ 
(right half of figure).  In this way the coupled-assay assesses a sample’s ability to inhibit 
the auto-palmitoylation step by monitoring the relative amount of fluorescent NADH 
produced.  A secondary assay is performed to confirm a given sample does not inhibit 
the α-ketoglutorate conversion independently; this assay utilizes just the components on 
the right hand side of the figure. 
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Figure 4.2. Auto-palmitoylation 54 Individual Compounds.   
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Figure 4.2 (continued). Auto-palmitoylation 54 Individual Compounds  (Compounds 98 
to 105). 
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Figure 4.2 (continued). Auto-palmitoylation 54 Individual Compounds  (Compounds 
106 to 113). 
106 107
110
108
112
111
109
113
N
HN
N
N N
HN
N N
N
HN
N
N
N
NH
N
N
N
HN
N
N N
HN
N
N
N
NH
N
N
N
HN
N
N
F
F
F
F
FF
F
F
F
F
F F
F
F
F
F
F F
 220 
 
Figure 4.2 (continued). Auto-palmitoylation 54 Individual Compounds  (Compounds 
114 to 121). 
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Figure 4.2 (continued). Auto-palmitoylation 54 Individual Compounds  (Compounds 
122 to 129). 
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Figure 4.2 (continued). Auto-palmitoylation 54 Individual Compounds  (Compounds 
130 to 137). 
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Figure 4.2 (continued). Auto-palmitoylation 54 Individual Compounds  (Compounds 
138 to 143). 
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Figure 4.3. Individual Compounds 90 to 143 Inhibit Erf2 Auto-palmitoylation.   
The relative velocity of Erf2 auto-palmitoylation with 100 µg/ml for predicted active 
individual compounds (90-137), non-specific individual compounds (49-54)The velocity 
of Erf2 auto-palmitoylation was detected as an increase in fluorescence over time. 
Average values of three reactions presented as a fraction of vehicle control (1% DMF) 
+/- standard deviation. A reaction lacking Erf2 ( - ) represents baseline activity in the 
assay.  50 µM 2-BP is a control for inhibition of Erf2 auto-palmitoylation. 
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Figure 4.4. Synthesis of Bis-piperazines. 
a) 5%DIEA/DCM b) Fmoc-Lys(Boc), DIC, HOBt, DMF c) 20% Piperidine/DMF d) R1-
COOH, DIC, HOBt, DMF e) 55% TFA/DCM; 5% DIEA/DCM f) Boc-AA(R2)-OH, DIC, 
HOBt, DMF g) R3-COOH, DIC, HOBt, DMF h) Borane-THF 65 oC 96 hr; Piperazine 65 
oC, 24 hr i) Oxalyldiimidazole, DMF j) HF 0 oC 1.5 hr 
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